





















The Dissertation Committee for Meredith Hodges Vazquez 
certifies that this is the approved version of the following dissertation: 
 
ECONOMIC EVALUATION OF USING ADENOVIRUS 
TYPE 4 AND TYPE 7 VACCINES IN UNITED STATES 
MILITARY BASIC TRAINEES 
 
 
    
      Committee: 
 
            
      James P. Wilson, Supervisor    
            
            
      Patrick M. Garman 
            
            
      Kenneth A. Lawson 
            
            
      Esmond D. Nwokeji 
            
            






ECONOMIC EVALUATION OF USING ADENOVIRUS 
TYPE 4 AND TYPE 7 VACCINES IN UNITED STATES 





Meredith Hodges Vazquez, BS, MPH 
Dissertation 
Presented to the Faculty of the Graduate School of 
The University of Texas at Austin 
in Partial Fulfillment  
of the Requirements  
for the Degree of  











This dissertation is dedicated to my mom and dad, Charlie and Kathi Hodges, 
for being my heroes, loving and supporting me, and making this dream possible 
 
 
And my loving husband, Jonathan Vazquez, 
for always believing in me when I do not believe in myself, loving me the way I am, and 













I would like to thank my supervisor, Dr. James P. Wilson, for all of his support, guidance, 
and encouragement throughout my time in graduate school. He helped me to find a 
balance between my public health background and pharmacy when he pointed me in the 
direction of military vaccines, which is now my passion. I would also like to thank my 
committee members: Dr. Karen Rascati for her advice and expertise in 
pharmacoeconomics; Dr. Kenneth Lawson for his guidance and expertise in scientific 
writing; Dr. Esmond Nwokeji for his encouragement and expertise on the US military 
and pharmacoeconomics; and Col Patrick Garman for his expertise on the US Military 
Vaccine Agency, the US military, and vaccines in general and for answering all of my 
numerous questions involving military vaccine policies. I would like to acknowledge Dr. 
Clifford E. Snyder, the product manager for the adenovirus vaccine for the US Army 
Medical Material Development Activity, and Dr. Charles Hoke, an infectious disease 
specialist for the Army, for their expertise on the adenovirus vaccine.   
 
I would like to thank all of our brave soldiers, sailors, airmen, Marines, and Coast 
Guardsmen for your dedication, service and sacrifice and for defending our freedoms and 





    
 
ECONOMIC EVALUATION OF USING ADENOVIRUS 
TYPE 4 AND TYPE 7 VACCINES IN UNITED STATES 
MILITARY BASIC TRAINEES 
 
 
Meredith Hodges Vazquez, Ph.D. 
The University of Texas at Austin, 2014 
 
Supervisor: James P. Wilson 
 
  
 Adenoviruses, particularly types 4 and 7, are associated with febrile respiratory 
illness (FRI) outbreaks in US military basic trainees. Vaccines against these two 
serotypes controlled FRI in basic trainees until production ceased in the mid-1990s. After 
contracting a new manufacturer, adenovirus vaccination of military basic trainees 
resumed in 2011. The purpose of this dissertation was to assess the cost – effectiveness of 
using the new adenovirus type 4 and type 7 vaccines for the prevention of FRI in US 
military basic trainees from the perspective of each military branch. 
vii 
 
 Two decision tree models comparing adenovirus vaccination to no adenovirus 
vaccination were used for this dissertation. The first model is similar to previous models 
used to assess the cost – effectiveness of the adenovirus vaccine in the military, where the 
outcome is number of FRI hospitalizations prevented. The second model created for this 
dissertation used information gathered from published literature and conversations with 
experts on the adenovirus vaccine. The outcome for the second model was number of 
training days lost (TDL) averted.  
 Results from part I indicated that adenovirus vaccination of basic trainees was 
cost – effective as measured by FRI hospitalizations prevented in all US military service 
branches but the Coast Guard.  The model showed that reintroducing the adenovirus 
vaccine to basic trainees saved the Army $5.8 million, the Navy, $1 million, the Marine 
Corps, $238,000, and the Air Force, $5.2 million, annually. In addition, adenovirus 
vaccination prevented 1,221, 543, 317, 677 cases of FRI hospitalization annually in the 
Army, Navy, Marine Corps, and Air Force respectively. 
 In part II of this study, adenovirus vaccination of basic trainees was the dominant 
strategy as measured by TDL averted in all US military service branches but the Marine 
Corps and the Coast Guard. Results indicate that it would cost approximately $37.63 and 
$563.78 per TDL averted for the Marine Corps and Coast Guard respectively.  
 Both models used for this dissertation provide evidence supporting the cost – 
effectiveness of using the adenovirus vaccine in US basic trainees in all services but the 
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CHAPTER 1: BACKGROUND 
 
1.1. INTRODUCTION 
Adenoviruses (AdVs), particularly serotypes 4 and 7, are associated with febrile 
respiratory illness outbreaks in United States military basic trainees. 1 –6 Febrile 
respiratory illness (FRI) is a common cause of hospitalization and morbidity in military 
recruits, costing the US government millions of dollars in direct medical costs every year. 
7 Adenovirus vaccines controlled FRI in military recruits until 1996, when the sole 
manufacturer, Wyeth, ceased production. In October 2011, after a twelve – year break 
and contracting with a new manufacturer, adenovirus vaccine administration to military 
basic trainees resumed. 8 Previous economic models agree that vaccination of military 
recruits against adenovirus is beneficial from the perspective of reducing military medical 
costs. 7, 9 - 10  However, these cost analyses have been modeled under the assumptions that 
adenovirus epidemiology in military recruits has not changed, does not differ between 
military service branches, and that the manufacturer’s cost for the new vaccine would be 
comparable to that seen before production ceased in 1996. Therefore, this dissertation 
proposes a cost – effectiveness analysis, assessing vaccination costs, FRI cases prevented, 
and duty days lost, using the adenovirus types 4 and 7 vaccines versus no vaccination in 
US military basic trainees.  
1.2. ADENOVIRUS OVERVIEW 
Human adenoviruses are a group of ubiquitous pathogens causing mild human infections, 
including respiratory, gastrointestinal, renal, urinary tract, ocular surface infections, 
2 
 
opportunistic infections in immunocompromised patients, 1, 11 - 12 and possibly obesity. 13 
Adenovirus infections occur worldwide, and between two and five percent of all 
respiratory infections are due to adenovirus. 12 Children less than four years of age, 
military basic trainees, adults in closed and crowded settings, and immunocompromised 
patients such as cancer and transplant patients are most susceptible to adenoviruses.  In 
healthy hosts, approximately half of adenoviral infections are sub – clinical, yet the 
infections induce type - specific immunity. While the majority of adenovirus – associated 
disease is self – limiting, dissemination or pneumonia can be fatal in both 
immunocompromised and immunocompetent patients. 1 
Adenoviruses are responsible for sporadic cases and epidemics of febrile respiratory 
infections (FRIs), pharyngoconjunctival fever, keratoconjunctivitis or gastroenteritis. 1, 11 
– 12, 14 However, this document focuses on epidemics of febrile respiratory infections. 
Patients with FRI have symptoms seen with upper respiratory tract infections or 
“common colds,” including fever, runny nose, sore throat, and/or persistent cough. FRIs 
occur throughout the year, but a higher frequency of cases is seen in winter and spring. 
Adenovirus transmission occurs through direct contact with an infected individual, 
inhalation of small droplet aerosols, the fecal – oral route, or contact with contaminated 
environmental surfaces. 1, 11 – 12, 14 AdVs spread easily between humans and can survive 
for up to two weeks on environmental surfaces such as pillows and sinks. 15 The 
incubation period for respiratory infections ranges from two to fourteen days depending 
on the viral serotype and mechanism of transmission. Infections are most contagious in 
the first few days of illness; however, asymptomatic carriage of the adenovirus continues 
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for weeks or months.16 Treatment of FRI consists of primarily treating symptoms. 
Considering adenovirus is self – limiting in people with healthy immune systems, no 
approved antiviral therapy exists.16  - 18 Therefore, vector control and immunization are 
currently used as preventive measures. 
1.3. ADENOVIRUS CLASSIFICATION 
Adenoviruses are non – enveloped, double - stranded DNA viruses belonging to the 
Adenoviridae family. The lack of an envelope allows adenoviruses to evade destruction 
by chemical and physical agents and adverse pH conditions, allowing for prolonged 
survival outside the body and challenging infection – control measures. 1, 14, 19 Since 
AdVs were first isolated in the adenoids of a US military basic trainee in 1953, 53 
serotypes (AdV1 – AdV53) associated with a variety of clinical syndromes have been 
identified. Based on physical, chemical, and biological properties, serotypes are grouped 
into species (A – G). Species B is divided into subspecies B1 and B2 based on DNA 
sequences. 20 Some AdV species are directly linked to different clinical syndromes, but 
more than half of the known serotypes are not associated with a specific clinical disease 
process.1, 19 AdV species most often associated with respiratory infections include those 
within subspecies B1 (AdV3, AdV7, AdV11, and AdV21), subspecies B2 (AdV14), 
species C (AdV1, AdV2, AdV5, and AdV6), and species E (AdV4). Table 1.1 shows the 














Acute febrile pharyngitis Nasal congestion, pharyngitis, 
fever, sore throat 
1, 2, 3, 5, 6, 7 
Pharynconjunctival fever Pharyngitis, conjunctivitis, 
fever 
3, 7 
Febrile respiratory illness 
(FRI) of recruits  
Fever, nasal congestion, 
muscle pain, sore throat 
3, 4, 7, 14, 21  
Pneumonia Fever, respiratory distress, 
cough 
1, 2, 3, 4, 7, 14, 
21 
aAll serotypes listed have been identified in each disease; serotypes in bold are those most often found in 
military basic trainees 
Adapted from: Kunz AN, Ottolini M. The role of adenovirus in respiratory tract infections. Curr Infect 
Dis Rep. 2010; 12:81 -7.  
 
1.4. LABORATORY DIAGNOSIS OF ADENOVIRUS 
Cases of adenovirus are routinely diagnosed through clinical presentation and symptoms. 
1, 11, 17, 19 However, it is difficult to distinguish between viral and bacterial respiratory 
infections without the use of laboratory techniques. Laboratory techniques used to 
diagnose adenovirus include viral cell culture, immunofluorescence, and polymerase 
chain reaction (PCR).14, 21 - 22 Viral cell culture involves infecting living cells with a 
patient’s specimen and observing for cellular changes due to the viral infection, known as 
cytopathic effects. 23 Viral isolation through cell culture was considered the “gold 
standard” for diagnosing adenovirus for decades. However, only 50 to 70 percent of 
samples yield positive results, the process takes five to seven days to see a result, and 
results are subjective because laboratory technicians observe and make a decision on the 
presence or absence of a virus. 19 Currently, researchers are shifting to molecular 
diagnostic techniques like PCR for viral isolation because results only take one to two 
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days, making PCR the ideal test during outbreaks and epidemics. The PCR technique 
amplifies the viral genetic sequence from a patient’s specimen into many identical copies. 
In addition to more timely results, the sensitivity and specificity of PCR is higher. 22, 24 – 25 
Viral isolation through immunofluorescent stains uses immunofluorescence and enzyme 
– linked immunosorbent assays. These techniques are based on the immunological 
reaction between an antibody and an antigen, are less expensive than PCR, and give 
results in two to three days. The sensitivity and specificity of these tests are low, so 
negative tests need to be confirmed with a cell culture, which adds four to five days. 14, 19, 
22 Viral cell culture, antigen detection, and PCR are all effective diagnostic techniques 
that have different uses in different environments. 
With the development of restriction enzyme analysis and multiplex PCR, identification of 
different genome types within serotypes is possible. 1, 26  Li and Wadell created a 
classification system based on restriction enzyme analysis, using BamHI as the defining 
enzyme.27 -  28 The different genome types are symbolized with a character of the 
alphabet. The prototype AdV strain for a specific serotype is labeled “p” whereas 
subsequent genome types are labeled “a” through “k.” These genome types are further 
classified by restriction pattern using additional enzymes and are given an Arabic number 
(ie.,. Ad4p, Ad4p1, etc.). Researchers use this molecular characterization system to 
correlate specific genome types with geographic distribution and pathogenic potential, 




1.5. THE UNITED STATES ARMED FORCES BASIC TRAINING 
ENVIRONMENT 
Basic combat training is the process by which civilians from the United States and its 
territories are transformed into US Armed Forces service members able to perform basic 
military skills to defend the United States.  This transformation is a result of immersing 
basic trainees into an environment consisting of their chosen military service branch’s 
values, conduct, and military skills. 3, 29 -  30,  Each military service branch has a specific 
term for their initial training, but for simplicity, this document refers to the experience as 
“basic training” and the participants as “basic trainees.” According to 2011 Department 
of Defense (DoD) figures, basic trainees range from 17 to 35 years of age, with 73 
percent under the age of 21.32  The DoD allows each service branch to set their own age 
limit, and all branches except the Army have an age limit less than 35 years of age. 33 
Seventeen percent of basic trainees are female, 17 percent are Hispanic, 81 percent are 
non – Hispanic, and two percent listed ethnicity as unknown. 32 Before beginning basic 
training, basic trainees must undergo a physical examination, be free of chronic diseases, 
and pass their initial physical fitness test, so they are considered healthy. 34 Upon arriving 
at basic training, basic trainees go through entrance processing, which includes medical 
screenings and routine immunizations. Routine immunizations administered to basic 
trainees include one or all of the following vaccines: adenovirus, influenza, 
meningococcus, inactivated polio, typhoid, yellow fever, measles, mumps, rubella, 
varicella, hepatitis A, hepatitis B, diphtheria, tetanus, and pertussis. 35 By the end of 
entrance processing, basic trainees are divided into smaller groups known as units, 
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companies, platoons, or flights, depending on military branch. In these groups, basic 
trainees eat, sleep, and attend classes together in an intense, crowded environment. Each 
military branch has their own training requirements, but all include classroom, field, and 
physical fitness components. 29 
The following section gives a brief description of each branch of the United States Armed 
Forces and points out differences between training environments.  
1.5.1. ARMY  
The Department of the Army is the largest and oldest component of the Armed Forces, 
with about 550,000 active duty members called soldiers.32 The Army’s mission is to fight 
and win our Nation’s wars by providing prompt, sustained land dominance across the full 
range of military operations and spectrum of conflict in support of combatant 
commanders. 36 Approximately 60,500 basic trainees enter the Army annually and attend 
basic combat training for 10 weeks, including one week of indoctrination and nine weeks 
of training. 31, 37 - 38 Currently, four Army basic training installations exist. Army basic 
training installations include: Fort Benning, Georgia; Fort Jackson, South Carolina; Fort 
Leonard Wood, Missouri; and Fort Sill, Oklahoma.  
1.5.2. NAVY  
The Department of the Navy includes the US Navy and US Marine Corps. 39 However, 
the Marine Corps is treated as a separate branch of the Armed Forces in this document. 
The Navy consists of 320,000 active duty sailors who “defend our right to travel and 
trade freely on the world’s oceans and protects national interests overseas.” 40 In the 2012 
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fiscal year, 36,329 civilians entered the Navy’s eight-week basic training program, which 
occurs at the Recruit Training Command in Great Lakes, Illinois. 37, 41 
1.5.3. AIR FORCE  
The Air Force includes 325,000 members referred to as airmen. 32 The Air Force’s 
mission is “to fly, fight and win in air, space and cyberspace.” 42 Basic military training 
lasts for eight – and – a – half weeks, where approximately 30,000 individuals become 
airmen annually. 37 Lackland Air Force Base (AFB) in San Antonio, Texas, is the only 
Air Force basic training site.  Air Force trainees live, eat, and train as a flight that 
includes 55 airmen. 29 Week five of basic training is “Warrior Week,” which is a field 
training exercise and “aims to expose recruits to field conditions, teach survival skills, 
threat assessment, the law of armed conflict, security, self – aid and buddy –aid, 
explosive ordinance recognition, and use of M – 16 rifle, conduct nuclear, chemical, and 
biological warfare training, and infuse the warrior spirit.” 43 
1.5.4. MARINE CORPS   
As mentioned above, the US Marine Corps is a division of The Department of the Navy. 
39 The Marine Corps is a deployable and combat – ready force consisting of around 
200,000 Marines. 32 Marines are “forward deployed to respond swiftly and aggressively 
in times of crisis,” which is where their motto “First to Fight” comes from. 44 Each year, 
30,500 civilians enter the 12 - week training program to become Marines. Two Marine 
Corps Recruit Depots exist in San Diego, California and Parris Island, South Carolina. 
37The final hurdle of Marine basic training is “The Crucible,” which is an endurance test 
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lasting more than 50 hours that requires physical stamina, problem solving, and 
teamwork. 44 
1.5.5. COAST GUARD  
 The US Coast Guard is unique because it is part of the Department of Homeland 
Security instead of the Department of Defense. During times of war and national 
emergencies, the US Coast Guard becomes a part of the Department of the Navy and 
functions as a specialized military service. 39 With only 38,000 active duty Coast 
Guardsmen, the Coast Guard is the smallest branch of the military. 30 The Coast Guard is 
“a military, multi – mission, maritime force offering a unique blend of military, law 
enforcement, humanitarian, regulatory, and diplomatic capabilities.” 39 The Coast Guard 
has one basic training site in Cape May, New Jersey.  
1.6. FEBRILE RESPIRATORY ILLNESS IN UNITED STATES MILITARY 
TRAINEES 
The US military has used the names acute respiratory disease (ARD), acute respiratory 
illness (ARI), and febrile respiratory illness (FRI) to describe adenovirus – associated 
respiratory cases, but for simplicity, the term FRI is used throughout this document 
unless specifically noted. Adenovirus was first isolated from basic trainees in 1953 
during an “influenza – like” epidemic at the Army base in Fort Leonard Wood, Missouri. 
This epidemic was unique because in contrast to “seasoned” soldiers, the incidence of 
FRI in basic trainees was abnormally high. It is assumed that the low rate found in 
“seasoned” soldiers was due to immunity gained early in their military career. 45 - 48 
During the 1950s and 1960s, AdVs were responsible for more than 50 percent of FRIs 
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and 90 percent of pneumonia cases among healthy military basic trainees, 49 making 
adenovirus – associated febrile respiratory illness a major cause of morbidity, a burden to 
the military healthcare system, and a source of lost training time in military basic trainee 
populations. The Wyeth adenovirus vaccine introduced in 1971 reduced adenovirus – 
specific disease rates by 95 to 99 percent. 50 While adenovirus disease rates decreased, 
rates of other respiratory infections like influenza were much higher when the vaccine 
was not used. By 1996, AdV infections accounted for only four percent of total 
adenovirus morbidity in US military basic trainees. 51 The Wyeth adenovirus vaccine was 
manufactured and used by the DoD for 28 years. Wyeth discontinued production of their 
adenovirus vaccine in 1994, but vaccine stock was not completely exhausted until 1999.52 
Surveillance at eight basic training sites showed that about 73,000 AdV infections 
occurred between 1999 and 2004 (Figure 1.1.). 6 Adenovirus rates in US military basic 
trainees increased between 1998 and 2003 but started declining in 2004. 35 Even though 
FRI rarely causes death in healthy adults, adenovirus was responsible for five military 
















FIGURE 1. 1.  FEBRILE RESPIRATORY ILLNESS (FRI) AND ADENOVIRUS 
RATES, BY YEAR, US MILITARY BASIC TRAINEES, (1997 – 2012) 
 
 
Adapted from: Hoke CH, Hawksworth A, Snyder CE. Initial assessment of impact of adenovirus type 4 and type 7 
vaccine on febrile respiratory illness and virus transmission in military basic trainees, March 2012. MSMR. 2012; 
19(3):2 – 5. 
  
 
1.6.1. BASIC TRAINEE RISK FACTORS 
Important factors making military basic trainees vulnerable to AdV and other infectious 
diseases include lack of pre – existing immunity, physical and mental stress, 
overcrowding, and poor hygiene habits. 46 – 48, 54 Due to lack of exposure during 
childhood to serotype - specific adenoviruses four and seven seen in basic training 
installations, susceptible civilians continuously arrive at basic training camps. 
Approximately 90 percent of incoming basic trainees are susceptible to at least one of 
these serotypes. 55 In addition, recent research shows that certain environmental 
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psychological stress can cause changes in your immune system resulting in a higher 
probability of contracting a respiratory illness. 56 Basic training exposes basic trainees to 
extreme environmental conditions and psychological stress to prepare them for combat 
situations where anything can happen. Due to the strict training schedule and trainee 
environment, basic trainees might relax their personal hygiene practices during basic 
training. Results of a survey administered during an adenovirus outbreak at Lackland 
AFB included comments from basic trainees about their personal hygiene practices. Basic 
trainee comments included “I’ve seen people wash their hands in toilet water because the 
latrine crew was going to have an inspection” and “trainees do not have enough time 
week 1 – 4 to wash.” 48 These basic trainee comments characterize the relaxation of 
personal hygiene practices found in basic training, which, in turn, increases transmission 
of infectious respiratory infections. For decades, epidemiologists focused on the 
transmission of adenovirus through aerosol droplets and direct contact. Current 
epidemiology shows FRI in basic trainees is closely associated with overcrowding and 
transmission of adenovirus through environmental surfaces.15, 48 Basic training is a 
unique experience and environment that facilitates disease transmission, and one sole 
factor is not responsible for the vulnerability of military basic trainees to adenovirus. The 
transmission of adenovirus in the basic training environment is a perfect example of the 
complex interaction between the host (susceptible basic trainee), agent (adenovirus), and 





1.7. FRI SURVEILLANCE IN US MILITARY BASIC TRAINEES 
 
1.7.1. THE NAVAL HEALTH RESEARCH CENTER FRI SURVEILLANCE 
The Naval Health Research Center defines a case of febrile respiratory illness as a trainee 
seeking medical care that meets both of the following criteria: a fever of greater than or 
equal to 100.50F (380C) or equivalent and at least one sign or symptom of acute 
respiratory tract inflammation (e.g., sore throat, cough, runny nose, chest pain, shortness 
of breath, or headache). Also, any trainee having clinical or radiographic evidence of 
pneumonia is considered an FRI case. 52 In 1998, as the military was depleting their 
remaining Wyeth adenovirus vaccine supply, The Naval Health Research Center (NHRC) 
began documenting febrile respiratory infections at eight of the nine military basic 
training centers.  These eight basic training centers include three Army, one Navy, one 
Air Force, two Marine Corps and one Coast Guard training installation (Figure 1.2) 57 
The FRI surveillance program is voluntary, and currently, Fort Sill is the only basic 
training installation not participating. The definition for FRI mentioned above is used by 
NHRC for surveillance purposes. Personnel at each training installation collect data and 
specimens to determine rates of FRIs, identify types of pathogens in upper respiratory 
swabs obtained from sick personnel, and provide weekly reports to the military 
community. 52 The NHRC laboratory processes specimens for respiratory virus isolation 
from Army, Navy, and Air Force basic training posts. FRI rates are reported as numbers 
of cases per 100 trainees per week. Even though the military reintroduced the adenovirus 
vaccine in October of 2011, FRI surveillance continues, and the NHRC publishes reports 





FIGURE 1.2. NHRC FEBRILE RESPIRATORY ILLNESS SURVEILLANCE SITES                                    
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1.7.2. ACUTE RESPIRATORY DISEASE (ARD) SURVEILLANCE PROGRAM 
In 1966, the Army started its Acute Respiratory Disease Surveillance program that 
observed cases of ARD in individuals attending basic training. The Army’s ARD 
surveillance definition has three criteria instead of just the two criteria used by NHRC 
mentioned above. In addition to fever and upper respiratory tract infection symptoms, a 
basic trainee must be given a limited duty profile or removed from duty for at least eight 
hours. A throat culture is ordered for all trainees meeting this ARD case definition. 58 
ARD cases are found in outpatient settings like Troop Medical Clinics. In order to 
capture all ARD cases, it is important to search both inpatient and outpatient settings for a 
range of diagnoses. Table 1.2 shows International Classification of Diseases, Ninth 
Edition Clinical Modification codes often associated with respiratory illness. An ARD 
report is submitted weekly by each bases’ Chief of Preventive Health to the ARD 
Surveillance System. The report contains the following data: company identification, 
number of men and women assigned, number of men and women ARD cases 
hospitalized, and week of training. Before submission, each report is reviewed for 
accuracy and potential ARD outbreaks. 35, 58 The Army Medical Surveillance Activity 
combines and analyzes weekly reports from each Army basic training installation. A 
weekly summary report is produced and distributed each Wednesday and is found on the 

















a International Classification of Diseases, Ninth Edition, Clinical Modification 
Source: Functional Proponent for Preventive Medicine Michael B. Cates. Army Acute Respiratory Disease 
(ARD) Surveillance Program. Memorandum for the Surgeon General of the Army. Falls Church, VA, 12 
June 2006.  
 
1.8. SPECIFIC SEROTYPES FOUND IN MILITARY BASIC TRAINEES 
 
1.8.1 ADENOVIRUS SEROTYPE 4 (AdV4) 
AdV4 is the prototype adenovirus strain and was first isolated in 1953 from FRI cases 
during an “influenza – like” epidemic at Fort Leonard Wood, Missouri. AdV4 is 
TABLE 1.2. ICD – 9 – CMa DIAGNOSTIC CODES FOR 
RESPIRATORY ILLNESS  
 
ACUTE UPPER RESPIRATORY DISEASE 
460 Acute nasopharyngitis (common cold) 
462 Acute pharyngitis  
463 Acute tonsillitis 
464 Acute laryngitis and tracheitis 
         464.0x Acute laryngitis 
         464.1x Acute tracheitis 
         464.2x Acute laryngotracheitis 
         464.3x Acute epiglottis 
         464.4   Croup 
         464.5x Supraglottitis, unspecified 
465 Acute upper respiratory infections of multiple/unspecified sites 
        465.0   Acute laryngopharyngitis 
        465.8   Other multiple sites 
        465.9   Unspecified site 
ACUTE BRONCHITIS AND BRONCHIOLITIS 
        466.0   Acute bronchitis  
        466.1   Acute bronchiolitis 
        466.19 Acute bronchiolitis due to other infectious organisms 
PNEUMONIA 
        480.0   Pneumonia due to adenovirus 
        480.9   Viral pneumonia, unspecified 
        485.0      Bronchopneumonia, organism unspecified 
        486.0      Pneumonia, organism unspecified 
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responsible for sporadic infections in civilians but is the predominant serotype found in 
basic trainees. 60 In the United States from 2004 to 2006, AdV4 was responsible for 4.8 
percent of respiratory AdV infections in civilians. However, during the same period, 
AdV4 was responsible for 92.8 percent of respiratory AdV infections in basic trainees. 1 
1.8.2. ADENOVIRUS SEROTYPE 7 (AdV7) 
Ad7V is one of the most common adenovirus serotypes reported worldwide, and in 
combination with AdV4, is a predominant cause of FRI in military recruits. In terms of 
clinical presentation, AdV7 is indistinguishable from AdV4, but those infected with 
AdV7 often also experience gastrointestinal symptoms. AdV7 is not as efficient at 
spreading as other respiratory viruses, which is why it appears predominantly in closed or 
crowded communities. 26 Adenovirus 7 often occurs in conjunction with AdV3. In 1997, 
an outbreak of FRI, involving 541 cases at the Naval Recruit Training Command in Great 
Lakes, Illinois, was attributed to serotypes AdV7 and AdV3. Seventy percent of the cases 
were due to AdV7 and 24 percent to AdV3. 1, 61 Due to the appearance of AdV14 in 
2007, which like AdV7 is a species B adenovirus, AdV7 has essentially disappeared as a 
cause of FRI in US military recruits. 1   
1.8.3. ADENOVIRUS SEROTYPE 3 (AdV3) 
Globally, AdV3 is the most common serotype implicated in adenovirus infections. 1 
However, in military recruits, it is only responsible for sporadic epidemics at basic 
training sites, and it often occurs in conjunction with AdV7. Between 2004 and 2006, 
AdV3 accounted for 2.6 percent of FRI cases among military basic trainees. 60 The 
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medical literature on AdV3 in military recruits is scarce, but AdV3 is known to cause 
severe respiratory illness, especially pneumonia. 
 
1.8.4. ADENOVIRUS SEROTYPE 14 (AdV14) 
 
In 1955, AdV14 was first discovered in Dutch military recruits. 62 However, a minimal 
number of cases of FRI due to AdV14 were reported between 1960 and 2006.  In March 
and April of 2006, AdV14 isolates appeared in three of the eight United States basic 
training sites. However, this strain was an AdV14 variant associated with severe clinical 
illness. This AdV14 variant ultimately spread to all US basic training sites and caused 
outbreaks of variable severity. 63 - 65 In 2007, the AdV14 variant caused severe outbreaks 
at Lackland AFB and the Marine Corps Recruit Depot in Parris Island, SC and was 
responsible for an estimated 48 percent of 1147 trainee cases with FRI. 62, 66 Twenty – 
three of the FRI cases at Lackland Air Force base caused by the AdV14 variant resulted 
in hospitalization, where four recruits entered the intensive care unit and one died. 67 
1.8.5. ADENOVIRUS SEROTYPE 21 (AdV21) 
 
In the 1960s, AdV21 was associated with FRI epidemics in Dutch basic trainees but only 
sporadic cases were noted over the next couple of decades. AdV21 is responsible for 
sporadic cases but not epidemics in American basic trainees. In the United States between 
the years of 2004 and 2006, AdV21 accounted for 2.4 percent of FRI cases in military 
basic trainees.1  Over this same period, a statistically significant increase was seen in 
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AdV21 FRI cases in military basic trainees. 60 In addition, research shows that AdV21 is 
more prevalent than AdV4 and AdV7 among vaccinated trainees. 51 In 2007, a FRI 
outbreak due to AdV21 occurred at the US Coast Guard training site in New Jersey. 
Culture – positive throat swabs tested during this outbreak showed that AdV21 
completely replaced the endemic serotype, 4p. 68 Although only a small percentage of 
trainees develop FRI because of AdV21, monitoring for AdV21 outbreaks in trainees is 
practical because of the increasing baseline prevalence and the reintroduction of the 
adenovirus vaccine.  
1.8.6. ADENOVIRUS SPECIES C 
 
Adenovirus species C includes serotypes AdV1, AdV2, AdV5, and AdV6. Species C 
adenoviruses are endemic in most countries and infect more than 80 percent of the 
population by the age of three. 11, 69 In the United States between 2004 and 2006, AdV1 
and AdV2 accounted for 0.4 percent and 0.4 percent, respectively, of AdV respiratory 
isolates from military basic trainees. 1 Since the reintroduction of the adenovirus vaccine, 
the percentage of FRIs attributed to species C serotypes increased. Due to the fact that 
most children develop antibodies against adenovirus species C, only sporadic cases of 






1.9. ADENOVIRUS PREVENTION 
 
1.9.1 NON – VACCINE INFECTION CONTROL MEASURES 
 
During the adenovirus vaccine’s absence, the US military focused on non – vaccine 
infection control measures.  These methods include personal measures, administrative 
procedures, and environmental controls.70 - 72 Non – vaccine prevention measures differ 
not only between military services but between military service installations. Unlike a 
vaccination program, non – vaccine prevention methods involve guidelines and 
recommendations that are not always strictly enforced. Therefore, vaccination always 
seems to be the most practical control measure.    
Personal measures to prevent adenovirus infections include hand hygiene, respiratory 
hygiene, cough etiquette, and mask wearing. 70 - 71 Epidemiologic evidence on the 
importance of personal measures as a means of preventing adenovirus in basic trainees is 
rare. One Navy program titled “Operation Stop Cough” implemented at the Naval 
Training Command included five daily, mandatory hand washes, installation of more 
liquid soap dispensers at sinks, and monthly education on hygiene importance for basic 
trainees. The program reduced total outpatient respiratory visits by 45 percent but had no 
influence on hospitalization rates for respiratory illness. 70, 73 Even though it was 
successful, continuing the program was difficult because of the time constraint placed on 
basic trainees. The importance of hand washing is emphasized to Army basic trainees, 
but certain barriers exist such as lack of training discipline, lack of time, and lack of 
facilities.  Other personal measures recommended to prevent adenovirus infections 
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include covering one’s mouth when coughing or sneezing and using masks to limit 
exposure to other trainees. 70 No evidence exists supporting the use of masks to prevent 
FRIs in the military, and currently, masks are not given to military basic trainees for FRI 
prevention. Personal measures to prevent adenovirus infections in basic trainees are less 
reliable than other control measures because they require individual compliance at a time 
when basic trainees have little to no control over their environment and schedule. 70, 72 
Administrative procedures to reduce respiratory infections include isolation of infectious 
trainees, bed spacing requirements and arrangement, and barrack/room hygiene. Isolating 
infectious trainees from susceptible trainees requires appropriate facilities and support, 
which requires more funding for the basic training installation. 70, 72 Some training sites 
include “respiratory disease barracks” or “fever flights,” where infectious trainees live 
until they are healthy enough to return to training. 15 Crowding is a known risk factor in 
the transmission of respiratory illnesses, so to reduce crowding of basic trainees, the DoD 
has guidelines for per – person space requirements. Each basic trainee is to receive 72 
square feet of floor space to minimize disease transmission unless an emergency waiver 
is issued. 48, 70 Using this DoD guideline that was adopted by the Marine Corps, the squad 
bays at the Marine Corps Recruit Depot in Parris Island should hold a maximum of 72 
basic trainees. In contrast, the Marine Corps Recruit Training Order states that 88 basic 
trainees be held in two of their squad bays. A Marine Corps study reported that squad 
bays at the Marine Corps Recruit Depot in Parris Island were overcrowded 50 percent of 
the time between 2004 and 2007. 74 Overcrowding is also seen in Army basic training 
installations, especially during “summer surge.”  “Summer surge” is the time between 
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May and September when high school graduates enter basic training. During “summer 
surge,” half of the Army basic training installations do not follow the DoD per – person 
guidelines. 71 One administrative recommendation that all basic training posts follow 
because it does not require any additional cost or resources is arranging bunks so 
individuals lay head – to – toe. This arrangement maximizes the amount of space 
between bunks and breathing room, while minimizing disease transmission. 70 – 72 
Administrative procedures do not rely on personal compliance, but they do require policy 
implementation, which as seen above, is not always enforced.  
Environmental controls to reduce respiratory infections include ventilation standards and 
air filters. 70 Since adenovirus is spread through aerosol droplets, indoor air quality issues 
facilitate transmission due to the increased concentration of adenovirus in the air. Indoor 
air quality is assessed by measuring carbon dioxide concentrations, where carbon dioxide 
concentration is a surrogate for air quality freshness. 72 The US Environmental Protection 
Agency and the American Society of Heating, Refrigerating, and Air – conditioning 
Engineers set the standard for a carbon dioxide concentration of 1000 parts per million 
(ppm) as an indicator for poor indoor air quality. 46 – 48, 75 Carbon dioxide levels above 
1000 ppm are associated with adverse health effects such as eye irritation, headache, 
drowsiness, difficulty concentrating, fatigue, and upper respiratory symptoms. A 2000 
AdV4 outbreak at Lackland Air Force Base showed that carbon dioxide levels exceeded 
1000 ppm in all basic trainee classrooms with one classroom peaking at 5000 ppm. 48 In 
addition, during a 1997 outbreak at Fort Jackson, researchers found that when more than 
40 basic trainees are in a sleeping “bay” the carbon dioxide threshold is exceeded. 48 
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Even though the impact on adenovirus is minimal, traditional air filters remove pathogens 
from the air. However, dirty or missing air filters is a problem at basic training sites. 
During the peak of a 1998 AdV4 outbreak at Fort Jackson, an air filter study revealed a 
correlation between number of AdV4 – related hospitalizations and the proportion of air 
filters containing AdV4. 75 High – efficiency particulate air filters remove more 
respiratory illness agents out of the air than traditional filters, but research examining the 
impact of different types of filters on disease rates in basic training installations do not 
exist.  
1.9.2. HISTORY OF ADENOVIRUS TYPE 4 AND 7 VACCINE 
 
In the 1950s due to the significant impact adenovirus – associated FRI had on military 
basic trainees, researchers decided to develop an adenovirus vaccine. In 1956, researchers 
at the Walter Reed Army Institute of Research (WRAIR) developed an inactivated 
adenovirus vaccine protecting against serotypes AdV4 and AdV7, which were 
responsible for the majority of FRI cases in basic trainees. 32, 76 -77 However, in 1963, the 
vaccine license was revoked by the Food and Drug Administration (FDA) because of 
production and standardization problems. During this same time, researchers at the 
National Institutes of Health developed an inactivated polyvalent vaccine containing 
serotypes AdV3, AdV4, and AdV7. However, researchers subsequently found that 
serotypes AdV3 and AdV7 were oncogenic in hamsters, and tumor – bearing genomes 
from simian virus (SV – 40) had integrated with the adenovirus vaccine strains. 78 Due to 
these complications, use of the polyvalent vaccine ceased.  
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In addition to the inactivated polyvalent vaccine, a monovalent, live serotype AdV4 
vaccine grown in human diploid embryonic cells was created in the early 1960s. This 
vaccine was distinctive because instead of the vaccine virus being attenuated, the vaccine 
was attenuated by the route of administration. The adenovirus vaccine was administered 
as an enteric – coated tablet that did not release the virus until it was in the lower 
intestinal tract. Using this route of administration allowed the virus to bypass the upper 
respiratory tract. Since adenovirus causes infections in the respiratory and gastrointestinal 
tract, the immunological response to the asymptomatic gastrointestinal infection protects 
against respiratory tract infections. 79 Between 1963 and 1966, clinical trials with this 
vaccine were performed on institutionalized adults and military basic trainees. A four – 
fold increase in type – specific neutralizing serum antibodies was observed in those 
receiving the vaccine. 80 The drawback of this vaccine was that it was highly type – 
specific. Since the vaccine protected against the specific serotype AdV4, basic trainees 
started developing FRI due to serotype AdV7. 76 This finding led to clinical trials of type 
AdV7 and AdV21 vaccines. Trials between 1964 and 1969 showed that simultaneous 
immunization with adenovirus serotype 4 and 7 enteric – coated tablets was both safe and 
effective. 77, 79, 81 The type 7 adenovirus tablet was added to the recruit immunization 
schedule in 1970. Due to the low rates of adenovirus serotypes 4 and 7 in the general 
population, the vaccine was only approved for use in military basic trainees. The 
adenovirus vaccine program had a significant impact on basic trainee morbidity, reducing 
total respiratory disease rates by 50 to 60 percent. 76 By 1984, both vaccines were 
routinely administered year round to basic trainees at all basic training camps. However, 
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in 1987, Lackland Air Force Base stopped administering the adenovirus vaccine to basic 
trainees because adenovirus was rarely identified at this base. 6 
Both of the vaccine tablets were given routinely as combined prophylactic oral doses 
until the manufacturer (Wyeth Laboratories) ended production in the mid – 1990s. In 
1984, the Food and Drug Administration instructed Wyeth to update their adenovirus 
vaccine manufacturing facility. Since the US military was the only consumer of the 
vaccine, Wyeth asked the DoD for $ 5 million to assist in manufacturing repairs. This 
budget increase was denied by senior officials at the Pentagon. When the DoD and 
manufacturer failed to reach an agreement by 1995, production of the adenovirus vaccine 
ceased. Rationing their existing product, the military used the AdV4 vaccine until 1998 
and the AdV7 vaccine until 1999. 52 Since early 1999, no adenovirus vaccine has been 
available. The incidence of FRI increased significantly to that of the pre – vaccine era in 
military basic trainees following the exhaustion of the adenovirus vaccine supply. 
Adenovirus outbreaks did not occur at Lackland AFB until 1999 when immunization 
ceased at other basic training camps. Recommendations from advisory bodies prompted 
the DoD to restore the adenovirus vaccine program, and in 2001, a contract was awarded 
to Barr Laboratories, Inc. 82 In October of 2004, then Assistant Secretary of Defense for 
Health Affairs, Dr. William Winkenwerder Jr., estimated that the initial vaccine 
production investment would be $50 million, and the annual cost of vaccine would be 




1.9.3. CURRENT ADENOVIRUS TYPE 4 AND TYPE 7 LIVE, ORAL VACCINE 
 
Since the Wyeth vaccine was so successful in terms of efficacy and safety, the DoD 
wanted to acquire new vaccines “as similar as possible to the old vaccines.” 84 Therefore, 
the new adenovirus type 4 and type 7 live vaccine tablets are manufactured from the 
same human adenovirus strains that Wyeth Laboratories developed, produced, and used. 
Wyeth transferred the adenovirus seeds and testing and production documents needed to 
produce the adenovirus vaccine to Barr Laboratories, Inc.  In 2008, Teva Pharmaceuticals 
acquired Barr Laboratories, Inc., and the name of the subsidiary responsible for the new 
vaccine changed to Teva Women’s Health, Inc. 85 With funding from the DoD, a new 
manufacturing and packaging facility with updated equipment and quality control 
procedures was built specifically for the production of the adenovirus vaccine. 86 Since 
Teva and Wyeth used similar starting materials and manufacturing processes, the old and 
new vaccines are nearly identical. Table 1.3 compares Wyeth and Teva’s manufacturing 
processes for the adenovirus type 7 and type 7 vaccine.  
Teva Women’s Health, Inc. performed two clinical trials to show their adenovirus 
vaccine is safe, efficacious, and immunogenic.  Since the military used the Wyeth 
vaccine for 20 years, the FDA only required a Phase I and Phase III clinical trial for 
vaccine approval. 87 The Phase I trial recruited participants attending the Combat Medic 
School at Fort Sam Houston in Texas to determine the immunogenicity and safety of the 




TABLE 1.3. COMPARISON OF TEVA AND WYETH ADENOVIRUS VACCINES 
MANUFACTURING PROCESSES87 
aADV4 = adenovirus type 4; bADV7 = adenovirus type 7; cEMEM = Eagle’s Minimal Essential Medium; dDMEM = 
Dulbecco’s Modified Eagle’s Medium; eFBS = Fetal Bovine Serum; fTCID50 = Tissue Culture Infectious Dose; gSPGA 















Cells Human Diploid Cells  
(WI – 38) 
Human Diploid Cells 
 (WI – 38) 
None None 
Virus ADV4a  CL68578p12 
 












EMEMc Media + 10% 
FBSe and antibiotics 





Infection Media Media + 2% FBS Media + 2% FBS None None 
MOI Estimated 0.1 – 1.0 
TCID50/cellf 
0.1 – 0.7 TCID50/cell None None 
Incubation 14 days 10 – 14 days None None 
Harvesting 0.8/0.45 micron filters 0.8/0.45 micron filters None None 
Stabilizer 10% SPGAg 10% SPGA None None 
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Thirty participants received the oral AdV4 and AdV7 vaccines manufactured by Teva 
Women’s Health simultaneously, while 28 participants received an oral placebo. 49, 88 The 
immunogenicity outcome measure was the seroconversion rate, which is the percentage 
of study subjects who develop specific (adenovirus) antibodies in their sera as a result of 
vaccination. 89 The seroconversion rate at day 28 showed 73 percent of non – immune 
participants developed antibodies to AdV4 and 65 percent to AdV7.  The most common 
adverse events were nasal congestion, cough, sore throat, headache, abdominal pain, 
arthralgia, nausea, and diarrhea. This Phase I trial showed that the new adenovirus 
vaccines are safe and able to induce an immune response in the study population. 49, 88 
A Phase III trial, including basic trainees from Fort Jackson and the Naval Training 
Center, evaluated efficacy and safety. 90 The primary endpoints for this trial were 
different for AdV4 and AdV7 because the AdV7 virus was not present in the basic 
trainee population during the study period. The primary efficacy endpoint for AdV4 was 
prevention of FRI through vaccination (vaccine efficacy), while the primary endpoint for 
AdV7 was serologic response to vaccination (immunogenicity). The AdV4 primary 
efficacy analysis included 49 people, where the placebo group had 48 people and the 
vaccine group had one person. 84, 87 – 88, 90 Since the only case of FRI occurred before the 
vaccine was protective, vaccine efficacy for AdV4 against FRI was 99.3 percent. 
Seroconversion rates for vaccine recipients were 94.5 percent for AdV4 and 93.8 percent 
for AdV7. During the six-month study period, 92 percent of basic trainees reported at 
least one adverse event (N = 17,654), while 1.2 percent reported serious adverse events 
(N = 57).  The most common adverse events included headache, upper respiratory tract 
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infection, and arthralgia. Serious adverse events included psychiatric disorders and 
traumatic injuries. A significant difference was not found between the vaccine and 
placebo group in terms of adverse event numbers. 84, 87- 88, 90 
With data from both trials showing that the Teva adenovirus vaccines are safe, 
efficacious, and immunogenic, the FDA approved the Adenovirus Type 4 and Type 7, 
Live, oral enteric coated vaccine in March of 2011 for use only in US basic trainees 
between the ages of 17 and 50. In late October and early November of 2011, the US 
Armed Forces began administering the two – capsule adenovirus vaccine to basic trainees 
at all basic training installations. The current price per dose (AdV4 + AdV7) with the 
additional shipping cost is $126.12, which is approximately $30 million a year. Six 
months after the new adenovirus vaccine introduction, FRI rates had declined 75 percent. 
8 To date the DoD has spent approximately $160 million* on the new Adenovirus vaccine 
program. Despite the positive preliminary results, the US Armed Forces continue to 
monitor FRI rates to evaluate the molecular epidemiology of adenovirus serotypes at 
basic training installations.  
1.10. JUSTIFICATION FOR NEW COST STUDIES 
1.10.1. VARIATION IN MOLECULAR EPIDEMIOLOGY OF ADENOVIRUS 
SEROTYPES AND GENOME TYPES 
Scientific advancements, especially diagnostic techniques, occurring since the 
development of the Wyeth adenovirus vaccine allow researchers to understand 
adenovirus serotypes on a molecular level. Before 1997, FRI surveillance and diagnosis 
                                                          
* Value calculated by author using contract information 
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in basic trainees did not have laboratory support.22 Scientific advancements used to 
understand adenovirus on a molecular level include restriction enzyme analysis, 
multiplex polymerase chain reaction techniques targeting fiber genes or hypervariable 
regions of the hexon genes, and sequencing of the fiber and hexon genes. With 
knowledge gained from these new techniques, researchers are able todetermine genetic 
variability within serotype strains circulating in the United States and at basic training 
installations. 1 
Epidemiological research shows that adenovirus serotypes have different geographical 
and temporal distributions and associated virulence. Single serotypes dominating in 
specific regions are replaced by other serotypes over a few years, which leads to small 
outbreaks and epidemics. 1, 91 – 93 Figure 1.3 shows the geographical and temporal 
distribution of adenovirus serotypes at basic training installations between the years 2002 
and 2006. 63 In addition to serotype variance, data confirm that genetic variants within 










Figure 1.3. Serotype identification of 1867 adenovirus isolates from military recruits at 8 
US basic training centers, 2002 – 2006. Each block represents 1 sample from a recruit 
with febrile respiratory illness. Split blocks represent co - infections with two serotypes. 
Changes in sampling volume are not representative of changes in disease rate but rather 
of changes in sampling effort. Ad – positive samples were chosen randomly for 
serotyping.  
Source: Metzgar D, Osuna M, Kajon AE, Hawksworth AW, Irvine M, Russell KL. Abrupt emergence of 
diverse species B adenoviruses at US military recruit training centers. JID. 2007; 196:1469 
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The effectiveness of immunization can be hindered by the emergence of novel adenovirus 
serotypes and genome types. The effect of antigenic drift on the influenza vaccine was 
seen at Fort Jackson, South Carolina in 2011. Antigenic drift led to insufficient influenza 
vaccine efficacy, which led to 64 cases of influenza and one fatality in vaccinated basic 
trainees. 94 To determine if using the same virus strains used in the Wyeth vaccine in the 
Teva vaccine was appropriate, investigators completed comprehensive studies on strain 
variation in adenovirus serotypes AdV4 and AdV7. 91 – 92 In terms of AdV7, one study 
concluded there was essentially no variability among strains between the years of 1963 
and 1997. All vaccine and wild – type strains recovered from military basic trainees 
between 1963 and 1997 had the AdV7a genome type. 92 Beginning in 1997, other AdV7 
genome types commonly seen in US civilian populations were identified in the military 
basic trainee population. AdV7d2 appeared as the predominant strain, followed by 
AdV7b, AdV7p, and AdV7h.  Evidence of differences in virulence between AdV7 
genome types is inconclusive. However, some genome types such as AdV7b and AdV7h 
are regularly isolated from patients with serious clinical outcomes. 26 The evolution of 
AdV4 is more complex than AdV7 because of constant genetic drift that is emphasized 
by the replacement of former strains by new strains.  The current strain circulating in 
military basic trainees is significantly different from the prototype (AdV4p) and vaccine 
strain (AdV4p1). The new variant strain looks like a recombinant between serotype 
AdV4 and an AdV – B1 serotype, probably AdV7. 91 - 92 Between 1997 and 2003, seven 
distinct genome types of AdV4 were found across the basic training installations, which 
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can be seen in Figure 1.4. All of the variant genome types were significantly different 
from the prototype (AdV4p) and vaccine strain (AdV4p1). 93 If  
 
 
Figure 1.4. Geographic and temporal distribution of adenovirus 4 genome types in 
United States military basic training sites (1997 – 2003) 
Source: Kajon AE, Moseley JM, Metzgar D, Huoung HS, Wadleigh A, Ryan MAK, Russell KL. 
Molecular epidemiology of adenovirus type 4 infections in US military recruits in the postvaccination era 





AdV4 and AdV7 serotypes and genome types continue to drift, it is plausible the vaccine 
will not be as effective in the future. 
1.10.2. US BASE REALIGNMENT AND CLOSURE 
In addition to serotypes and genome types varying across current US basic training 
installations, the realignment and closure of many US basic training installations make 
the need for new adenovirus vaccine cost studies paramount. The original adenovirus 
epidemiologic and cost studies performed in the 1960s and 70s occurred at the basic 
training locations of the time that included: Fort Dix, New Jersey, Fort Lewis, 
Washington, Fort Campbell, Tennessee, Fort Ord, California, and Fort Polk, Louisiana. 
None of these Army bases are still used for basic training. Current basic training 
installations are in the Midwest and southeast United States, where the temperature and 
humidity have an influence on the spread of respiratory infections, so data collected will 
vary from previously collected data. As discussed above, the military service branches all 
have unique basic training programs and unique regulations, so it is difficult to generalize 
incidence data to all service branches.  Two previous cost studies are discussed in 
Chapter 2 assessing cohorts of Army basic trainees. 7, 9 and one assessed a cohort Navy 
basic trainees 10 to determine cost – effectiveness of adenovirus vaccine. No cost studies 
exist that assess Marine Corps, Air Force, or Coast Guard basic trainees in terms of the 
cost – effectiveness of vaccines. This dissertation intends to add to the literature by 
creating specific models for each military service branch.  
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1.10.3. EVOLUTION OF VACCINE ECONOMIC MODELS 
As diagnostic techniques advanced and military basic training installations changed, 
economic analyses of infectious diseases and vaccination evolved over the last decade. 
Economic models of vaccines that were based on decision analytic models are now 
incorporating transmission dynamics and herd immunity, so cost – effectiveness is not 
misrepresented. 95 – 98 These transmission dynamic models merge epidemiological models 
and pharmacoeconomic techniques to determine if the vaccine is a good value for the 
money invested.  The modeler must understand the unique features of the disease and 
intervention to create a comprehensive model.  However, by increasing the complexity of 
the model, the amount of uncertainty in your assumptions also increases. 97 For example, 
economic models account for uncertainty by varying parameters and performing 
sensitivity analyses. However, in addition to parameter uncertainty, transmission dynamic 
models often include structural uncertainty, model uncertainty, and methodological 
uncertainty. 97 The limitation with adenovirus is that its transmission in US basic trainees 
is still unclear. It is known that adenovirus is transmitted through aerosols and contact 
with fomites, but it is still unclear whether the environment, the basic trainees, or both are 
the original contaminant. A more in – depth explanation of models used for the economic 
evaluation of vaccines is given in Chapter 2, where the focus is specifically the economic 






PHARMACOECONOMICS AND ECONOMIC STUDIES ON 
ADENOVIRUS VACCINE USED IN BASIC TRAINEES 
 
2.1. INTRODUCTION 
With increasing Department of Defense health care costs and a decreasing health care 
budget, economic evaluations of military vaccinations and other health care interventions 
are a priority. Vaccinations are considered one of the most cost – effective public health 
interventions in developed and developing countries. 96 However, policy makers want 
more pharmacoeconomic (PE) information on newer vaccines because of their high cost. 
97 Costs associated with FRI morbidity and hospitalization in military basic trainees have 
always been a significant concern to the US military, but to date, only three cost studies 
investigating the adenovirus vaccine and its health outcomes have been published. The 
following chapter gives an introduction to pharmacoeconomic study techniques, takes an 
in – depth look at the three existing studies, and presents the objectives and hypotheses 
for this dissertation.  
2.2. INTRODUCTION TO PHARMACOECONOMIC TECHNIQUES 
Pharmacoeconomics is a “branch of health economics primarily concerned with 
identifying, measuring, and comparing the costs and outcomes of pharmaceutical 
products and services.” 98 The two distinguishing characteristics of a PE evaluation 
include: (1) Are two or more alternatives being compared? (2) Are both costs and 
outcomes of alternatives examined? 99   A true pharmacoeconomic analysis must compare 
both costs and outcomes of at least two alternatives, while a partial PE analysis addresses 
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only one. A cost – of – illness (COI) evaluation is an example of a partial PE analysis 
because it only looks at overall costs. Four types of true PE analyses exist, including cost 
– minimization analysis (CMA), cost – effectiveness analysis (CEA), cost – utility 
analysis (CUA), and cost – benefit analysis (CBA). These true PE techniques all estimate 
costs in monetary units but are characterized by the different ways they measure health 
outcomes. 99 – 100 These PE techniques are discussed in the following sections.  
2.2.1. Costs 
In PE analyses, costs are grouped into categories, including direct medical costs, direct 
nonmedical costs, indirect costs, and intangible costs. The types of costs included in a PE 
analysis is dependent on the perspective of the evaluation. Direct medical costs are costs 
for any services or treatments used to detect, prevent, and treat disease and include 
hospitalizations, medications, and health professionals’ time. Direct nonmedical costs are 
costs to patients and their families as a result of an illness or disease but are not 
purchased medical services. Examples of direct nonmedical costs are transportation to 
receive health care and home aides. 100 - 101 Indirect costs are costs of reduced productivity 
due to morbidity or mortality. Indirect costs include lost wages or income lost because of 
an early death. Indirect costs are determined by the human capital and willingness to pay 
approaches. The human capital approach values morbidity and mortality losses using 
standard labor wage rates to estimate an individual’s earning capacity. The willingness – 
to – pay approach asks patients how much they are willing to spend to reduce the 
likelihood of illness. The human capital approach is controversial because it directly 
relates value of life to income, and the willingness – to – pay approach is subjective and 
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produces a variety of answers. Before choosing an approach to determine indirect costs, 
the researcher needs to determine which limitations are most important to them. 
Intangible costs are nonfinancial outcomes of a disease such as pain and suffering and are 
difficult to quantitatively measure. These cost categories are often mentioned in the 
literature, but they are not the only cost categories used in PE analyses. 100 – 101 
2.2.2. Cost – of – Illness Evaluation 
The COI evaluation, also known as the burden of illness evaluation, identifies and 
estimates the overall cost of a particular disease in a target population. This type of 
evaluation measures direct and indirect costs associated with a specific disease. The COI 
technique does not compare two alternatives but does provide an estimate of the financial 
burden of illness. 101 
2.2.3. Cost – Minimization Analysis 
Cost – minimization analysis is the simplest technique to perform because it assesses 
interventions that have identical outcomes. The aim of CMA is to determine the least 
costly way to deliver the same outcome. This type of analysis is often used when 
comparing generic and therapeutic equivalents or “me too” drugs. 100, 102 If evidence to 
support the equivalency of outcomes does not exist, a more comprehensive PE technique 





2.2.4. Cost – Benefit Analysis 
Cost – benefit analyses compare benefits due to an intervention with the costs of 
providing it, where both costs and benefits are measured in monetary units. The goal of a 
CBA is to establish which intervention has the highest net benefit, which is the difference 
between benefits and costs. Results of CBAs are presented as a benefit – to – cost ratio, a 
net benefit, or a net cost. The program or intervention with the highest net benefit or the 
greatest benefit – to – cost ratio are of value, meaning the benefits of an intervention 
outweigh the costs of providing it. 100, 102 – 103 Since all outcomes are assigned monetary 
values, CBA is useful for comparing interventions with different objectives. The human 
capital and willingness – to – pay approaches to determine indirect costs are often used in 
CBAs.  However, using the human capital approach to determine the economic value of 
saving a life is problematic and leads to societal and ethical debates. Therefore, unless 
benefits of an intervention are already expressed in dollars, a CBA should not be 
performed. 101 
2.2.5. Cost – Effectiveness Analysis 
Cost – effectiveness analyses are the most common type of PE analyses found in the 
literature. Cost – effectiveness analyses measure costs in monetary values and outcomes 
in physical units, natural health units, or non – dollar units such as lives saved, cases 
cured, or changes in blood pressure. 101 CEAs assume there is a single treatment objective 
and selects the agent with the lowest cost. 102 Like CBAs, CEAs present their results as a 
ratio, either a cost – effectiveness ratio (CER) or an incremental cost – effectiveness ratio 
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(ICER). The CER signifies the dollar cost per specific clinical outcome gained, 
independent of intervention alternatives and condenses costs and outcomes into a single 
value. 101 Contrastingly, the ICER divides the difference in costs by the difference in 
units of effectiveness.   





The ICER denotes the additional cost required to get the additional effect when switching 
from one intervention (i.e., Drug A) to the other intervention (i.e., Drug B). If the result is 
a negative ICER, one treatment intervention, also known as the dominant treatment 
intervention, is more effective but less expensive. To help with interpretation and clarity, 
ICERs are presented on a cost – effectiveness grid or a cost – effectiveness plane. 98, 100 



























An intervention is placed anywhere on the cost – effectiveness plane according to its 
incremental costs and effects. Costs are placed on the north – south axis, while the effects 
are placed on the east – west axis. Costs and effects can be negative, positive, or zero. 
The origin is the point where costs or effects are equal among treatment interventions. 
Each quadrant of the plane represents the differences in costs and effectiveness between 
the intervention and the “gold standard” alternative. 98, 100 If an intervention falls in 
quadrants II or IV, one intervention clearly dominates another treatment intervention. An 
intervention falling in quadrant IV is more expensive and less effective than its 
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its alternative. If an intervention falls in quadrants I or III, it is up to the decision maker to 
determine if lower costs or greater effectiveness is more important. Quadrant I represents 
an intervention that is more expensive and more effective than its alternative. Conversely, 
quadrant III shows an intervention that costs less and is also less effective than its 
alternative. 98, 100 
Interpretation of the ICER is dependent on the decision maker’s judgment. A newer 
measure known as the incremental net benefit ratio (INB) overcomes the subjectivity 
associated with the ICER. The INB technique takes into consideration the decision 
maker’s maximum acceptable willingness to pay for an intervention, which is represented 
as lambda in the INB equation. The INB equation is calculated as follows: 100, 101 
𝐼𝑁𝐵 = (𝜆 ∗ ∆𝐸𝑓𝑓𝑒𝑐𝑡𝑠) − ∆𝐶𝑜𝑠𝑡𝑠 
 
If the resulting INB is positive, the intervention is considered cost – effective, while a 
negative INB is considered not cost – effective. A limitation of the INB measure is that a 
monetary value must be assigned to the health benefit in terms of how much a decision 
maker is willing to pay. However, it is still accepted because a sensitivity analyses is 
conducted using a range of λ values.100 
2.2.6. Cost – Utility Analysis 
Cost – utility analysis is similar to CEA, but CUA incorporates patient preferences and 
health related quality of life (HRQoL). Costs are measured in a monetary value and 
outcomes are measured in patient - weighted utilities instead of natural units. A utility 
measures the changes in a patient’s satisfaction and well – being resulting from a move 
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between health states. 101 - 103 Utility value estimates range from zero to one, with zero 
indicating death and one indicating perfect health. Three methods commonly used to 
calculate utility for a specific health state include the rating scale, the standard gamble, 
and the time tradeoff method. In each of these methods, a specific health state is 
described to subjects who help determine where on a scale of zero to one the described 
health state falls. The resulting utility is then multiplied by the length of life associated 
with each intervention to get an outcome measure known as the quality adjusted life – 
year (QALY). Therefore, the QALY incorporates increases in survival time and changes 
in quality of life. Results of CUA are expressed as an ICER that translates into costs per 
QALY gained, where the intervention with the lowest cost per QALY is preferred. CUA 
is most appropriate when comparing interventions that extend life but have serious side 
effects, those that reduce morbidity instead of mortality, and when HRQoL is the most 
important outcome examined. CUA is not used as frequently as other PE techniques 
because of disagreements concerning utility measurement, difficulty comparing QALYs 
across populations, and difficulty quantifying patient preferences. 100 
2.3. DECISION ANALYSES 
Decision analysis modeling is a powerful tool that “uses mathematical models to 
quantitatively compare multiple decisions while taking into account both costs and 
effects on quality of life.” 104 The two main types of decision analyses include decision 
trees and Markov models. A decision tree “graphically presents treatment alternatives, 
outcomes, and probabilities, and algebraically reduces into a single value that can be used 
in comparisons.” 105 Decision trees are the most basic form of decision analyses, so 
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concepts used in decision trees are used in more advanced analyses like Markov models. 
As implied by its name, the most critical component of a decision analysis is the clinical 
decision, usually focusing on the cost – effectiveness of screening and diagnostic tools or 
the choice between two alternative interventions. 104 
Decision analyses have several limitations that must be considered. Decision analyses are 
dependent on initial assumptions and the quality of data acquired from the literature. In 
addition, complex health states are oversimplified and the choice of which costs to use is 
subjective. 104 The QALY is often used in decision analyses, and researchers are 
concerned about incorporating personal, cultural, and psychological beliefs into a single 
value. 104, 106 Despite these limitations, decision analyses are a necessary tool for decision 
makers, especially with increasing health care costs.  
 2.3.1. DECISION TREES 
After determining the clinical decision and intervention alternatives to evaluate, a 
decision tree is constructed. Each intervention has a branch extending from the initial 
node, which is a decision node indicating a choice between the alternatives. Chance and 
terminal nodes on subsequent branches of the decision tree symbolize the probability of 
experiencing a particular outcome and the outcome for each alternative, respectively. 
Each branch following a chance node includes cost and health outcomes of the 
corresponding alternative, and each chance node is assigned a probability. 100, 105 Once all 
of the components of the decision tree are gathered, the decision tree is analyzed. Costs 
for each branch from the chance node to the terminal node are summed, while the 
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probabilities for the same branches are multiplied. The sum total cost for the branch is 
then multiplied by the product of probabilities for the same branch to get a single 
weighted cost measure for that path. To calculate the average cost per alternative, sum the 
weighted cost measures for all paths corresponding with that alternative. An ICER or 
INB can now be calculated to help determine which alternative is most cost – effective. 
100 Due to the difficulty in assigning dollar values to outcomes and costs varying between 
locations, it is best to determine the robustness of your model with sensitivity analyses. 
Sensitivity analyses allow researchers to vary probabilities, costs, and quality parameters, 
while keeping everything else constant. 104 Decision trees represent events that occur at a 
single point in time, so if evaluating chronic disease states where outcomes vary over 
time, a Markov model may be necessary. 99, 105, 107 
2.3.2. MARKOV MODELING 
Diseases and conditions are often more complex than what is depicted in decision trees 
and occur over a period of time, so a Markov model is appropriate. A Markov model is a 
cyclic decision tree that is useful when the risk of an event is continuous, when timing of 
events is important, and when important events may happen more than once. 108 Markov 
models assume individuals are always in one of a finite number of health states, also 
known as Markov states. A general example of Markov states is “sick, well, or dead.” 
Events are modeled as transitions from one health state to another, and the time spent in 
each state determines the overall expected outcome. 100, 108 
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The first step in creating and running a Markov model is to establish the health states to 
be examined, including all significant states a patient experiences because of a disease or 
treatment. The second step is to determine possible transitions between states. Patients 
can transition from one health state to another and back again, but it is important to note 
that patients cannot be in more than one health state during a cycle. When an event only 
has short – term effects, a temporary health state is used.100 Temporary health states only 
transition to other health states and not to themselves. In order to end a Markov process, 
the model must have at least one health state that a patient cannot leave in a later cycle. 
This state is known as the absorbing state, which is often the state when a patient dies. 
The third step in creating a Markov model is to choose the cycle length and number of 
cycles, which is dependent on the disease being modeled. Once a model is created, 
transition probabilities are estimated and costs and outcomes are calculated. In Markov 
models, outcomes are cumulative and are calculated for each cycle in the model instead 
of at the end like decision tree analyses. 99 – 100, 108 - 110 
Cohort and Monte Carlo simulations are two types of calculations used in Markov 
models. In a cohort simulation, a hypothetical group of patients, known as a cohort, 
begins the Markov process with a determined distribution of patients among the health 
states. In the following cycle, the cohort is divided according to the transition 
probabilities. The cohort is tracked through the model simultaneously and produces a 
Markov trace that shows the movement of the cohort through the health states and the 
cumulative utilities and costs calculated. The cumulative utility computed when the entire 
cohort reaches the absorbing state is the expected QALY of the cohort. In comparison to 
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Monte Carlo simulations, cohort simulations are faster to run, easy to correct, and more 
transparent. 99 – 100, 107, 111 A disadvantage of a cohort simulation is that it does not take 
into account variability or uncertainty at the patient level. The Monte Carlo technique 
tracks random individual patients as they transition through the model and records the 
resulting outcome. Patients are randomly sent through the model, and the path an 
individual takes is due to random variation. The total outcome measure is computed by 
summing the individual outcome measures. Monte Carlo simulations take into account 
uncertainty or variability at the patient level, take longer to run, and are not as transparent 
as cohort simulations. 99, 109 – 111 
2.3.3. SENSITIVITY ANALYSES 
Markov models combine evidence from multiple sources, including published literature 
and scientific experts, into a single structure to be analyzed. Markov modeling always 
involves uncertainty. Four types of uncertainty that generally occur in Markov modeling 
are parameter uncertainty, analytical uncertainty, structure uncertainty, and 
generalizability. Parameter uncertainty encompasses the variation in model estimates 
such as data on probabilities, health outcomes, and costs. Analytical uncertainty refers to 
methods chosen such as costing measures, outcome measures, and inclusion of indirect 
costs. Structure uncertainty concerns how accurately the model simulates disease 
progression and health outcomes. Generalizability relates to how well results and findings 
from the population you studied extend to the general population. Sensitivity analyses are 





Results from Markov models are dependent upon values assigned to probabilities and 
outcomes. Sensitivity analyses vary the probability and outcome values to measure the 
change in model output values. Sensitivity analyses are either deterministic or 
probabilistic. Deterministic analyses vary an uncertain parameter, or set of parameter 
values, one at a time while all other parameters are held at their baseline value. Since 
only one parameter is varied at a time, it is known as a one – way sensitivity analysis. 
The name of the sensitivity analysis changes with the number of parameters varied. 100 
Limitations of deterministic sensitivity analyses include difficulty presenting results of 
multi – way analyses, arbitrarily choosing parameters to vary, highly subjective 
interpretation of results, and inadequately capturing interactions and correlations between 
parameters. These limitations are addressed when using a probabilistic sensitivity 
analysis. 112 
Probabilistic sensitivity analysis (PSA) uses simulation to produce a distribution of 
estimates to represent the variance of results. PSAs involve two distinct methods: first – 
order simulation and second – order simulation. In first order simulation, a single patient 
travels through the model a finite number of times to generate the distribution of 
estimates. In second – order simulation, parameters are assumed to have specific 
probability distributions. 109 A random sample of parameter values from the probability 
distribution is used to generate a distribution for the outcome. This process is repeated a 
finite number of times to get a distribution of parameter estimates. In addition to the 
probability that each alternative is effective, the output includes expected values for costs, 
effects, and benefits. 110 
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2.4. ECONOMIC STUDIES ON ADENOVIRUS VACCINE USE IN MILITARY 
BASIC TRAINEES 
In the 1950s and 1960s, adenovirus and vaccination in US military basic trainees was a 
priority for the DoD. After an effective vaccine was created for basic trainees in 1971, 
interest in this topic fell and did not increase again until adenovirus vaccination ceased in 
the late 1990s. 114 Economic evaluations on adenovirus and vaccination were only 
published when adenovirus vaccinations were a priority for the DoD. Therefore, only 
three economic evaluations on adenovirus and vaccination in military basic trainees have 
been published. 7, 9 - 10 Taking into consideration that the US military is the only consumer 
of the adenovirus vaccine worldwide, it is clear why literature on the topic is scarce. This 
section discusses the three published articles and differences between them.  
2.4.1. Collis et al. (1973)  
In a 1973 study, Collis et al. examined the costs and benefits of the Army’s Adenovirus 
Surveillance Program that monitored FRI (Febrile Respiratory Illness) in basic trainees 
and the efficacy of the adenovirus type 4 and type 7 vaccine in reducing FRI due to these 
serotypes. Since this was an Army program, only Army male basic trainee costs were 
considered. At the time of this study, females were not administered the adenovirus 
vaccine because of unknown reproductive health concerns. The total cost of the 
Adenovirus Surveillance Program included vaccine development, purchases, and 
administration, which equaled $4.83 million. Direct costs of caring for a FRI patient 
amounted to $183.50 and included one pharmacy visit and a three - day stay at the 
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hospital.  Indirect costs included the salary of the basic trainee during hospitalization plus 
costs of lost training time, which equaled $95.46. Thus, the total cost associated with the 
hospitalization of one trainee with FRI was $279. Using data collected the first two years 
the Army vaccinated basic trainees for both serotypes, it was estimated that the vaccine 
prevented 26,979 FRI hospitalizations. The money saved by using the vaccine and 
introducing the Army’s Adenovirus Surveillance Program during 1970 and 1971 was 
$7.53 million. 7 
Collis et al.’s cost study aided Army policy makers in their decision to continue 
providing the adenovirus vaccine to basic trainees. In fact, this was the only cost study 
performed on the use of the adenovirus vaccine in basic trainees until 1998 when the 
DoD needed a new vaccine manufacturer. For decades, military preventive medicine 
physicians considered the risk of FRI to be the same in all military service branches. 
Therefore, the savings from this original study were extrapolated to the other service 
branches and assumed to be constant through the years.  
2.4.2. Howell et al. (1998) 
In 1998, Howell et al. conducted a cost – effectiveness analysis to evaluate the 
consequences of discontinuing the United States Army’s year – round adenovirus 
vaccination program completely or vaccinating basic trainees during high risk months 
only.  This study was performed from the perspective of the US Army. Outcomes 
associated with each policy change included expected vaccination costs, direct and 
indirect medical and military training cost savings, and the number of FRI 
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hospitalizations prevented. Reference case cost estimates are shown in Table 2.1. 
Outcomes were modeled for a projected cohort of 76, 171 male Army recruits entering 
training over a 1 – year period. When this study was performed, neither the DoD nor the 
Department of the Army had an official position on the use of adenovirus vaccines in 
women concerning reproductive health concerns, so only males were included in the 
model. Reference case cost and probability parameters were varied in sensitivity analyses 
to see how results were affected. 1 
TABLE 2.1. REFERENCE CASE COST ESTIMATES* IN  







Vaccine costs  
Tablet costs $ 9.85 
DPSCa Surcharge (55%) $ 5.42 
Administration $ 0.05 
Total $ 15.32 
  
Illness Related Costs  
Training costs   
(3 days @ $157/day) 
$ 471 
Outpatient medical costs $ 51 
Inpatient medical costs 
 (3 days @ $537/day) 
$ 1,612 
Total $ 2,134 
*All costs calculated in 1995 U.S. dollars, using a 5% annual discount rate 
a U.S. Department of Defense Personnel Support Center, Philadelphia, PA 
 
Based on their analysis, discontinuing the vaccination program would cost $26.4 million 
in medical – related and training - related costs and would result in a projected 12,370 
cases of FRI. A seasonal vaccination program would prevent 7,800 cases of FRI and save 
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$16.1 million over no vaccination. A year round vaccination program would save $15.5 
million over no vaccination but would not prevent any more cases of FRI than the 
seasonal program. Therefore, the most cost – effective strategy would be the seasonal 
vaccination program. Expected costs under the three vaccination programs are shown in 
Table 2.2.  The sensitivity analysis showed that if FRI incidence during the low – risk 
months were to increase, the year – round program would be the most cost – effective 
program.  
 
TABLE 2.2. REFERENCE CASE EXPECTED COSTS UNDER THE THREE 
VACCINATION POLICIES IN HOWELL ET AL.’S STUDY 
 
Howell’s article had several limitations that need to be discussed. The authors stated that 
this was a cost – effectiveness analysis, but after scrutinizing the article, it is clear that it 
more closely resembles a cost - benefit analysis (CBA). Conclusions for this analysis are 
misleading because no direct comparisons are made between a no vaccination policy, a 
year – round vaccination policy, and a seasonal vaccination policy. Another limitation of 
the analysis was that the authors assumed there was no risk of adenovirus infection 
between the months of April and August. This estimate was based on the seasonality of 
FRI seen in basic trainees during times of vaccination. However, during times of no 









Total Costs Total Cost - 
Savings 






















Seasonally $   583,477 $  7,595,895 $2,152,470 $10,340,975 $16,053,739 
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2.4.3. Hyer et al. (2000) 
Hyer et al. assessed the cost – effectiveness of reinstating the adenovirus vaccine program 
in Navy basic trainees.  The authors compared three policy options, including no 
vaccination, seasonal vaccination, and year – round vaccination. The analysis was done 
from the perspective of the US Navy. Costs modeled in this decision tree analysis 
included outpatient costs, inpatient costs, training costs, and costs to resume production 
of the adenovirus vaccine. Number of FRI cases prevented and total costs associated with 
each policy option were compared to each other and the no vaccination policy option. 11 
Outcomes were modeled for an actual cohort of 49,079 male and female Navy basic 
trainees who entered the Naval Recruit Training Center in 1997. Navy policy is to 
vaccinate all basic trainees because men and women are similarly exposed. Incidence of 
FRI, costs of illness, and vaccination program costs were varied in sensitivity analyses to 
determine how varying essential parameters affected the stability of the authors’ 
conclusions.  
Results of the analysis show that when compared to no vaccination, seasonal vaccination 
prevented 4,015 cases and saved $2.8 million per year, while year – round vaccination 
prevented 4,555 cases and saved $2.6 million per year. When comparing seasonal and 
year – round vaccination, a year – round vaccination policy cost an extra $263 per case of 
FRI prevented over seasonal vaccination. Cost – effectiveness ratios and ICERs are 
shown in Table 2.3. Either type of vaccination policy is cost – saving, but the seasonal 
vaccination policy is more cost – effective. 11 
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TABLE 2.3. EXPECTED COSTS AND SAVINGS UNDER THE THREE 











No vaccination $9,860,000   
Seasonal $7,099,000 - $688 - $688 
Year – round $7,241,000 - $575    $263 
* Average cost – effectiveness (C/E) ratio represents cost per case prevented with the seasonal or year – round options,  
   compared to the no vaccination option. A negative ratio indicates a cost saving strategy 
† Incremental cost – effectiveness (C/E) ratio represents cost per case prevented over the next most effective strategy.  
  A negative ratio indicates a cost – saving strategy  
 
Limitations of this analysis need to be considered when interpreting the results. Like the 
Army study previously discussed, this analysis used a vaccine – preventable FRI winter 
incidence rate that was 10 percent higher than the summer incidence rate. The summer 
incidence rate of FRI is about the same or even higher than the winter rate when the 
adenovirus vaccine is not in use.7 At the time of this study, respiratory illness in basic 
trainees was usually classified as an “upper respiratory infection.” However, upper 
respiratory infection was not specifically defined, so the FRI incidence rate may be 
higher than the actual rate. Despite these limitations, the sensitivity analysis showed the 
robustness of the model. 11 
2.5. ECONOMIC EVALUATIONS IN THE US MILITARY 
When comparing economic evaluations of healthcare interventions found in published 
literature, it is important to be conscious of the environment in which the study was 
performed. Factors specific to the military add to the variation in military economic 
evaluations, including differences in policies between US military service branches, 
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differences between basic training sites, and differences in salaries and training costs 
across military service branches.  
When performing and comparing economic evaluations focusing on the US military 
population, specific factors need to be considered. Each service branch of the US military 
has their own policies concerning preventive medicine and hospitalization. For example, 
Army basic trainees with FRI are usually hospitalized, while the Naval Recruit Training 
Command primary care clinic usually classifies respiratory illnesses in basic trainees as 
upper respiratory infections resulting in less hospitalizations. 11 As mentioned in Chapter 
1, geography, poor air quality, and adenovirus serotype affect FRI rates, and surveillance 
shows the differences in FRI rates between basic training sites. In addition to differing 
policies, military service branches have varying salaries and training costs, so it is 
difficult to decide which service branches’ costs should be used in an economic 
evaluation. However, in an effort to standardize costs in economic evaluations, especially 
in terms of military manpower, the DoD recently provided a list of cost estimates and 
methodologies for estimating and comparing full costs of active duty military, data 
sources and calculations for direct labor cost estimates, and a list of non – labor cost 
factors.114 With the DoD providing more information about costs and calculations, 
military economic evaluations should be more standardized in the near future.  
2.6. PROBLEM STATEMENT 
As mentioned above, current literature on adenovirus and the Teva adenovirus vaccine is 
scarce, and previous economic research 9, 10 on the use of a hypothetical adenovirus 
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vaccine in basic trainees used manufacturer bids for vaccine costs and generalized their 
results to all service branches of the US military. However, since reinstating the 
adenovirus vaccination program, no cost analyses with the actual adenovirus vaccine 
price have been reported. In addition, no one has looked at the differences between 
service branches concerning costs. In part I of this study, a simple decision analytic 
model using parameters from each military service branch was used to determine the cost 
– effectiveness of the adenovirus vaccine in basic trainees. In part II of this study, another 
decision tree analysis using an outcome relevant to the military, basic trainees’ training 
days lost (TDL), is created to calculate the incremental cost – effectiveness ratio. 
2.7. STUDY OBJECTIVES 
Lack of DoD health care funds makes it important that the funds they do have are used 
efficiently. Due to the high cost of the Teva adenovirus vaccine and the low mortality risk 
of FRI, this dissertation will evaluate the cost – effectiveness of using the adenovirus type 
4 and type 7 vaccines versus no vaccination. Keep in mind that both decision tree 
analyses will be run separately for each service branch with service specific data.  
This dissertation is divided into two parts. Part I uses the decision analysis model from 
Howell et al.’s and Hyer et al.’s study with current data, while the second part uses a 






Objectives of Part I include: 
  1. Estimate and compare annual direct medical costs, including only  
   outpatient and inpatient costs associated with adenovirus   
   vaccination and no vaccination    
  2. Estimate and compare annual lost training costs associated with  
   adenovirus vaccination and no vaccination  
  3.  Estimate and compare annual total costs associated with   
   adenovirus vaccination and no vaccination  
  4. Determine whether using adenovirus vaccines in basic trainees is  
   cost – effective in each service branch of the military based on  
   incremental cost per FRI hospitalization case prevented 
Objectives of Part II include: 
  5. Based on current, best available evidence on FRI and adenovirus  
   vaccination, develop a decision analysis model to calculate training 
   days lost (TDL), costs, and incremental cost – effectiveness 
  6.  Estimate and compare total TDL associated with each adenovirus  
   vaccination strategy 
  7. Estimate and compare average total cost associated with each  
   adenovirus strategy.  
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STUDY OBJECTIVES (CONTINUED)   
  8. Evaluate the cost – effectiveness of adenovirus vaccines as   
   measured by TDL averted by computing an ICER.    
 
2.8. STUDY HYPOTHESES 
 Objective 1 involves using Howell et al.’s and Hyer et al.’s decision tree with 
 current military service branch – specific information from the literature and 
 experts on the  adenovirus vaccine. Hypothesis 1 posits that direct medical costs, 
 including inpatient and outpatient visits only, associated with adenovirus type 4 
 and type 7 vaccination are less than the direct medical costs associated with no 
 vaccination.   
 H1:  Direct Medical Costs AdV Vaccination < Direct Medical Costs No Vaccination 
 Objective 2 is to estimate and compare lost training costs associated with each 
 vaccination strategy.  Hypothesis 2 posits that lost training costs associated with 
 adenovirus type 4 and type 7  vaccination are less than lost training costs  
 associated with no vaccination 





STUDY HYPOTHESES (CONTINUED) 
 Objective 3 is to estimate and compare annual total costs associated with each  
 vaccination strategy. Annual total costs include vaccine, direct medical, and 
 training costs. Hypothesis 3 posits that total costs associated with adenovirus 
 vaccination are less than total costs associated with no vaccination. 
  H3: Total Costs AdV Vaccination < Total Costs No Vaccination 
 Objective 4 is to evaluate the cost – effectiveness of adenovirus vaccines as
 measured by FRI hospitalizations prevented by computing an incremental cost – 
 effectiveness ratio (ICER).  A negative incremental cost – effectiveness ratio 
 indicates a cost – saving strategy. Hypothesis 4 postulates that the ICER is less 
 than zero.  
  H4: ICER < 0 
 Objective 5 involves the development of a decision analysis model using military 
-  specific data collected from the literature and experts on the military’s adenovirus 
 vaccine. No hypothesis was developed for this objective.  
 Objective 6 is to estimate and compare total TDL associated with each 
 adenovirus vaccination strategy Hypothesis 5 postulates that TDL associated with 
 adenovirus vaccination is less than TDL associated with no vaccination.  




STUDY HYPOTHESES (CONTINUED) 
 Objective 7 is to calculate and compare average total cost associated with each 
 adenovirus strategy. Hypothesis 6 posits that average total cost of adenovirus 
 vaccination is less than average total cost of no vaccination. 
  H6: Avg. Total Cost AdV Vaccination < Avg. Total Cost No Vaccination 
 Objective 8 is to evaluate the cost – effectiveness of adenovirus vaccines as 
 measured by TDL averted by computing an ICER. Hypothesis 7 posits that the 
 ICER is less than zero.    
  H7: ICER < 0 
 Objectives 1 through 4 and objectives 6 through 8 and their corresponding 
 hypotheses will be addressed for the Army, Navy, Air Force, Marine Corps, and 
 Coast Guard. Therefore, each model will be run five times, once for each service 








CHAPTER 3: METHODOLOGY 
3.1. INTRODUCTION 
This chapter presents the methodology proposed for two decision analysis models 
examining the cost – effectiveness of the adenovirus type 4 and type 7 vaccine in US 
military basic trainees. Specific topics to be discussed include: model characteristics, 
model inputs, costs, outcomes, and assumptions.  
PART I 
3.2. DECISION TREE MODEL CHARACTERISTICS 
A computerized (TreeAge Software, Inc., Williamstown, MA) decision – analytic model 
was used to calculate the cost – effectiveness of alternative adenovirus type 4 and type 7 
vaccination strategies in US military basic trainees. The model used was from Howell et 
al.’s and Hyer et al.’s articles discussed in Chapter 2. 10 The two alternative vaccination 
strategies included adenovirus vaccination and no vaccination. Outcomes associated with 
each vaccination strategy included number of febrile respiratory illness (FRI) 
hospitalization cases prevented, direct and indirect medical costs associated with FRI, 
lost military training costs, and vaccination costs. Outcomes were modeled for a 
hypothetical cohort of male and female basic trainees (age ≥17 years old) entering 
training over a one – year period. The number of basic trainees in each service branch’s 
hypothetical cohort is shown in Table 3.1. These basic trainee population numbers were 
from fiscal year (FY) 2013 and were published quarterly on the DoD’s website. 115 
Reference case costs and probability parameters were based on Navy and Army 
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surveillance data for FRI, Department of Defense and Department of Homeland Security 
budget justification documents for fiscal year 2013, TRICARE reimbursement databases 
and guidelines, and experts on military vaccination, vaccine acquisition, and FRI 
surveillance. Clinical data and data on efficacy of adenovirus vaccination were gathered 
from a review of the literature. 
It is important to note that since the Army has four basic training sites and the Marine 
Corps has two, their incidence data and cost estimates are weighted by the proportion of 
basic trainees attending each site during FY2013 and then combined into one measure for 
each branch.  Incidence rates and inpatient and outpatient costs were obtained for each 
basic training site and a weighted total was calculated. This is the same method used in a 
previous Army study to combine rates from more than one basic training site. 11  
 
TABLE 3.1. HYPOTHETICAL POPULATION SIZES 116 
 




MARINE CORPS 29,757 
AIR FORCE 36,392 
COAST GUARD  2,136 







This study was conducted from the perspective of each US military service branch. 
Military basic trainees were treated at Military Treatment Facilities (MTF), which 
included outpatient clinics and hospitals, and were covered by the Defense Health 
Agency’s (DHA) TRICARE insurance program.  
TRICARE is the health insurance program of the US Armed Forces that provides health 
benefits for military personnel, their dependents, and military retirees. Nine different plan 
options are available that include coverage for outpatient services, hospitalizations, 
immunizations and prescriptions. 116 
3.4. PROBABILITIES 
The following probabilities were included in the model: (1) probability of FRI when 
adenovirus vaccination is not in use; (2) probability of FRI when adenovirus vaccination 
is in use; (3) probability of hospitalization for FRI; (4) and probability of outpatient 
treatment for FRI. Data for these probabilities were collected from published surveillance 
documents and published literature. 
3.4.1. PRE – VACCINE INCIDENCE DATA 
Research showed that the incidence of FRI varies by military service branch and military 
basic training site.  Incidence rates for FRI from the pre – vaccine era for eight of nine 
basic training sites were obtained from FRI surveillance performed by the Naval Health 
Research Center (NHRC) and published in Russell et al.’s article discussed below. 6 The 
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one Army basic training site not included in the NHRC’s surveillance was Fort Sill, so its 
pre-vaccine incidence data was calculated using the Army Public Health Command’s 
(APHC) Acute Respiratory Disease Surveillance (ARDS) Summary, which was 
published weekly. 117 In addition to number of FRI cases, the ARDS included weekly unit 
size, so it was possible to calculate an incidence rate in trainee – weeks to correspond 
with incidence rates published in Russell et al.’s article.  
3.4.1.1. Russell et al. Article 
In 2006, Russell et al. published FRI surveillance results from eight military basic 
training sites during the five – year period from July 1999 to June 2004. Russell et al.’s 
study aimed to document FRI rates after adenovirus vaccine usage ceased and to define 
pathogen – specific FRI rates and site – specific trends in the basic trainee population. 
Surveillance data for the article came from the NHRC. As part of the NHRC’s 
surveillance program, NHRC staff members conducted surveillance at all basic training 
sites. NHRC staff members gathered numerator data, which included individuals meeting 
the FRI case definition, and denominator data, which was the total basic trainee 
population at each site, and calculated weekly rates of FRI. Russell et al. used the 
resulting weekly FRI rates to calculate an average site – specific, five – year FRI rate that 
was reported as cases per 100 recruit - weeks. Since these rates were for the period after 
adenovirus vaccination ceased, these average site – specific, five – year FRI rates 
published by Russell et al. were used to calculate incidence probabilities for the no 
adenovirus vaccination alternative branch in this study’s economic models. 
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Nearly 12 million recruit – weeks were followed over the five years, with 110,172 FRI 
cases occurring at the eight basic training sites. Over the five – year surveillance period, 
average site – specific FRI rates ranged from 0.34 cases per 100 recruit – weeks at the 
Marine Corps Recruit Depot in San Diego to 1.35 cases per 100 recruit – weeks at 
Lackland Air Force base. These rates are shown in Table 3.2. With the exception of Fort 
Leonard Wood and Fort Jackson, the FRI rates at the different basic training sites were 
significantly different from each other (p < 0.0001). This difference between basic 
training sites is one reason each service branch was analyzed separately in this 
dissertation. 
TABLE 3.2. REFERENCE CASE FRI INCIDENCE PARAMETERS FOR THE 
PRE – VACCINE PERIOD 
 a Cumulative incidence is the reference case probability value used in the analysis; Calculated using the formula 
𝐶𝐼𝑅𝑡 = 1 −  𝑒−𝐼𝐷∆𝑡 
 
The pre – vaccine era incidence data reported in Russell et al.’s article is an incidence 
density rate (IDR), where trainee – weeks, also known as person – time, is in the 
denominator. Person – time represents the total disease – free time experience for the 
population at risk, and the incidence density rate ranges from 0 to infinity. Therefore, it 
was not a probability and needed to be converted before it could be used in economic 
 INCIDENCE DENSITY CUMULATIVE 
INCIDENCE a 
REFERENCE 
    
ARMY 0.89 cases/100 trainee - weeks 0.085 [6, 117] 
NAVY 1.20 cases/100 trainee - weeks 0.092 [6] 
MARINE 
CORPS 
0.38 cases/100 trainee - weeks 0.045 [6] 
AIR FORCE 1.35 cases/100 trainee - weeks 0.108 [6] 
COAST GUARD 0.50 cases/100 trainee - weeks 0.039 [6] 
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models. An exponential function was used to convert the incidence density rate into a 
cumulative incidence risk (CIR), also known as just risk. 118  
The exponential function is shown below:   
𝐶𝐼𝑅𝑡 = 1 − 𝑒−𝐼𝐷𝑅∆𝑡 
The CIR was the probability that an individual develops a disease in a specified period of 
time and ranges from 0 to one. 118 Once the IDR was converted to a CIR, it could be used 
in economic models. Table 3.2 shows the resulting probabilities/cumulative incidence 
reached by using the exponential function.  
3.4.2. INCIDENCE DATA AFTER REINTRODUCTION OF ADENOVIRUS 
VACCINE 
 Incidence data for after re – introduction of the adenovirus vaccine was collected from 
the weekly FRI surveillance reports published on the NHRC and APHC’s respective 
websites. 117, 119 The APHC’s Acute Respiratory Disease Surveillance summary included 
the number of FRI cases and number of trainees for each Army basic training site. To 
compute the Army’s incidence rate for after re – introduction of the adenovirus vaccine, 
APHC surveillance summaries were collected for a year (April 21, 2012 – March 30, 
2013) and a weighted average incidence rate was calculated. 118 This composite incidence 
rate was then converted into a CIR to be used in this study’s economic models. FRI 
incidence rates for all other service branches were collected from the NHRC’s weekly 
FRI surveillance updates. 119 Surveillance updates were collected weekly from August 4, 
2012, until August 10, 2013, and an average incidence rate was calculated for each 
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service branch. These rates were converted into probabilities using the equation in the 
previous section.  
TABLE 3. 3. REFERENCE CASE FRI INCIDENCE PARAMETERS FOR 
VACCINE PERIOD 
a Cumulative incidence is the reference case probability value used in the analysis; Calculated using the formula 
𝐶𝐼𝑅𝑡 = 1 −  𝑒−𝐼𝐷∆𝑡 
 
The NHRC weekly surveillance update did not supply the reader with raw data, so  to 
confirm that average incidence rates collected from the NHRC updates, pre -  and post -  
vaccination program incidence probabilities were entered into the equation to compute 
vaccine effectiveness (VE). The Navy and Air Force have reported adenovirus vaccine 
effectiveness to be approximately 89.5 and 87 percent, 120, 121 respectively, and using 
Army incidence probabilities, adenovirus VE was calculated to also be 89 percent. 
Therefore, incidence probabilities for each service branch were entered into the vaccine 
effectiveness equation to determine if the calculated VE was between 87 and 89 percent. 
The vaccine effectiveness formula is: 122  
𝑅𝑖𝑠𝑘 𝑖𝑛 𝑢𝑛𝑣𝑎𝑐𝑐𝑖𝑛𝑎𝑡𝑒𝑑 𝑔𝑟𝑜𝑢𝑝−𝑅𝑖𝑠𝑘 𝑖𝑛 𝑣𝑎𝑐𝑐𝑖𝑛𝑎𝑡𝑒𝑑 𝑔𝑟𝑜𝑢𝑝
𝑅𝑖𝑠𝑘 𝑖𝑛 𝑢𝑛𝑣𝑎𝑐𝑐𝑖𝑛𝑎𝑡𝑒𝑑 𝑔𝑟𝑜𝑢𝑝 
  X 100 = VE (87% - 89%) 
 INCIDENCE DENSITY CUMULATIVE 
INCIDENCE a 
REFERENCE 
    
ARMY 0.09 cases/100 trainee - weeks 0.009 [116] 
NAVY 0.12 cases/100 trainee - weeks 0.010 [118] 
MARINE 
CORPS 
0.03 cases/100 trainee - weeks 0.004 [118] 
AIR FORCE 0.17 cases/100 trainee - weeks 0.014 [118] 
COAST GUARD 0.06 cases/100 trainee - weeks 0.005 [118] 
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The Navy and Air Force vaccine effectiveness values equaled values reported in previous 
articles. These percentages were interpreted as an 89 percent reduction in FRI occurrence 
in the vaccinated group. Since vaccine effectiveness values were not reported for the 
Marine Corps and Coast Guard, their average incidence rates could not be confirmed.  
3.4.3. HOSPITALIZATION INCIDENCE  
Following the discontinuation of the adenovirus vaccination program in the late 1990s, 
FRI outbreaks occurred at three basic training sites, Fort Jackson, Fort Benning, and 
Lackland AFB. In response to these outbreaks, the Army’s Center for Health Promotion 
and Preventative Medicine and the Air Force’s Institute for Environment, Safety, and 
Occupational Health Risk Analysis performed in – depth epidemiologic investigations. 
Each investigation consisted of several reports, including but not limited to, hospital 
cohort and FRI hospitalization surveillance, adenovirus carriage prevalence estimation, 
indoor air quality assessment, and personal practices among basic trainees. 46 – 48 
Incidence of FRI hospitalization during the epidemiologic investigations was 2.4 per 100 
trainee – weeks of training in the Army 46 and 2.6 per 100 trainee – weeks of training in 
the Air Force. 48 Since FRI hospitalization incidence rates were similar in the Army and 
Air Force and FRI hospitalization incidence rates were not available for the other service 
branches, an average FRI hospitalization incidence rate of 2.5 per 100 trainee – weeks of 
training was used for the other service branches. Risk of FRI hospitalization was 




TABLE 3.4. REFERENCE CASE HOSPITALIZATION INCIDENCE 
PARAMETERS 
a Cumulative incidence is the reference case probability value used in the analysis; Calculated using the formula 




3.5.1. COSTS ASSOCIATED WITH FRI 
 3.5.1.1. TRAINING COSTS 
Costs to the DoD associated with FRI included missed training costs, direct medical 
costs, including inpatient and outpatient costs, and vaccination costs. Training costs for 
this study included the cost of running the basic training site plus military personnel 
appropriation costs paid by the DoD. Cost of basic training per trainee in all military 
service branches but the Coast Guard was published in a 2004 report by the Office of the 
Under Secretary of Defense, Comptroller. Since Coast Guard basic training cost was 
unavailable, the average training cost of all other service branches was used as an 
estimate. 123 Costs included in this 2004 number included manpower costs, support 
equipment costs, facility costs, and all other costs associated with indoctrinating basic 
trainees into military culture, raising their standards of physical conditioning, and 
instructing them in basic military skills. 123 These 2004 costs were adjusted to 2013 US 
 INCIDENCE DENSITY CUMULATIVE 
INCIDENCE a 
REFERENCE 
    
ARMY 2.4 cases/100 trainee - weeks 0.213 [46] 
NAVY 2.5 cases/100 trainee - weeks 0.181 [Estimate]* 
MARINE 
CORPS 
2.5 cases/100 trainee - weeks 0.259 [Estimate]* 
AIR FORCE 2.6 cases/100 trainee - weeks 0.198 [48] 
COAST GUARD 2.5 cases/100 trainee - weeks 0.181 [Estimate]* 
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dollars using the Consumer Price Index (CPI).124 Once training costs were adjusted to 
2013 US dollars, a daily training cost was calculated by dividing the basic training cost 
per trainee by the number of days spent in basic training, which varied by service branch. 
The second component of training costs for this analysis was the annual military 
appropriation costs paid by the DoD, also known as the annual composite rate.  The DoD 
recommended using the annual composite rate when determining the cost of military 
personnel for budget and management studies and published this rate for each service 
branch on the Office of the Under Secretary of Defense (OUSD), Comptroller’s website. 
125 For this analysis, the annual composite rate for a basic trainee with a military pay 
grade of E-1 was used. A military pay grade of E – 1 was chosen because in 2012, 77.6 
percent of civilians entering basic training had a high school education only, which 
indicated they entered basic training with a pay grade of E – 1. 126 Costs included in the 
DoD annual composite rate were average basic pay plus retired pay accrual, Medicare 
eligible health care accrual, basic allowance for housing, basic allowance for subsistence, 
incentive and special pay, permanent change of station expenses, and miscellaneous pay. 
125 Military pay rates, including the DoD annual composite rate, for the Coast Guard were 
not published by the OUSD, Comptroller, so a DoD composite rate was estimated by 
averaging all other service branches’ annual composite rates for an E – 1 pay rank. This 
method was used by the DoD in a recent economic publication. 127 The annual composite 
rate for each service branch was converted into a daily rate for use in this economic 
analysis. The resulting training cost for each service branch is shown in Figure 3.5 and 
used in calculations for outpatient and inpatient costs.  
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TABLE 3.5. REFERENCE CASE COST ESTIMATES PER TRAINEE PER DAY 
*Estimates for the Coast Guard are averages of values from these references; DoD = Department of Defense; 












SERVICE BRANCH COST ($)† REFERENCE 
   
ARMY   
Training cost per day per trainee $240 [123] 
Daily average wage and DoD benefits $137 [125] 
Total cost per trainee per day $377  
   
NAVY   
Training cost per day per trainee $268 [123] 
Daily average wage and DoD benefits $119 [125] 
Total cost per trainee per day $387  
   
MARINE CORPS   
Training cost per day per trainee $171 [123] 
Daily average wage and DoD benefits $115 [125] 
Total cost per trainee per day $286  
   
AIR FORCE   
Training cost per day per trainee $112 [123] 
Daily average pay and DoD benefits $110 [125] 
Total cost per trainee per day $222  
   
COAST GUARD   
Training cost per day per trainee $254  [123]* 
Daily average wage and DoD benefits $119  [125]* 
Total cost per trainee per day $373  
72 
 
 3.5.1.2. OUTPATIENT COSTS 
Outpatient costs were determined using Current Procedural Terminology (CPT) codes for 
outpatient office visits, including new and established patients. FRI did not have 
corresponding CPT codes, so the average FY 2013 DoD Uniform Business Office’s 
(UBO) maximum allowable charge for outpatient office visits was used as a proxy for 
FRI outpatient costs. The Military Health System (MHS) Professional Services Coding 
Guidelines recommended using these CPT codes for upper respiratory infections. 129 
Since the study population contains basic trainees, it was assumed that all basic trainees 
were new patients for one visit. CPT codes for new patient office visits were 99201, 
99202, 99203, 99204, and 99205. 130 The CPT code used depends on the complexity of 
the patient’s illness. The UBO maximum allowable charge for each new patient office 
visit CPT code (99201 – 99205) was collected and an average value was calculated to be 
included in the analysis. 128 Follow – up outpatient costs were determined using CPT 
codes for an established patient’s office visits. The value used in the analysis for 
established patients was the average UBO maximum allowable charge for CPT codes 
99211, 99212, 99213, 99214, and 99215. 128, 130 Outpatient costs for each service are 
shown in Tables 3.6 - 3.10. 
According to Hyer et al., it was the opinion of preventive medicine physicians at the 
Navy’s basic training site that 95 percent of basic trainees who were not hospitalized for 
FRI were treated with bed rest for 2.5 days. 10 Therefore, this model assumed that basic 
trainees with FRI who attended an outpatient clinic and were not hospitalized were 
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treated with bed rest in sick quarters for 2.5 days. The cost of one trainee in sick quarters 
was calculated with the following formula:  
𝑆𝑄𝑐 = [ 𝑐𝑜𝑠𝑡 𝑜𝑓 1 𝑛𝑒𝑤 𝑜𝑢𝑡𝑝𝑎𝑡𝑖𝑒𝑛𝑡 𝑣𝑖𝑠𝑡 + (2.5) ∗ (𝐷𝑎𝑖𝑙𝑦 𝑡𝑟𝑎𝑖𝑛𝑖𝑛𝑔 𝑐𝑜𝑠𝑡)] 
Furthermore, five percent of patients placed in sick quarters required one follow – up 
visit, where cost was calculated with the formula below: 
𝑆𝑄𝐹𝑐 = [𝑐𝑜𝑠𝑡 𝑜𝑓 1 𝑛𝑒𝑤 𝑜𝑢𝑡𝑝𝑎𝑡𝑖𝑒𝑛𝑡 𝑣𝑖𝑠𝑖𝑡 + (2.5) ∗ (𝐷𝑎𝑖𝑙𝑦 𝑡𝑟𝑎𝑖𝑛𝑖𝑛𝑔 𝑐𝑜𝑠𝑡)
+ 𝑐𝑜𝑠𝑡 𝑜𝑓 1 𝑒𝑠𝑡𝑎𝑏𝑙𝑖𝑠ℎ𝑒𝑑 𝑜𝑢𝑡𝑝𝑎𝑡𝑖𝑒𝑛𝑡 𝑣𝑖𝑠𝑖𝑡] 
These equations were used to calculate the total cost, including training and direct 












TABLE 3.6. ARMY COST† ESTIMATES FOR FRI OUTPATIENT VISITS 
CPT 
CODE 
DESCRIPTION REIMBURSEMENT  VALUE 
USED 
    
99201 Office/Outpatient, New, minimal 
severity 
$25  




99203 Office/Outpatient, New, low/moderate 
severity 
$72 $83 
99204 Office/Outpatient, New, moderate/high  
severity; 45 minutes a 
$123  
99205 Office/Outpatient, New, moderate/high  
severity; 60 minutes 
$159  
    
99211 Office/Outpatient, Est., minimal 
severity 
$9  
99212 Office/Outpatient, Est., minor severity $24  
99213 Office/Outpatient, Est., low/moderate 
severity 
$48 $52 
99214 Office/Outpatient, Est., moderate/high 
severity; 25 minutes 
$74  
99215 Office/Outpatient, Est., moderate/high 
severity; 40 minutes 
$104  
    
CPT = Current Procedural Terminology; Est = Established patient; a Time included to distinguish between 








TABLE 3.7. NAVY COST† ESTIMATES FOR FRI OUTPATIENT VISITS 
FRI = Febrile Respiratory Illness; CPT = Current Procedural Terminology; Est.= Established patient; a 





DESCRIPTION REIMBURSEMENT  VALUE 
USED 
    


















99204 Office/Outpatient, New, moderate/high  





99205 Office/Outpatient, New, moderate/high  




    





99212 Office/Outpatient, Est., minor severity $27 
 
 






99214 Office/Outpatient, Est., moderate/high 




99215 Office/Outpatient, Est., moderate/high 
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DESCRIPTION REIMBURSEMENT  VALUE 
USED 
    
99201 Office/Outpatient, New, minimal 
severity 
$25  








99204 Office/Outpatient, New, moderate/high  
severity; 45 minutes a 
 
$126  
99205 Office/Outpatient, New, moderate/high  
severity; 60 minutes 
$162  
    
99211 Office/Outpatient, Est., minimal 
severity 
$9  
99212 Office/Outpatient, Est., minor severity $24  
99213 Office/Outpatient, Est., low/moderate 
severity 
$49 $53 
99214 Office/Outpatient, Est., moderate/high 
severity; 25 minutes 
$76  
99215 Office/Outpatient, Est., moderate/high 
severity; 40 minutes 
$106  
    
FRI = Febrile Respiratory Illness; CPT = Current Procedural Terminology; Est = Established patient; a 






TABLE 3.9. AIR FORCE COST† ESTIMATES FOR FRI OUTPATIENT VISITS 
FRI = Febrile Respiratory Illness; CPT = Current Procedural Terminology; Est = Established patient; a 




DESCRIPTION REIMBURSEMENT VALUE 
USED 
    
99201 Office/Outpatient, New, minimal 
severity 
$25  








99204 Office/Outpatient, New, moderate/high  
severity; 45 minutes a 
 
$123  
99205 Office/Outpatient, New, moderate/high  
severity; 60 minutes 
$159  
    
99211 Office/Outpatient, Est., minimal 
severity 
$9  
99212 Office/Outpatient, Est., minor severity $24  
99213 Office/Outpatient, Est., low/moderate 
severity 
$48 $52 
99214 Office/Outpatient, Est., moderate/high 
severity; 25 minutes 
$74  
99215 Office/Outpatient, Est., moderate/high 
severity; 40 minutes 
$104  
    
78 
 
TABLE 3.10. COAST GUARD COST† ESTIMATES FOR FRI OUTPATIENT 
VISITS 
FRI = Febrile Respiratory Illness; CPT = Current Procedural Terminology; Est = Established patient; a 









DESCRIPTION REIMBURSEMENT  VALUE 
USED 
    
99201 Office/Outpatient, New, minimal 
severity 
$27  








99204 Office/Outpatient, New, moderate/high  
severity; 45 minutes a 
 
$135  
99205 Office/Outpatient, New, moderate/high  
severity; 60 minutes 
$173  
    
99211 Office/Outpatient, Est., minimal 
severity 
$9  
99212 Office/Outpatient, Est., minor severity $26  
99213 Office/Outpatient, Est., low/moderate 
severity 
$52 $56 
99214 Office/Outpatient, Est., moderate/high 
severity; 25 minutes 
$81  
99215 Office/Outpatient, Est., moderate/high 
severity; 40 minutes 
$114  
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  3.5.1.3. INPATIENT COSTS 
Inpatient treatment costs were estimated using the TRICARE reimbursement amount for 
Diagnosis Related Groups (DRG) associated with respiratory diseases 131 and the DoD 
UBO’s inpatient adjusted standardized amount (ASA) for admission to base – specific 
MTFs. 132  FRI was not associated with one specific DRG code, and the DoD did not 
support patient - level billing. Therefore, inpatient costs for this study were based on 
costs associated with TRICARE DRG code 203 for bronchitis and asthma without 
complications and comorbidities and TRICARE DRG code 206 for other respiratory 
system diagnoses without complications and comorbidities. DRG code 203 included 
patients with a primary diagnosis of acute bronchitis, acute bronchiolitis, and other 
specified disease of the upper respiratory tract, 133 while DRG code 206 included lower 
respiratory infections. 134 The relative weights for DRG codes 203 and 206 were 0.6022 
and 0.7274, respectively, and were used to calculate the cost of a basic trainee’s inpatient 
hospital stay. The cost of an inpatient hospital stay for FRI used in this study was an 
average of the reimbursement rates for the two DRG groups.  Each base – specific MTF 
has its own applied ASA rate that was adjusted for indirect medical education costs. 132 
All basic training sites were in an inpatient MTF catchment area except for the Navy and 
Coast Guard basic training sites. Since the Navy and Coast Guard were not associated 
with base – specific inpatient MTFs, their adjusted standardized amount was less than the 
other basic training sites because indirect medical education costs were not taken into 
account. The total inpatient cost used in the economic model for this study was the 
product of the MTF or facility’s inpatient adjusted standardized amount and the DRGs 
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relative weight. 132 This calculated inpatient cost was the TRICARE reimbursement 
amount. This study assumed that the calculated TRICARE reimbursement amount was 
the actual cost allowed by the DoD for FRI inpatient hospitalization.  
Previous research showed that hospitalization for FRI usually lasted four days and was 
followed by two outpatient visits. 10 Therefore, it was assumed that hospitalization lasted 
four days, so total inpatient cost was the sum of the cost of four missed training days, two 
outpatient visits, and the TRICARE reimbursement amount for FRI hospitalization that 
lasted four days. The TRICARE reimbursement amount for FRI hospitalization remained 
the same unless a patient’s length of stay surpassed the maximum stay threshold, which 
was not the case in this analysis 132 Reference case inpatient hospitalization costs used in 
the decision tree are shown in Table 3.11. The following formula was used to calculate 
total inpatient cost:  
𝐼𝑁𝑃𝑐 = [𝐻𝑜𝑠𝑝𝑖𝑡𝑎𝑙 𝐷𝑅𝐺 𝐶𝑜𝑠𝑡 + (4) ∗ (𝐷𝑎𝑖𝑙𝑦 𝑡𝑟𝑎𝑖𝑛𝑒𝑒 𝑐𝑜𝑠𝑡) + 
(2) ∗ (𝐶𝑜𝑠𝑡 𝑜𝑓 𝑒𝑠𝑡𝑎𝑏𝑙𝑖𝑠ℎ𝑒𝑑 𝑝𝑎𝑡𝑖𝑒𝑛𝑡 𝑓𝑜𝑙𝑙𝑜𝑤 − 𝑢𝑝 𝑣𝑖𝑠𝑖𝑡)] 
Therefore, the total inpatient cost per basic trainee hospitalized for FRI included both 








TABLE 3.11. REFERENCE CASE INPATIENT HOSPITALIZATION 
REIMBURSEMENT FOR RESPIRATORY DISEASES USING TRICARE 
DIAGNOSIS – RELATED GROUPS (DRG)  
SERVICE 
BRANCH 
DRG DESCRIPTION REIMBURSEMENT VALUE 
USED 
     
ARMY     
 203 Bronchitis & asthma age > 17   $6,499 $7,175 
 206 Other respiratory system 
diagnoses  
$7,851  
NAVY     
 203 Bronchitis & asthma age > 17 $3,682 $4,065 





    
 203 Bronchitis & asthma age > 17  $8,339 $9,075 
 206 Other respiratory system 
diagnoses 
$9,810  
AIR FORCE     
 203 Bronchitis & asthma age >17 $9,816 $10,836 





    
 203 Bronchitis & asthma age > 17 $3,822 $4,219 
 206 Other respiratory system 
diagnoses 
$4,617  









3.5.2. COSTS ASSOCIATED WITH ADENOVIRUS VACCINATION 
The 2013 cost of the adenovirus vaccine per dose (1 AdV4 + 1 AdV7) was $125.45. An 
additional $0.67 was added to this base price for shipping. This information was received 
by personal communication with Dr. Clifford Snyder who was product manager for the 
adenovirus vaccine at the US Army’s Medical Material Development Activity. Vaccines 
were administered to basic trainees during entrance processing, while basic trainees were 
completing other administrative tasks. The adenovirus vaccine was different from other 
vaccines because it was taken orally instead of being injected, thus basic trainees had 
minimal contact with a clinician. 9 Previous economic models included a small vaccine 
administration fee of $0.05 in 1997 US dollars, which was adjusted to 2013 dollars using 
a medical CPI inflation rate for this model. 124 After adjustment, the vaccine 
administration fee totals $0.10. The total vaccine cost per basic trainee was the sum of the 
vaccine price per dose, shipping cost, and administration fee and totals $126.22. Since 
this analysis focuses on individual service branch costs and outcomes, vaccination 
program costs such as start – up costs were not included in the model. The DoD was the 
only consumer of the adenovirus vaccine, so they were financially responsible for all 
doses Teva manufactures regardless of the number of basic trainees (Personal 





3.6. OUTCOME MEASURE – PART I 
For this decision tree analysis, expected costs savings, and an incremental cost – 
effectiveness ratio was calculated. The incremental cost – effectiveness ratio represented 
cost per case of FRI hospitalization prevented with adenovirus vaccination compared to 
no vaccination. Previous articles reported annual costs and outcomes, so annual values 
were reported for this analysis.  To calculate annual number of hospitalizations for both 
vaccination strategies, the annual number of basic trainees was multiplied by the 
probability of developing FRI. The resulting product was then multiplied by the 
probability of being hospitalized for FRI. The following is an example for the Army, 
using the adenovirus strategy.  
 # of FRI hospitalizations = 75,373 * 0.009 = 678 (annual # of FRI cases) 
            = 678 * 0.213 = 144 annual FRI hospitalizations for  
                   Army 
The difference of FRI hospitalizations between strategies was the annual number of FRI 
hospitalizations prevented. To get the average number of FRI hospitalizations prevented, 
which was needed for the ICER calculations, the number of FRI hospitalizations was 
divided by the annual number of basic trainees.        
 3.6.1. INVERTING EFFECTIVENESS CALCULATIONS 
 An assumption of cost – effectiveness analyses is that higher effectiveness values 
 are always better. 135 However, in this dissertation, lower values of the 
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 effectiveness  measures, FRI hospitalizations and training days lost, represent a 
 more effective treatment. Therefore, effectiveness measures should be minimized 
 rather than maximized, which TreeAge handled by inverting the incremental 
 effectiveness values. If not using TreeAge and effectiveness values need to be 
 inverted, the following formula can be used to calculate the ICER.  
  𝐼𝐶𝐸𝑅 =  
(𝑇𝑜𝑡𝑎𝑙 𝐶𝑜𝑠𝑡 𝐵)−(𝑇𝑜𝑡𝑎𝑙 𝐶𝑜𝑠𝑡 𝐴)
(𝑇𝑜𝑡𝑎𝑙 𝐸𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒𝑛𝑒𝑠𝑠 𝐴)−(𝑇𝑜𝑡𝑎𝑙 𝐸𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒𝑛𝑒𝑠𝑠 𝐵)
 
   
3.7. SENSITIVITY ANALYSES – PART I 
To determine the robustness of the model used in Part I, tornado diagrams were 
constructed to indicate variables that showed the most change when parameter values 
were varied. In addition, one – way sensitivity analyses were performed on each cost and 
probability parameter to determine their impact on cost – effectiveness.  
3.8. ASSUMPTIONS FOR DECISION TREE – PART I 
Assumptions made for this analysis are outlined below: 
1. All basic trainees received the adenovirus vaccine within two days of 
arriving at the basic training camp (100% coverage) 
2. Assumed costs accrued by vaccine adverse events were not substantial 
enough to be included in the analysis 




ASSUMPTIONS FOR DECISION TREE – PART I (CONTINUED) 
4. Due to the lack of a CPT code associated with FRI, the average maximum 
allowable charge for outpatient office visits for new patients (CPT codes 
99201 – 99205) and established patients (CPT codes 99211 – 99215) was 
assumed to estimate outpatient costs 
5. Due to the lack of one specific FRI – associated DRG code, an average 
reimbursement rate for DRG code 203 and DRG code 206 was calculated 
6. Assumed that TRICARE reimbursement amounts were the actual costs 
allowed by the DoD for FRI treatment 
7. Patients who attended an outpatient clinic and were not hospitalized were 
treated in sick quarters for 2.5 days 
8. Five percent of patients who attended an outpatient clinic and were not 
hospitalized were treated in sick quarters for 2.5 days and required one 
follow – up visit 
9. In addition to two outpatient clinic visits, patients hospitalized for FRI 
















PART II  
3.10. ANALYTIC HORIZON 
For this study, the analytic horizon was the length of basic training for each respective 
service branch. The Marine Corps has the longest basic training with 12 weeks, 44 
followed by the Army with 10 weeks,38  the Air Force with eight and a half weeks,43 and 
the Navy and Coast Guard with eight weeks.41 Duration of protection of the adenovirus 
vaccine was not known past eight weeks because that was the length of the phase III trial. 
90 In addition, a basic trainee’s risk of adenovirus decreased once he/she graduated from 
basic training.  These factors supported the decision to have an analytic horizon equal to 
the length of basic training for this analysis.  
3.11. MODEL INPUT 
Several variables with the same value were used in all service branches in Part II. These 
values are shown in Table 3.12.  
3.11.1. PROBABILITIES 
The following probabilities were included in the second decision tree analysis: (1) 
probability of FRI before vaccination reintroduced; (2) probability of FRI after 
vaccination reintroduced; (3) probability of hospitalization for FRI; (4) probability of 
minor adverse events after vaccination; (5) probability of developing Guillain – Barre 




 3.11.1.1. INCIDENCE OF FRI 
 Incidence data for FRI before and after the adenovirus vaccine was reintroduced 
 to the basic trainee population collected by military surveillance activities used in 
 the prior analysis were also used in this analysis and are found in Table 3.2.  
 3.11.1.2. PROBABILITY OF HOSPITALIZATION 
 Probability data for hospitalization due to FRI used in the prior analysis were also 
 used in this analysis and are found in Table 3.4.  
 3.11.1.3. PROBABILITY OF DEVELOPING PNEUMONIA AS RESULT OF 
 FRI 
 Current numbers on basic trainees with FRI that developed viral pneumonia were 
 not in the literature. Therefore, data for the probability of developing pneumonia 
 as a complication of FRI was obtained from dated studies. Well - controlled 
 studies in the 1950s and 1960s found that five to ten percent of basic trainees with 
 FRI developed severe signs and symptoms of pneumonia. 136 – 138 Another study 
 published in 1971 on  basic trainees  who received the adenovirus vaccines found 
 that 12 percent of basic trainees hospitalized for FRI developed pneumonia 
 complications. 139Using data from these studies, an average of eight percent was 





3.12. MORTALITY DUE TO ADENOVIRUS VACCINATION AND 
ADENOVIRUS INFECTION 
Death from adenovirus - associated respiratory illness in military basic trainees was not 
common. From 1967 to 1998, while the adenovirus vaccine was still in use, five deaths 
due to adenovirus serotypes four and seven were reported in active duty military service 
members. 53 To determine the impact of adenovirus on military mortality when the 
adenovirus vaccine was not in use, the Mortality Surveillance Division of the Armed 
Forces Medical Examiner System collected records of active duty service members who 
died since 1998. 53 Eight out of approximately 14,000 non – combat related deaths were 
attributed to adenovirus, and seven of the eight deaths were basic trainees. Two cases 
were caused by adenovirus serotype 14, and two other cases were not associated with any 
serotype. Therefore, between 1999 and 2012, four deaths due to adenovirus serotypes 
four and seven occurred in active duty military service members. 53 Due to this small 
number, adenovirus mortality was not modeled in this analysis.  
3.13. SAFETY OF THE ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE 
Thirty years of use by the DoD established the safety of Wyeth’s adenovirus vaccine, 
where the most common adverse reaction associated with Wyeth’s adenovirus vaccine 
was diarrhea. To evaluate the safety of the new Teva adenovirus vaccine, phase I and III 
clinical trials were performed. 49, 90 These trials showed that adverse events occurred at 
the same rate in the placebo and vaccine groups.  Abdominal pain and diarrhea occurred 
more often in the vaccine group, but the difference in number of cases between the 
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placebo and vaccine groups did not reach statistical significance. Even though the 
difference between placebo and vaccine groups did not reach significance, The Vaccine 
Information Statement (VIS) for the adenovirus vaccine stated that systemic adverse 
reactions such as abdominal pain and diarrhea occurred approximately 10 percent of 
patients. 140 In addition to the phase I and III trials, a phase IV study examining the safety 
of Teva’s adenovirus vaccine in the “real world” was scheduled to be completed at the 
beginning of 2013. Results of the phase IV study were not publically available, however, 
Teva reported adverse events observed in the phase IV study to the Center for Disease 
Control and Prevention’s (CDC) Vaccine Adverse Event Reporting System (VAERS). 
All reports submitted by the manufacturer to VAERS concerning the adenovirus phase IV 
observational study were collected and reviewed by the author of this study. 141 The only 
adverse reaction occurring more often in the vaccine group was acute infective 
polyneuritis also known as Guillain – Barre Syndrome (GBS). A medical monitor 
reviewed VAERS reports to assess causal relationships between vaccines and adverse 
events and noted his/her conclusions on the VAERS report. The medical monitor who 
reviewed the reports on adenovirus and GBS determined that in those specific cases, GBS 
was possibly related to adenovirus vaccination. 142 Besides systemic adverse reactions 
and GBS, adverse event reports due to adenovirus vaccination were rare. Nonetheless, 
based on the two clinical trials and reports submitted to VAERS, systemic adverse events 





3.13.1. PROBABILITY OF SYSTEMIC ADVERSE REACTIONS 
According to the CDC’s VIS, systemic adverse reactions to the adenovirus vaccine 
included: upper respiratory infections, headache, nasal congestion, cough, arthralgia, sore 
throat, nausea, abdominal pain, diarrhea, and vomiting. 140 As mentioned in the previous 
section, these reactions occurred in approximately 10 percent of patients. Therefore, 0.10 
is the probability used for the economic model.  
3.13.2. PROBABILITY OF GUILLAIN BARRE – SYNDROME 
Guillain – Barre syndrome (GBS) is a rare autoimmune disorder that damages nerve 
cells, causing muscle weakness and sometimes paralysis often associated with infectious 
illness and live vaccines. 143 Cases range from mild to severe disease and recovery 
depends on disease severity. Scientists believe that stimulation of the immune system 
plays a role in its development, but the cause is not fully understood. About two – thirds 
of people developing GBS symptoms do so several days or weeks after experiencing a 
respiratory illness. 143 
Since GBS was not identified in the phase I and phase III trials, risk of GBS was 
calculated using data from the phase IV observational study. The exposed (vaccinated) 
and unexposed (no vaccine) groups both had 55,989 participants. Three patients in the 
exposed group had GBS, while two patients in the unexposed group had GBS. 142 Risk in 
the exposed group was calculated by dividing three by the total number of participants in 
the exposed group. The calculated risk of the exposed group was 0.00005 and was the 
probability used in this economic analysis.  
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3.13.3. COSTS ASSOCIATED WITH PNEUMONIA COMPLICATIONS 
Inpatient treatment costs for pneumonia complications of FRI were calculated the same 
way as inpatient costs for FRI, using MTF – specific adjusted standardized amounts and 
DRG discharge rates. Unlike FRI, adenoviral pneumonia was associated with a specific 
DRG code. Adenoviral pneumonia is classified under DRG code 194 for viral pneumonia 
with complications and comorbidities, with a DRG weight of 0.9779. As with other 
inpatient calculations, the final inpatient amount was calculated using the MTF specific 
ASA and the DRG code weight.  
3.13.4. COSTS ASSOCIATED WITH GUILLAIN – BARRE SYNDROME (GBS) 
GBS is a poorly understood disease that varies in severity and treatment.143 A 2009 study 
on the epidemiology of GBS in the US military showed that after initial case 
presentation, follow – up encounters included physical therapy, occupational therapy, 
rehabilitation, and speech therapy.144 Since treatment included encounters with various 
specialties and depended on the severity of disease, it was difficult to capture all costs 
related to GBS without performing a prospective observational study in basic trainees. In 
addition, including just one inpatient hospital visit for GBS will greatly underestimate the 
cost of GBS to the military. To avoid underestimating the cost of GBS, an average cost 
per patient with GBS as calculated in a 2008 article was used. 145 
In 2008, Frenzen published a study estimating the annual economic cost of GBS in the 
US in 2004 dollars that included direct costs of medical care and indirect costs due to lost 
productivity and premature death. 145 The mean cost per GBS patient was $318,966 in 
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2004 US dollars. To date, no deaths have been reported due to vaccine associated GBS in 
US military basic trainees.  Direct costs of medical care for GBS were obtained from 
Frenzen’s article, but because of differences in lost productivity and premature death 
rates between the general population and the US military, costs from lost productivity and 
premature death were excluded. Therefore, an average direct medical cost of GBS per 
patient was $196,317 in 2004 dollars. 145 This cost was adjusted to 2013 US dollars using 
the Consumer Price Index. 124 The 2013 average direct medical cost of GBS per patient 
used in this analysis was $243,342.66. 
3.14. MODEL OUTCOMES 
Since the outcome measure quality adjusted life year (QALY) is not operationally 
relevant to the DoD, the health – related outcome of training days lost (TDL) due to FRI 
was selected for the outcome of this cost – effectiveness analysis. Estimates for TDL for 
each branch of the decision tree were based on a review of the literature. Estimates for 
TDL included in this analysis are: (1) TDL due to systemic adverse reactions (2) TDL 
due to outpatient visits (3) TDL due to time spent in sick quarters (4) TDL due to time 
spent hospitalized for FRI (5) TDL due to time spent hospitalized for adenovirus 
pneumonia; (6) TDL due to reduced productivity.  
3.14.1. TRAINING DAYS LOST TO SYSTEMIC ADVERSE REACTIONS 
Systemic adverse events such as abdominal pain, diarrhea, headache and/or cough do not 
require a visit to a healthcare professional, but they do affect a basic trainee’s 
productivity. Previous research on the effect vaccine adverse reactions have on work 
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productivity estimates that systemic adverse reactions decrease productivity by ten 
percent. 146 Systemic reactions can begin hours after vaccination and last up to two days, 
therefore, this study assumed systemic reactions lasted for 1.5 training days. 147 To 
calculate TDL due to systemic adverse reactions, number of days of decreased 
productivity was multiplied by the percentage of reduced effectiveness. Therefore, 0.15 
training day was lost for each systemic adverse reaction. 
3.14.2. TRAINING DAYS LOST TO GUILLAIN – BARRE SYNDROME 
Once GBS symptoms develop, they can progress over the course of hours, days, or 
weeks. Most people reach the stage of greatest weakness within the first two weeks after 
symptoms appear. 143 Details in VAERS reports from the Phase IV study showed an 
average of 15 to 25 days between vaccination and disease onset. 142 This study assumed 
basic trainees developed GBS around the 21st day of training. Recovery from GBS is not 
quick, and the recovery period can range from a few weeks to a few years. 143 This 
analysis assumed that trainees did not return to basic training after a diagnosis of GBS. 
To calculate training days lost due to GBS, 21 training days were subtracted from the 
total number of basic training days for the respective service branch. For example, Army 
basic training lasts for 10 weeks, so subtract 21 days from 70 days to get 49 training days 
lost.  
3.14.3. TRAINING DAYS LOST TO OUTPATIENT VISITS 
Outpatient appointment times and basic trainee sick call, which is “a summons for those 
reporting sick to attend treatment,” 148 both take time from training. One study performed 
95 
 
in Marine Corps basic trainees showed that on average, basic trainees spent around two 
hours at sick call. 149 A study performed by the Army looked at the benefits of a self – 
care program in soldiers and showed that on average, the length of time spent at a troop 
medical clinic visit was 1.4 hours. 150 An average of these two values (one hour, 40 
minutes) was calculated, but since our outcome is in days, it was converted into 0.07 
training day lost to be used in this analysis.   
3.14.4. TRAINING DAYS LOST TO SICK QUARTERS 
Previous Navy research stated that basic trainees receiving outpatient services who were 
not hospitalized spent an average of 2.5 days in sick quarters. 10 During an FRI outbreak 
at Fort Benning in 2000, basic trainees with FRI who were not hospitalized were placed 
in sick quarters for an average of 2.1 days. 47 Studies on training time lost to FRI in other 
service branches were not available. Therefore, an average of the two study values was 
calculated and used in this analysis. For this analysis, training days lost to sick quarters 
was 2.3 days.  
3.14.5. TRAINING DAYS LOST TO FRI HOSPITALIZATION 
Previous cost – effectiveness analyses used an average inpatient hospitalization stay of 
three to four days. 9 – 10 A 2002 study on an outbreak at the Naval Recruit Training Center 
showed that basic trainees lost an average of three training days because of fever and 
respiratory symptoms.61 Another study of an FRI outbreak at an Army basic training site 
showed that basic trainees were hospitalized for an estimated 2.8 training days. 46 Based 
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on this literature, a three - day hospital stay, resulting in three lost training days, was used 
in this analysis.  
3.14.6. TRAINING DAYS LOST TO ADENOVIRAL PNEUMONIA 
HOSPITALIZATION 
Literature on the development of adenoviral pneumonia as a result of FRI in military 
basic trainees is limited. The one study found addressing adenoviral pneumonia was 
conducted at Lackland Air Force Base and showed that adenoviral pneumonia patients 
spent an average of four days in the hospital. 64 Since this was the only literature 
available, four days was chosen as the length of a hospital stay due to adenoviral 
pneumonia.  
3.14.7. TRAINING DAYS LOST DUE TO LOST PRODUCTIVITY 
Basic trainees with FRI participating in training are likely to be less efficient. Several 
economic studies have addressed the impact influenza – like illness has on a worker’s 
productivity. Three levels of reduced efficiency were analyzed in these studies, including 
70 percent, 50 percent, and 30 percent. 146 Even though these studies were not performed 
in military basic trainees, the calculation used to determine lost productivity could be 
used in the military population. To calculate training days lost, the number of days basic 
trainees wait before visiting a health care professional was needed. One epidemiologic 
investigation of an FRI outbreak at Fort Jackson revealed that on average, basic trainees 
waited 3.1 days before seeking medical treatment for an FRI. 46 Therefore, basic trainees 
were less efficient for 3.1 days before seeking medical attention. Since this was the only 
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value found concerning the length of time basic trainees wait before seeking health care, 
it was the value used to calculate training days lost. This pre – treatment duration was 
assumed to be the same for all basic trainees seeking treatment.  To calculate lost training 
days using 50 percent as the percent of reduced effectiveness, the number of days of 
reduced productivity (3.1 days) was multiplied by 50 percent to get 1.6 training days lost 
due to decreased productivity. Information on reduced productivity after outpatient 
and/or inpatient treatment does not exist. Therefore, lost productivity was only 
considered for the time period before treatment.  
All TDL variables are shown in table 3.12.  
3.15. WILLINGNESS – TO – PAY THRESHOLD 
Little research on the amount individuals are willing to pay to avoid febrile respiratory 
illness exists. Since the US military is currently the only consumer of the adenovirus 
vaccine, no information is available on the DoD’s willingness – to – pay (WTP) for FRI 
prevention. The DoD uses a different WTP threshold for each new vaccine. A common 
willingness – to – pay value used in economic analyses is $50,000 per quality – adjusted 
life year (QALY). However, using this threshold to judge new treatment is criticized for 
being unrealistic, not generalizable, and not scientifically defined. 151 Using the WTP 
threshold of $50,000 for vaccines is impractical.  
A WTP threshold for adenovirus – associated FRI hospitalization was not published in 
the literature. Therefore, for part I, the WTP threshold was based on results from a 2007 
survey that used time trade off or willingness – to – pay questions to ask respondents to 
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value seasonal influenza illness, including hospitalization, and possible vaccine – related 
adverse events. Median WTP amounts to avoid an influenza – related hospitalization 
ranged from $500 to $2,750. 152 To determine the WTP threshold for part I of this study, 
an average of the two values was calculated, which resulted in a WTP threshold of 
$1,625. Therefore, the WTP threshold to avoid FRI hospitalization was $1,625 per case. 
Since an adenovirus vaccine WTP threshold was not published, studies analyzing WTP 
for flu – like illness, acute illness, and the influenza vaccine were used in this analysis. A 
2012 study used a survey – based approach to measure individuals WTP to avoid death, 
blindness, and specific illnesses, with one of those illnesses being flu – like illness. The 
study found that the mean individuals were WTP to prohibit an episode of flu – like 
illness was $403 per day, which was $409 per day in 2013 US dollars. 153 Another study 
measured individuals WTP to avoid one symptom day of acute illness. Results showed 
the median WTP to avoid one symptom day of acute illness in 2000 dollars ranged from 
$67 for an acute illness with mild symptoms to $114 for an acute illness with severe 
symptoms. These values were converted to 2013 US dollars, which equaled $91 and $154 
for mild and severe symptoms respectively.154 Lastly, a 2001 survey – based study in 
North Carolina found people’s WTP to avoid one day of influenza was $15.49, which is 
$20 in 2013 US dollars. 155 The WTP values from these articles were averaged and 
resulted in a WTP of $184. However, for this analysis, the WTP was rounded to $200. .  
99 
 
TABLE 3.12.  REFERENCE CASE INPUT VARIABLES FOR ALL SERVICE 
BRANCHES 
[P] = Probability; AdV = Adenovirus; FRI = Febrile Respiratory Illness; GBS = Guillain – Barre Syndrome; † Personal 




VARIABLES BASE LOW HIGH SOURCE 
     
PROBABILITIES     
[P] of sick quarters only 0.950 0.760 0.990 [10] 
[P] developing adenoviral 
pneumonia 
0.08000 0.072 0.152 [136 – 139] 
[P] systemic adverse 
reactions 
0.10000 0.080 0.120 [146] 
[P] Guillain – Barre 
Syndrome (GBS) 
0.00005 0.000005 0.0005 [141 – 142] 
     
COSTS     
Adenovirus vaccine     
Tablet costs $125.45   [Expert]† 
Shipping costs $0.67   [Expert]† 
Administration $0.10   [9 – 10] 
AdV vaccine total $126.22 $100.98 $151.46  
GBS per patient $243,342.66 $194,674.13 $292,011.19 [145] 
     
TRAINING DAYS LOST 
(TDL) 
    
Systemic adverse 
reactions 
0.15 0.03 0.18 [146 – 147] 
Outpatient visits 0.07 0.056 0.084 [149 – 150] 
Sick quarters 2.30 1 3 [10, 47] 
FRI Hospitalization 3 1 12 [9 – 10 , 46, 61] 
Adenoviral pneumonia 
hospitalization 
4 3 7  
[64] 
Lost productivity  1.6 0.93 2.17 [46, 146] 
GBS TDL      
ARMY 49 39 59 [141 – 142] 
NAVY 35 28 42  
MARINE CORPS 63 50 76  
AIR FORCE 39 31 47  
COAST GUARD 35 28 42  
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3.16. SENSITIVITY ANALYSES – PART II 
To determine the robustness of the model used in Part II, a one – way sensitivity analysis 
was performed on each cost, effectiveness, and probability parameter. A tornado diagram 
was constructed to indicate variables that showed the most change. A probabilistic 
sensitivity analysis using Monte Carlo simulation was performed on all parameters 
simultaneously. Triangular, beta, and gamma distributions were used for TDL, 
probabilities, and cost estimates respectively. When range estimates were not available in 
the literature, estimates for costs and probabilities were varied by +/- 20 percent.   
3.17. ASSUMPTIONS FOR DECISION TREE - PART II 
Assumptions made for decision tree model two are outlined below: 
1. All basic trainees received the adenovirus vaccine within two days of 
arriving at the basic training site 
2. FRI was assumed to be contracted from the basic training environment 
and transferred from person – to – person, so the potential for herd 
immunity was not included in this analysis 
3. Due to the lack of a CPT code associated with FRI, the average maximum 
allowable charge for outpatient office visits for new patients (CPT codes 
99201 – 99205) and established patients (CPT codes 99211 – 99215) was 
assumed to estimate outpatient costs 
4. Due to the lack of one specific FRI – associated DRG code, an average 
reimbursement rate for DRG code 203 and DRG code 206 was calculated 
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ASSUMPTIONS FOR DECISION TREE – PART II (CONTINUED) 
5. TRICARE reimbursement amounts were the actual costs allowed by the 
DoD for FRI treatment 
6. Patients who attended an outpatient clinic and were not hospitalized were 
treated in sick quarters for 2.3 days 
7. Basic trainees developed GBS around day 21 of training 
8. Basic trainees who developed GBS did not return to basic training 
9. Lost productivity pre – treatment duration was the same for all basic 
trainees 
 
3.17. INPUT TABLES 
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TABLE 3.13 ARMY MODEL INPUT VARIABLES  
[P] = Probability; DoD = Department of Defense; CPT = Current Procedural Terminology; FRI = Febrile Respiratory Illness; DRG = Diagnosis Related Group;† = Costs 





VARIABLES BASE LOW HIGH SOURCE COMMENTS 
      
PROBABILITIES      
[P] of FRI without vaccine 0.085 0.068 0.102 [6, 117]  
[P] of FRI with vaccine 0.009 0.008 0.010 [117]  
[P] of hospitalization due to FRI 0.213 0.135 0.440 [46]  
TRAINING/DoD COSTS†      
Training per day $240 $192 $288 [123]  
DoD Costs per day $137 $50 $151 [125]  
Total $377 $242 $439   
OUTPATIENT COSTS      
Outpatient visit, New $83 $73 $113 [128] Average cost of CPT codes 99201 - 99205 
Outpatient visit, Est.  $52 $44 $73 [128] Average cost of CPT codes 99211 - 99215 
INPATIENT COSTS      
FRI hospitalization 
 (DRG 203/206) 
$7,175 $5,740 $8,610 [131] [(Adjusted standardized amount)*(DRG 
weight)] 
Adenoviral pneumonia  
(DRG 194 with complications) 
$10,554 $8,443 $12,665 [131]  
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TABLE 3.14 NAVY MODEL INPUT VARIABLES 
 [P] = Probability; * Great Lakes, IL falls in a domestic catchment area, so an adjusted standardized amount for a military treatment facility is not available for this 
training center; DoD = Department of Defense; CPT = Current Procedural Terminology; FRI = Febrile Respiratory Illness; DRG = Diagnosis Related Group;† = Costs 







VARIABLES BASE LOW HIGH SOURCE COMMENTS 
      
PROBABILITIES      
[P] of FRI without vaccine 0.092 0.074 0.110 [6]  
[P] of FRI with vaccine 0.010 0.008 0.012 [119]  
[P] of hospitalization due to FRI 0.181 0.145 0.217 [Estimate] Estimate based on hospitalization data for 
other services 
TRAINING/DOD COSTS†      
Training per day $268 $214 $321 [123]  
DoD Costs per day $119 $48 $138 [125]  
Total per day  $387 $262 $459   
OUTPATIENT COSTS      
Outpatient, New $97 $83 $129 [128] Average cost of CPT codes 99201 -  99205 
Outpatient, Est. $58 $49 $83 [128] Average cost of CPT codes 99211 - 99215 
INPATIENT COSTS      
FRI hospitalization  
(DRG 203/206) 
$4,065 $3,252 $4,878 [131] [(Adjusted standardized amount)*(DRG 
weight)] 
Adenoviral pneumonia  
(DRG 194 with complications) 
$3,964 $3,172 $4,757 [131]  
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TABLE 3.15 MARINE CORPS MODEL INPUT VARIABLES 
 [P] = Probability; DoD = Department of Defense; CPT = Current Procedural Terminology; FRI = Febrile Respiratory Illness; DRG = Diagnosis Related Group; † = All 







VARIABLES BASE LOW HIGH SOURCE COMMENTS 
      
PROBABILITIES      
[P] of FRI without vaccine 0.045 0.036 0.054 [6]  
[P] of FRI with vaccine 0.004 0.003 0.004 [119]  
[P] of hospitalization due to FRI 0.259 0.207 0.311 [Estimate] Estimate based on hospitalization data for 
other service branches 
TRAINING/DoD COSTS†      
Training per day $171 $136 $205 [123]  
DoD Costs per day $115 $50 $134 [125]  
Total Per Day $286 $186 $339   
OUTPATIENT COSTS      
Outpatient Visit, New $87 $74 $117 [128] Average cost of CPT codes 99201 - 99205 
Outpatient Visit, Est.  $53 $45 $77 [128] Average cost of CPT codes 99211 - 92215 
INPATIENT COSTS      
FRI hospitalization  (DRG 203/206) $9,075 $7,260 $10,890 [131] [(Adjusted standardized amount)*(DRG 
weight)] 
Adenoviral pneumonia  
(DRG 194 with complications)  




TABLE 3.16 AIR FORCE MODEL INPUT VARIABLES 
[P] = Probability; DoD = Department of Defense; CPT = Current Procedural Terminology; FRI = Febrile Respiratory Illness; DRG = Diagnosis Related Group;†= All 






VARIABLES BASE LOW HIGH SOURCE COMMENTS 
      
PROBABILITIES      
[P] of FRI without vaccine 0.108 0.086 0.130 [6]  
[P] of FRI with vaccine  0.014 0.011 0.017 [119]  
[P] of hospitalization due to FRI 0.198 0.159 0.238 [48]  
TRAINING/DoD COSTS†      
Training per day $112 $90 $135 [123]  
DoD Costs per day $110 $47 $129 [125]  
Total Per Day $222 $137 $264   
OUTPATIENT COSTS      
Outpatient, New $85 $73 $113 [128] Average cost of CPT codes 99201 - 99205 
Outpatient, Est. $52 $44 $73 [128] Average cost of CPT codes 99211 - 99215 
INPATIENT COSTS      
FRI hospitalization  
(DRG 203/206) 
$10,836 $8,669 $13,003 [131] [(Adjusted standardized amount)*(DRG 
weight)] 
Adenoviral pneumonia  
(DRG 194 with complications) 
$15,940 $12,752 $19,128 [131]  
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TABLE 3.17 COAST GUARD MODEL INPUT VARIABLES 
 [P] = Probability ; *Training costs for the US Coast Guard are not available, so this is an estimate based on the average of other service branch training costs; † Cape 
May, New   Jersey does not fall in a military treatment facility catchment area, so costs are based on adjusted standardized amount for domestic inpatient facility; ‡ = All 
costs are rounded to the nearest dollar; DoD = Department of Defense; CPT = Current Procedural Terminology; FRI = Febrile Respiratory Illness; DRG = Diagnosis 
related group 
 
VARIABLES BASE LOW HIGH SOURCE COMMENTS 
      
PROBABILITIES      
[P] of FRI without vaccine 0.039 0.031 0.047 [6]  
[P] of FRI with vaccine 0.005 0.004 0.006 [119]  
[P] of hospitalization for 
FRI 
0.181 0.145 0.217 [Estimate] Estimate based on hospitalization data for 
other services 
TRAINING/DOD COSTS‡      
Training per day  $254* $251 $301 [123]  
DoD Costs per day $119 $49 $148 [125]  
Total Per Day $373 $300 $449   
OUTPATIENT COSTS      
Outpatient, New $95 $79 $128 [128] Average cost of CPT codes 99201 - 99205 
Outpatient, Est.  $56 $48 $83 [128] Average cost of CPT codes 99211 - 99215 
INPATIENT COSTS      
FRI hospitalization  
(DRG 203/206) 
$4,219 $3,375 $5,063 [131] [(Adjusted standardized amount)*(DRG 
weight)] 
Adenoviral pneumonia 
(DRG 194 with 
complications) 
$5,642 $4,575 $6,771 [131]  
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CHAPTER 4: RESULTS 
 
Chapter 4 includes the results of each of the study objectives, cost – effectiveness analyses, and 
sensitivity analyses. Results are divided into two parts based on the model that was used.  
4.1. OBJECTIVES FOR PART I  
Part I used Howell et al.’s and Hyer et al.’s decision tree with current military service branch – 
specific information from the literature and experts on the adenovirus vaccine to accomplish 
objectives one through four.  
4.1.1. OBJECTIVE 1 was to calculate and compare direct medical costs, including inpatient and 
outpatient costs only, for the adenovirus vaccination strategy and the no vaccination strategy. 
The hypothesis tested for this objective was that annual direct medical costs associated with 
adenovirus type 4 and type 7 vaccination were less than annual direct medical costs associated 
with no vaccination. This hypothesis was the same for all service branches of the US military.   
 H1:  Direct Medical Costs AdV Vaccination < Direct Medical Costs No Vaccination 
Direct medical costs associated with FRI treatment included outpatient office visits and 
hospitalizations. Vaccine costs were not included in direct medical costs.  
 4.1.1.1. ARMY  
 Direct medical costs for the Army were based on an annual basic trainee population of 
 75,373. The adenovirus vaccination program cost the Army approximately $1.1 million 
 annually in direct medical costs, while no vaccination costs $10.4 million. This showed 
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 that annual direct medical costs with the adenovirus vaccination program were less than 
 direct medical costs associated with no adenovirus vaccination. Therefore, hypothesis 1 
 was not rejected for the Army.  
 4.1.1.2. NAVY  
 Direct medical costs for the Navy were based on an annual basic trainee population of 
 36,565. The adenovirus vaccination program cost the Navy approximately $330,838 in 
 direct medical costs, while no adenovirus vaccination costs $2.83 million.  This indicated 
 that direct medical costs to the Navy associated with adenovirus program were less than 
 those associated with no adenovirus vaccination, leading to hypothesis 1 not being 
 rejected.  
 4.1.1.3. MARINE CORPS 
 Direct medical costs for the Marine Corps were based on an annual basic trainee 
 population of 29,757. The adenovirus vaccination program cost the Marine Corps 
 approximately $282,196 in direct medical costs, while no adenovirus vaccinations costs 
 $3.27 million  in direct medical costs. This showed that direct medical costs to the 
 Marine Corps  associated with the adenovirus program were less than those associated 
 with no AdV vaccination, leading to hypothesis 1 not being rejected.  
 4.1.1.4. AIR FORCE 
 Direct medical costs for the Air Force were based on an annual basic trainee population 
 of 36,392. The adenovirus vaccination program cost the Air Force approximately $1.1 
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 million annually in direct medical costs, while no vaccination direct medical costs 
 equaled $8.8 million. This showed that annual direct medical costs to the Air Force 
 associated with the adenovirus program are less than those associated with no 
 vaccination, leading to hypothesis 1 not being rejected.  
 4.1.1.5. COAST GUARD 
 Direct medical costs for the Coast Guard were based on an annual basic trainee 
 population of 2,136. The adenovirus program cost the Coast Guard approximately $9,327 
 annually, while no vaccination direct medical costs equaled $72,274. This illustrated 
 that annual direct medical costs to the Coast Guard associated with the adenovirus 
 program were less than those associated with no vaccination, leading the researcher to not 
 reject hypothesis 1.  
 4.1.1.6. SUMMARY HYPOTHESIS 1 
 Annual direct medical costs associated with adenovirus vaccination were less than those 
 associated with no adenovirus vaccination in all service branches of the US military. 
 Hypothesis 1 was not rejected for each service branch in the military.  
4.1.2. OBJECTIVE 2 was to estimate and compare annual lost training costs associated with 
adenovirus vaccination and no vaccination. Hypothesis 2 posited that lost training costs 
associated with adenovirus type 4 and type 7 vaccination were less than lost training costs 
associated with no vaccination 
  H2: Lost Training Costs AdV Vaccination < Lost Training Costs No Vaccination 
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As mentioned above, training costs include actual training costs of the facility and costs to the 
DoD.  
 4.1.2.1. ARMY 
 The adenovirus vaccination strategy cost the Army approximately $720,447 
 annually in lost training costs, while the no adenovirus strategy cost the Army 
 approximately $6.81 million in lost training costs. These numbers indicated that lost 
 training costs for the adenovirus vaccination strategy were less than lost training costs for 
 the no adenovirus vaccination strategy, leading the researcher to not reject hypothesis 2.  
 4.1.2.2. NAVY 
 The adenovirus vaccination strategy costs the Navy approximately $392,418  
 annually in lost training costs, while the no adenovirus strategy costs the Navy 
 approximately $3.61 million in lost training costs. Therefore, annual lost training costs 
 for the adenovirus vaccination strategy were less than annual lost training costs for the no 
 vaccination strategy, leading the researcher to not reject hypothesis 2.  
 4.1.2.3. MARINE CORPS 
 The adenovirus vaccination strategy costs the Marine Corps approximately $98,098 
 annually in lost training costs, while the no adenovirus strategy costs the Marine Corps  
 approximately $1.11 million in lost training costs. Therefore, annual lost training costs 
 for the adenovirus vaccination strategy were less than annual lost training costs for the no 
 vaccination strategy, leading the researcher to not reject hypothesis 2.  
111 
 
 4.1.2.4. AIR FORCE 
 The adenovirus vaccination strategy costs the Air Force approximately $316,794 
 annually in lost training costs, while the no adenovirus strategy costs the Air Force  
 approximately $2.4 million in lost training costs. Therefore, annual lost training costs for 
 the adenovirus vaccination strategy were less than annual lost training costs for the no 
 vaccination strategy, leading the researcher to not reject hypothesis 2. 
 4.1.2.5. COAST GUARD 
 The adenovirus vaccination strategy costs the Coast Guard approximately $11,563
 annually in lost training costs, while the no adenovirus strategy costs the Coast Guard 
 approximately $85,790 in lost training costs. Therefore, annual lost training costs  for the 
 adenovirus vaccination strategy were less than annual lost training costs for the no 
 vaccination strategy, leading the researcher to not reject hypothesis 2.  
 4.1.2.6. SUMMARY HYPOTHESIS 2 
 Annual lost training costs associated with adenovirus vaccination were less than those 
 associated with no adenovirus vaccination in all service branches of the US military. 
 Hypothesis 2 was not rejected for each service branch in the military. 
4.1.3. OBJECTIVE 3 was to estimate annual total costs associated with the adenovirus 
vaccination strategy and the no vaccination strategy. The hypothesis tested for objective 3 
postulates that annual total costs associated with the adenovirus vaccination strategy are less than 
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annual total costs associated with the no adenovirus vaccination strategy. Annual total costs 
included vaccination, direct medical, and lost training costs. 
 H3: Total Costs AdV Vaccination < Total Costs No Vaccination 
 4.1.3.1. ARMY 
 The adenovirus vaccination strategy costs the Army approximately $11.3 million
 annually in total costs, while the no adenovirus strategy costs the Army $17.2 million  
 in total costs. Therefore, total annual costs for the adenovirus vaccination strategy were 
 less than total annual costs for the no vaccination strategy, leading the researcher to not 
 reject hypothesis 3. 
 4.1.3.2. NAVY 
 The adenovirus vaccination strategy costs the Navy approximately $5.34 million in total 
 annual costs, while the no adenovirus strategy costs the Navy $6.44 million in total 
 annual  costs. Therefore, total annual costs for the adenovirus vaccination strategy were 
 less than total annual costs for the no vaccination strategy, leading the researcher to not 
 reject hypothesis 3. 
 4.1.3.3. MARINE CORPS 
 The adenovirus vaccination strategy costs the Marine Corps approximately $4.14 million 
 in total annual costs, while the no adenovirus strategy costs the Marine Corps $4.37 
 million in total annual costs. Therefore, total annual costs for the adenovirus vaccination 
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 strategy were less than total annual costs for the no vaccination strategy, leading the 
 researcher to not reject hypothesis 3. 
 4.1.3.4. AIR FORCE 
 The adenovirus vaccination strategy costs the Air Force approximately $6.04 million 
 in total annual costs, while the no adenovirus strategy costs the Air Force $11.25 million 
 in total annual costs. Therefore, total annual costs for the adenovirus vaccination strategy 
 to the Air Force were less than total annual costs for the no vaccination strategy, leading 
 the researcher to not reject hypothesis 3. 
 4.1.3.5. COAST GUARD 
 The adenovirus vaccination strategy costs the Coast Guard approximately $290,496 
 in total annual costs, while the no adenovirus strategy costs the Coast Guard $158,064 in 
 total annual costs. In contrast to all other service branches, total annual costs for the 
 adenovirus vaccination strategy to the Coast Guard were greater than total annual costs 
 for the no vaccination strategy, leading to the rejection of hypothesis 3. 
 4.1.3.6. SUMMARY HYPOTHESIS 3 
 Annual total costs associated with adenovirus vaccination were less than those 
 associated with no adenovirus vaccination in all service branches of the US military 
 except for the Coast Guard. Hypothesis 3 was not rejected for the Army, Navy, Marine 
 Corps, and Air Force, but rejected for the Coast Guard. All numbers for the first three 
 hypotheses are shown in Table 4.1.  
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TABLE 4.1 REFERENCE CASE EXPECTED COSTS† UNDER ADENOVIRUS VACCINATION STRATEGIES 
FOR U.S. SERVICE BRANCHES 
















      
ARMY  
(n = 75,373) 
     
AdV Vaccination $9,513,580 $1,071,923 $720,447 $11,305,950 $5,879,094 
No Vaccination  $10,374,539 $6,810,505 $17,185,044  
NAVY 
 (n = 36,565) 
     
AdV Vaccination $4,615,234 $330,838 $392,418 $5,338,490 $1,096,950 
No Vaccination  $2,827,052  $3,608,388 $6,435,440   
MARINE CORPS 
(n = 29,757) 
     
AdV Vaccination $3,755,929 $282,196 $98,098 $4,136,223  $238,056  
No Vaccination  $3,268,031 $1,106,248 $4,374,279  
AIR FORCE  
(n = 36,592) 
     
AdV Vaccination $4,593,398 $1,130,879 $316,794 $6,041,071  $5,204,057  
No Vaccination  $8,804,904 $2,440,224 $11,245,128   
COAST GUARD 
 (n = 2,136) 
     
AdV Vaccination $269,606 $9,327 $11,563 $290,496 - $132,432 
No Vaccination  $72,274 $85,790 $158,064   
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4.1.4. OBJECTIVE 4 was to evaluate the cost – effectiveness of adenovirus vaccines as 
measured by FRI hospitalizations prevented by computing an incremental cost – 
effectiveness ratio (ICER).  A negative incremental cost – effectiveness ratio indicates a 
cost – saving strategy. Hypothesis 4 postulated that the ICER was less than zero.  
  H4: ICER < 0 
 4.1.4.1. ARMY, NAVY, MARINE CORPS, AND AIR FORCE 
 Before calculating the ICER, annual number of FRI hospitalizations prevented 
 was calculated in each service branch for each vaccination strategy.  Adenovirus 
 vaccination prevented 1,221, 543, 317, 677, and 13 FRI hospitalizations annually 
 in the Army, Navy, Marine Corps, Air Force, and Coast Guard respectively. This 
 number was then divided by annual number of basic trainees to determine the 
 average number of FRI hospitalizations prevented. Table 4.2 shows the base case 
 results of the decision analysis in terms of incremental cost – effectiveness. The 
 ICER was negative in all service branches but the Coast Guard. These resulting 
 ICER values indicate that adenovirus vaccination is the dominant strategy 
 compared with no adenovirus vaccination when measured by hospitalizations for 
 FRI prevented. Therefore, hypothesis 4 is not rejected in all service branches but 
 the Coast Guard. 
 4.1.4.2. COAST GUARD 
 The Coast Guard was the only service branch in the military that resulted in a 
 positive ICER. Implementation of the adenovirus vaccination program costs the 
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 Coast Guard $10,187 per case of FRI hospitalization prevented, which was 
 greater than the WTP  threshold of $1,625 per case of FRI hospitalization.   
 4.1.4.3. SUMMARY HYPOTHESIS 4 
 The ICER as measured by hospitalizations prevented was less than 0 in the Army, 
 Navy,  Marine Corps, and Air Force. However, the Coast Guard’s ICER was 
 greater than 0. These results indicate that the adenovirus vaccination strategy is 
 the dominant strategy  when compared to a no vaccination strategy in the Army, 
 Navy, Marine Corps, and Air  Force.   











AdV Vaccination $150 0.0019    
No Vaccination $228 0.0181 $78 -0.0162 -4,815 
NAVY 
AdV Vaccination $146 0.0018    
No Vaccination $176 0.0167 $30 -0.0149 -2,013 
MARINE CORPS 
AdV Vaccination $139 0.0010    
No Vaccination $147 0.0117 $8 -0.0107 -748 
AIR FORCE 
AdV Vaccination $166 0.0028    
No Vaccination $309 0.0214 $142 -0.0186 -7,634 
COAST GUARD 
AdV Vaccination $136 0.0009    
No Vaccination $74 0.0070 - $62 -0.0061 -10,163 
      
EFF = Effectiveness in terms of cases of FRI hospitalization; IC = Incremental Cost; IE = Incremental Effectiveness; 
ICER = Incremental Cost – Effectiveness Ratio; AdV = Adenovirus; † = All costs are rounded to the nearest dollar; 




4.2. SENSITIVITY ANALYSIS FOR PART 1 TORNADO DIAGRAMS 
Tornado diagrams show which model parameters have the largest impact on the decision 
analysis model. For each service branch, a tornado diagram was produced for all cost and 
probability parameters.  
 4.2.1. ARMY  
 The cost and probability parameter tornado diagrams for the Army are shown in 
 Figures 4.1 and 4.2. Figure 4.1 indicates that the cost of the adenovirus vaccine 
 has the largest  impact on the model, while results from Figure 4.2 show that 
































 4.2.2. NAVY 
 Cost and probability tornado diagrams for the Navy are shown in Figures   
 4.3 and 4.4. Like with the Army, Figure 4.3 shows that the cost of the   
 adenovirus vaccine had the largest impact on the model. Figure 4.4 shows   
 that the probability of FRI during times without the adenovirus    
 vaccination has a large impact on the Navy model.  
  














 4.2.3. MARINE CORPS 
 Figures 4.5 and 4.6 show cost and probability tornado diagrams for the Marine 
 Corps.  Just like the Army and Navy, the cost diagram, Figure 4.5, indicates that 
 cost of vaccine has the largest impact on the model. The probability with the 
 largest impact was the probability of FRI when adenovirus vaccination is not 
 available, which is shown in  Figure  4.6. The variable, cost of the adenovirus 
 vaccine, had a threshold value of $134.  














4.2.4. AIR FORCE 
 Figures 4.7 and 4.8 show tornado diagrams for costs and probabilities for the Air  
 Force.  Like with the Army, Navy, and Marine Corps, the tornado diagram shows 
 that the cost with the largest impact on the model was the cost of the adenovirus 
 vaccine. The cost tornado diagram is shown in Figure 4.7.  In addition, like the 
 Navy and Marine Corps, the tornado diagram in Figure 4.8 indicates that the 
 probability with the largest impact is the probability of FRI when an adenovirus 

































4.2.5. COAST GUARD 
 The tornado diagrams for the Coast Guard model are shown in Figures 4.9 and 
 4.10. Figure 4.9 shows that like all other service branches, the cost with the 
 largest impact on the model is the cost of the vaccine. The probability tornado 
 diagram also indicates that the probability with the largest impact is the 
 probability of FRI when the adenovirus vaccine is not available. The probability 
 tornado diagram is shown in Figure 4.10. This is the same result seen in all 

































4.3. ONE – WAY SENSITIVITY ANALYSES – PART I 
One – way sensitivity analyses were conducted on all cost (+/- 20%) and probability 
parameters (+/- 20%). The threshold value represents the point at which changes in the 
variable cause the vaccination strategy to no longer be cost – saving. If a variable was 
sensitive to changes in value, it was discussed below.  
 4.3.1. ARMY 
 The adenovirus vaccine strategy was the dominant strategy. Results were 
 insensitive to variations in all cost estimates but the cost of the adenovirus 
 vaccine. The threshold value was $204. Therefore, if the vaccine price increased 
 to above $204, the no adenovirus vaccine strategy would be dominant.  
 4.3.2. NAVY 
 The adenovirus vaccine strategy was the dominant strategy. Results were 
 insensitive to all variations in all cost estimates but the cost of the adenovirus 
 vaccine. The threshold value was $156. If the price of the adenovirus vaccine was 
 more than $156, the adenovirus vaccination strategy would not be the dominant 
 strategy anymore.   
 4.3.3. MARINE CORPS 
 The adenovirus vaccine strategy was the dominant strategy for the Marine Corps. 
 Results were insensitive to all variations in all cost estimates but the cost of the 
 adenovirus vaccine and all probability values but the probability of FRI without 
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 vaccination. The threshold value for cost of the vaccines was $134. If the price of 
 the adenovirus vaccine was more than $134, the adenovirus vaccination strategy 
 would not be the dominant strategy anymore. Further analysis of the variable, 
 probability of FRI without vaccination, showed that when this value decreased 
 below 0.0076, the adenovirus vaccination strategy ceased to be the dominant 
 vaccination strategy. 
 4.3.4. AIR FORCE 
 The adenovirus vaccine strategy was the dominant strategy in Air Force basic 
 trainees. Results were insensitive to variations in all cost and probability 
 estimates. 
 4.3.5. COAST GUARD 
 Neither the adenovirus vaccine strategy nor the no vaccine  strategy was 
 dominant. Results were insensitive to variations in all cost and probability 
 estimates.  
4.4. OBJECTIVES FOR PART II 
4.4.1. OBJECTIVE 5 involved the development of a decision analysis model using 
military - specific data collected from the literature and experts on the military’s 
adenovirus vaccine. No hypothesis was developed for this objective. 
The final decision tree was developed using data collected from the literature and experts 
on the military’s adenovirus vaccine. The decision tree is mainly based on Howell et al.’s 
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and Hyer et al.’s decision tree used in part 1 of this study. The model was assessed by 
estimating the average cost per training day lost. Figure 4.11 illustrates the two 
vaccination strategies compared. A description of model parameters is shown in appendix 
A.  
 




For the adenovirus vaccination branch, there are three possible adverse reaction pathways 
that are assessed: no adverse reactions, minor adverse reactions, and Guillain – Barre 
Syndrome. The GBS pathway is a terminal pathway because a basic trainee developing 
GBS will not return to basic training. The three pathways attached to the adenovirus 






FIGURE 4.12. ADENOVIRUS VACCINE ADVERSE REACTION BRANCH 
  
Two pathways are connected to the adverse reaction branches and are assessed. These 
pathways include a develop FRI branch and not develop FRI branch. The no FRI branch 
ends with a terminal node. From this point on, the branches for both vaccination 











FIGURE 4.13.  FRI PATHWAYS FROM ALL BRANCHES 
 
 
If a trainee develops FRI, he/she either receives outpatient treatment only, outpatient 
treatment with follow – up, or hospitalization. Two possible pathways diverge from the 
FRI branch. These pathways include outpatient treatment or hospitalization. This is 





FIGURE 4.14. DECISION TREE TERMINAL BRANCHES  
 
The outpatient service branch terminates with sick quarters only or sick quarters plus a 
follow – up outpatient visit. The hospitalization branch terminates with uncomplicated 
FRI or FRI complicated by pneumonia.  
4.4.2. OBJECTIVE 6 was to estimate and compare training days lost (TDL) associated 
with each adenovirus vaccination strategy. Hypothesis 5 postulates that TDL associated 
with adenovirus vaccination is less than TDL associated with no vaccination.  
  H5: TDL AdV Vaccination  <  TDL No Vaccination 
The average TDL is less than one day, so it is difficult to see the impact of the 




  4.4.2.1. ARMY 
  For the Army, the average TDL for the adenovirus vaccination strategy  
  was 0.05 TDL (1 hour, 12 minutes), while the average TDL for the no  
  adenovirus vaccination strategy was 0.35 TDL (8 hours, 40 minutes).  
  Annual TDL for the adenovirus vaccine strategy was 3,768.65, while the  
  no vaccination strategy resulted in 26,380.55 TDL. When comparing the  
  two adenovirus vaccination strategies, the average TDL averted was 0.30  
  and the annual TDL averted was 22,611.9. These results illustrate that  
  TDL with the adenovirus vaccination strategy is less than TDL with the no 
  vaccination strategy, which leads the researcher to not reject hypothesis 5.  
  4.4.2.2. NAVY 
  Results for the Navy show that the average TDL for the adenovirus  
  vaccination strategy was 0.06 TDL (1 hour, 26 minutes), while the average 
  TDL for the no adenovirus vaccination strategy was 0.38 TDL (9 hours).  
  Annual TDL for the adenovirus vaccination strategy was 2,193.9 TDL,  
  while the no vaccination strategy resulted in an annual TDL of 13,894.7  
  TDL. When comparing the two strategies, the average TDL averted (net  
  outcome) was 0.32 and the annual TDL averted was 11,700.8. These  
  results demonstrate that TDL with the adenovirus vaccination strategy is  
  less than TDL with the no vaccination strategy in the Navy, which led the  
  researcher to not reject hypothesis 5.  
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  4.4.2.3. MARINE CORPS 
  Results for the Marine Corps show that average TDL for the adenovirus  
  vaccination strategy was 0.02 TDL (30 minutes), while the average TDL  
  for the  no adenovirus vaccination strategy was 0.19 TDL (4 hours, 32  
  minutes). Annual TDL for the adenovirus vaccination strategy was 595.14  
  TDL and 5653.83 TDL for the no vaccination strategy. When comparing  
  the two strategies, the average TDL averted was 0.17 and the annual TDL  
  averted was 5,058.69. These results illustrate that TDL with the   
  adenovirus vaccination strategy is less than TDL with the no vaccination  
  strategy in the Marine Corps, which leads the researcher to not   
  reject hypothesis 5.  
  4.4.2.4. AIR FORCE 
  Results for the Air Force show that average TDL for the adenovirus  
  vaccination strategy is 0.06 TDL (1 hour, 26 minutes) and 0.45 TDL (10  
  hours, 40 minutes) for the no adenovirus vaccination strategy. Annual  
  TDL for the adenovirus vaccination strategy is 2,183.52 TDL, while the  
  annual TDL for the no vaccination strategy is 16,376.4 TDL. When  
  comparing the two vaccination strategies, average TDL averted 0.39 and  
  annual TDL averted was 14,192.88. These results show that TDL for the  
  adenovirus vaccination strategy is less than TDL for the no vaccination  
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  strategy, which leads the researcher to not reject     
  hypothesis 5.  
  4.4.2.5. COAST GUARD 
  Results for the Coast Guard show that average TDL for the adenovirus  
  vaccination strategy is 0.02 TDL (30 minutes) and 0.16 TDL (3 hours, 50  
  minutes) for the no vaccination strategy. Annual TDL for the adenovirus  
  vaccination strategy is 42.72 TDL, while annual TDL for the no   
  vaccination strategy is 341.76 TDL. When comparing the two adenovirus  
  vaccination strategies, average TDL averted was 0.14 and annual TDL  
  averted was 299.04. These Coast Guard results show that TDL for the  
  adenovirus vaccination strategy is less than TDL for the no vaccination  
  strategy, which leads the researcher to not reject hypothesis 5.  
  4.4.2.6. SUMMARY HYPOTHESIS 5 
  Average TDL for the adenovirus vaccination strategy were less than TDL  
  for the  no vaccination strategy in all service branches. Therefore,   






4.4.3. OBJECTIVE 7 was to estimate and compare the average total cost resulting from 
the adenovirus vaccination strategy and the no vaccination strategy. The hypothesis for 
this objective was that the average total cost for the adenovirus vaccination strategy was 
less than the average total cost for the no vaccination strategy.  
  H6: Avg. Total Cost AdV Vaccination  <  Avg. Total Cost No Vaccination 
  4.4.3.1. ARMY 
  Results for the Army show that the average total cost for the adenovirus  
  vaccination strategy is $162.74, while the average total cost for the no  
  adenovirus vaccination strategy is $221.29. When comparing the two  
  strategies, the  incremental cost shows that the no vaccination group’s  
  average total costs are $58.55 more than the adenovirus’ group. This  
  indicates the adenovirus vaccination strategy costs less than the no   
  adenovirus vaccination strategy in the Army, which leads the researcher to 
  not reject hypothesis 6.  
  4.4.3.2. NAVY 
  Navy results indicate that the average total cost for the adenovirus   
  vaccination strategy is $157.27, while the average total cost for the no  
  vaccination strategy is $166.80. The  incremental cost when comparing the 
  two strategies is $9.53, which means the average total cost in the no  
  adenovirus group is $9.53.more than  the average total cost in the   
  adenovirus group. These results show that the adenovirus vaccination  
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  strategy costs less than the no vaccination strategy in the Navy, which  
  leads the researcher to not reject hypothesis 6.  
  4.4.3.3. MARINE CORPS 
  Marine Corps results suggest that the average total cost of the adenovirus  
  vaccination strategy is $152.25, while the average total cost for the no  
  vaccination strategy is $145.90. The incremental cost when comparing the  
  two strategies is - $6.35, which means that the adenovirus vaccination  
  strategy costs more than the no adenovirus vaccination strategy.   
  Therefore, hypothesis 6 was rejected.  
  4.4.3.4. AIR FORCE 
  Air Force results indicate that the average total cost for the adenovirus  
  vaccination strategy is $178.89 and the average total cost for the no  
  vaccination strategy is $309.14. When comparing the two strategies, the  
  incremental cost is $130.25, which indicates the adenovirus vaccination  
  strategy cost less than the no vaccination strategy. The positive   
  incremental cost shows that the adenovirus vaccination strategy costs less  
  than the no adenovirus vaccination strategy in the Air Force, leading the  





  4.4.3.5. COAST GUARD 
  Coast Guard results demonstrate that the average total cost for the   
  adenovirus vaccination strategy is $148.11, while the average total cost for 
  the no adenovirus vaccination strategy is $70.13. When comparing the two 
  strategies, the  incremental cost is - $77.98. The negative incremental cost  
  shows that the  adenovirus vaccination strategy costs more than the no  
  adenovirus vaccination strategy in the Coast Guard, leading to the   
  rejection of hypothesis 6. 
  4.4.3.6. SUMMARY FOR HYPOTHESIS 6 
  The hypothesis tested for objective 7 was that the average total cost for the 
  adenovirus vaccination strategy was less than the average cost for the no  
  adenovirus vaccination strategy.  Army, Navy, and Air Force results led  
  the researcher to not reject hypothesis 6, whereas Marine Corps and Coast  
  Guard results led to the rejection of hypothesis 6.  
4.4.4. OBJECTIVE 8 was to evaluate the cost – effectiveness of adenovirus vaccines as 
measured by TDL averted by computing an incremental cost – effective ratio (ICER). 
The hypothesis tested for this objective is that the ICER is negative, meaning the 
adenovirus vaccination strategy is cost saving.  




  4.4.4.1. ARMY, NAVY, AND AIR FORCE 
  Incremental cost- effectiveness ratios for all service branches are shown in 
  Table 4.3. The cost – effectiveness ratios for the Army, Navy, and Air  
  Force are all negative. The negative ICER indicates that the adenovirus  
  vaccination strategy is the dominant strategy or the most cost – effective  
  strategy when compared with the no  vaccination strategy. The negative  
  ICER led the researcher to not reject hypothesis 7.  
  4.4.4.2. MARINE CORPS AND COAST GUARD 
  The cost – effectiveness ratio for the Marine Corps and Coast Guard are  
  both positive. Neither strategy is dominant, so the decision to use the  
  adenovirus vaccine depends on what the service branch is willing – to –  
  pay per TDL avoided. The interpretation of the cost – effectiveness ratio  
  for the Marine Corps is that they pay $37.35 per TDL averted. The  
  interpretation of the cost – effectiveness ratio for the Coast Guard is  
  $557.00 per TDL averted. The positive ICERs led to the rejection of  








TABLE 4.3. BASE CASE COST – EFFECTIVENESS OF ADENOVIRUS 









AdV Vaccination $162.74 0.05    
No Vaccination $221.29 0.35 $58.55 -0.30 -$195.17 
NAVY 
AdV Vaccination $157.27 0.06    
No Vaccination $166.80 0.38 $9.53 -0.32 -$29.78 
MARINE CORPS 
AdV Vaccination $152.25 0.02    
No Vaccination $145.90 0.19 -$6.35 -0.17 $37.35 
AIR FORCE 
AdV Vaccination $178.89 0.06    
No Vaccination $309.14 0.45 $130.25 -0.39 -$333.97 
COAST GUARD 
AdV Vaccination $148.11 0.02    
No Vaccination $70.13 0.16 -$77.98 -0.14 $557.00 
AdV = Adenovirus; Eff = Effectiveness as defined by training days lost ; IC = Incremental Cost; IE = 
Incremental Effect; ICER = Incremental Cost – effectiveness Ratio; TDL= Training Days Lost 
 
4.5. SENSITIVITY ANALYSES – PART II 
This section reports the results of one – way sensitivity analyses performed on the study 
variables. Tables 4.4 through 4.6 show the variables that had the largest relative impact 
on the results of the cost – effectiveness analysis in the Army, Navy, and Marine Corps 
respectively. All results of the one – way sensitivity analyses are shown in Appendix B. 
Findings were robust across all variables in the Air Force and Coast Guard. The 
adenovirus vaccination strategy was dominant in the Air Force, while no strategy was 




 4.5.1. ARMY ONE - WAY SENSITIVITY ANALYSES RESULTS 
 Table 4.4 shows the two variables that had the largest impact on the results of the  
 cost – effectiveness analysis in Army basic trainees. The conclusion that 
 adenovirus vaccination is more cost – effective than no adenovirus vaccination is 
 sensitive to the cost of the adenovirus vaccine and the probability of developing 
 GBS after vaccination. The optimal strategy would change from the adenovirus 
 strategy to the no adenovirus strategy if the cost of the adenovirus vaccine was 
 greater than $184.77 and the probability of developing GBS after vaccination was 
 greater than 0.00027. Findings were robust across all other variables with the 
 adenovirus vaccination strategy being the dominant strategy.  
 
TABLE 4.4. ARMY ONE –WAY SENSITIVITY ANALYSES RESULTS 







Cost of adenovirus vaccine 
(cADV_VAX) 
126.22 100.98 250.00 
AdV Vaccination vs. No Vaccination -198.91 -284.66 221.61 
[P] of developing GBS after AdV 
vaccination (pGBS) 
0.00005 0.000005 0.0005 
AdV Vaccination vs. No Vaccination  -19.49 -237.15 217.55 






 4.5.2. NAVY ONE – WAY SENSITIVITY ANALYSES RESULTS 
 Table 4.5 shows the variables that had the largest impact on the cost – 
 effectiveness analysis in Navy basic trainees. Cost of the adenovirus vaccine, cost  
 of FRI  hospitalization, and cost of basic training are the cost variables that had 
 the largest impact on cost – effectiveness. Threshold values were $135.75, 
 $3,366.70, and $338.35 for cost of adenovirus vaccine, cost of FRI hospitalization 
 and cost of basic training respectively. Training days lost to FRI hospitalization 
 and sick quarters were the two effectiveness variables that the largest impact on 
 cost – effectiveness. Threshold values were 1.19 and 1.93 for training days lost to 
 FRI hospitalizations and sick quarters respectively. Probability of FRI without 
 vaccine usage, probability of GBS after vaccination, and probability of FRI 
 hospitalization were the probability variables that had an impact on cost – 
 effectiveness. Threshold values were 0.087, 0.00009, and 0.115 for 
 probability of FRI without vaccine usage, probability of GBS after  vaccination, 
 and probability of FRI hospitalization respectively.  Threshold values represent 
 the point at which the optimal strategy changes. Cost – effectiveness conclusions 
 are sensitive to several variables when analyzing Navy basic trainees. Findings 
 were robust across all  other variables with the adenovirus vaccination strategy 





TABLE 4.5. NAVY ONE – WAY SENSITIVITY ANALYSES RESULTS  
[P] = Probability; ICER = Incremental Cost – effectiveness Ratio; TDL = Training Days Lost; FRI = Febrile 





 ICER ($/TDL averted) 
COST VARIABLES ($) 
 BASE LOW HIGH 
Cost of adenovirus vaccine 
(cADV_VAX) 
126.22 100.98 250.00 
AdV Vaccination vs. No Vaccination -29.65 -108.17 355.43 
Cost of FRI hospitalization  
(cHOSP) 
4,067.70 3,257.76 4,877.64 
AdV Vaccination vs. No Vaccination -29.78 4.63 -64.18 
Cost of training (cTRAIN) 360.63 262.15 459.10 
AdV Vaccination vs. No Vaccination -13.74 47.00 -74.46 
EFFECTIVENESS VARIABLES (TDL) 
 BASE LOW HIGH 
Training days lost to FRI hospitalization 
(effFRI_HOSP) 
3 1 12 
AdV Vaccination vs. No Vaccination -40.67 3.48 -128.30 
Training days lost to sick quarters 
(effSIQ) 
2.30 1 3 
AdV Vaccination vs. No Vaccination -5.79 103.39 -75.17 
PROBABAILITY VARIABLES 
 BASE LOW HIGH 
[P] of FRI without vaccine 
(pFRI_NOVAX) 
0.370 0.074 0.667 
AdV Vaccination vs. No Vaccination -349.60 97.06 -390.40 
[P] of GBS after vaccination (pGBS) 
 
0.00028 0.00005 0.0005 
AdV Vaccination vs. No Vaccination 155.46 -29.65 351.24 
[P] of FRI hospitalization 
(pHOSP_VAX) 
0.181 0.145 0.217 
AdV Vaccination vs. No Vaccination -29.65 12.26 -70.92 
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 4.5.3. MARINE CORPS ONE – WAY SENSITIVITY ANALYSES RESULTS 
 Table 4.6 displays results from one – way sensitivity analyses on variables that 
 impacted the findings of the cost – effectiveness analysis in Marine Corps basic 
 trainees. Conclusions about cost – effectiveness were sensitive to the following 
 variables: cost of adenovirus vaccine, cost of FRI hospitalization, cost of basic 
 training, and training days lost due to FRI hospitalization. Threshold values were 
 $119.87, $9,724.69, $348.91, and 5.28 for the cost of the adenovirus vaccine, cost 
 FRI hospitalization, cost of basic training, and training days lost due to FRI 
 hospitalization respectively. Findings were robust across all other variables where 
 the no adenovirus vaccination strategy was the dominant strategy.  
 
TABLE 4.6. MARINE CORPS ONE – WAY SENSITIVITY ANALYSES 
RESULTS 





 ICER ($/TDL averted) 
 BASE LOW HIGH 
Cost of adenovirus vaccine (cADV_VAX) 150.65 100.98 250 
AdV Vaccination vs. No Vaccination 182.44 -111.97 771.25 
Cost of FRI hospitalization (cHOSP) 9,074.84 7,259.88 10,889.80 
AdV Vaccination vs. No Vaccination 37.63 142.72 -67.46 
Cost of training (cTRAIN) 360.63 262.15 459.10 
AdV Vaccination vs. No Vaccination -6.90 51.13 -64.94 








AdV Vaccination vs. No Vaccination -16.75 79.89 -72.92 
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4.6. PROBABLISTIC SENSITIVITY ANALYSIS 
A probabilistic sensitivity analysis was conducted using a Monte Carlo simulation. 
Triangular, gamma, and beta distributions were created for TDL, costs, and probabilities 
respectively. Ranges for variables are shown in tables 3.13 through 3.17. Table 4.7 
summarizes results from the Monte Carlo sensitivity analysis. The mean costs for the 
adenovirus vaccination strategy for each service branch were $163.71 (SD $70.28, 
Range: $129.38 – $2,411.88), $158.31 (SD $79.28, Range: $64.55 - $3,117.77), $154.12 
(SD $94.15, Range: $62.25 - $3,715.07), $180.00 (SD $75.70, Range: $76.16 - 
$2,648.14), and $144.41 (SD $73.67, Range: $55.37 - $1,874.48) for Army, Navy, 
Marine Corps, Air Force, and Coast Guard respectively. Mean costs for the no 
vaccination strategy for each service branch were $233.16 (SD $136.99, Range: $22.54 - 
$1,375.43), $174.73 (SD $52.18, Range: $44.12 - $545.45), $151.60 (SD $46.50, Range: 
$39.82 - $401.62), $316.56 (SD $96.48, Range: $76.64 - $1,132.56), and $46.10 (SD 
$14.99, Range:$13.27 – $145.53) for Army, Navy, Marine Corps, Air Force, and Coast 
Guard respectively. Mean TDL values for the adenovirus vaccination strategy were 0.05 
(SD 0.01), 0.06 (SD 0.02), 0.03 (SD 0.02), 0.08 (SD 0.02), and 0.04 (SD 0.01) for Army, 
Navy, Marine Corps, Air Force, and Coast Guard respectively. Mean TDL values for the 
no vaccination strategy were 0.40 (SD 0.12), 0.39 (SD 0.10), 0.20 (SD 0.05), 0.47 (SD 
0.12), and 0.17 (SD 0.04) for the Army, Navy, Marine Corps, Air Force, and Coast Guard 
respectively.  
Figures 4.15 through 4.19 display the incremental cost – effectiveness scatter plots 
comparing the adenovirus vaccination strategy and the no vaccination strategy in each 
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service branch. The outcome of this analysis, training days lost, is a negative value, 
which means training days lost without the adenovirus vaccine is greater than training 
days lost with the adenovirus vaccine. Essentially, the adenovirus vaccine is more 
effective than no adenovirus vaccine in terms of training days lost. Therefore, when 
interpreting the incremental cost – effectiveness scatter plots for this analysis, one must 
remember that the quadrants are reversed. To help with interpretation, scatter plots are 
clearly labeled. For a more extensive explanation of TreeAge ICER scatter plots, see 
Appendix C.  
Each scatter plot is labeled with the percentage of iterations that fall in quadrant four, 
which represents the proportion of iterations where the adenovirus vaccination strategy is 
the dominant strategy over the no vaccination strategy. Those proportions are 68%, 65%, 
53%, 95%, and 0% for the Army, Navy, Marine Corps, Air Force, and Coast Guard. 
Including the areas where the ICER is less than a willingness – to – pay threshold of $200 
(section C2), results in increasing proportions where the adenovirus vaccine strategy is 
more cost – effective to 98%, 90%, 75%, 98%, and 3% for the Army, Navy, Marine 







TABLE 4.7. SUMMARY OF RESULTS FROM MONTE CARLO ANALYSIS 
AdV = Adenovirus; EFF = Effectiveness as measured by training days lost; IC = Incremental Cost; IE = Incremental 











AdV Vaccination $163.71 0.05    
No Vaccination $233.16 0.40 $69.45 -0.35 -$198.43 
NAVY 
AdV Vaccination $158.31 0.06    
No Vaccination $174.73 0.39 $16.42 -0.33 -$49.76 
MARINE CORPS 
AdV Vaccination $152.12 0.03    
No Vaccination $151.60 0.29 -$0.52 -0.26 $2.00 
AIR FORCE 
AdV Vaccination $180.00 0.08    
No Vaccination $316.56 0.47 $136.56 -0.39 -$350.15 
COAST GUARD 
AdV Vaccination $144.41 0.04    
No Vaccination $46.10 0.17 -$98.31 -0.13 $756.23 
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FIGURE 4.15. ARMY INCREMENTAL CE SCATTER PLOT – ADENOVIRUS 
VACCINATION VERSUS NO VACCINATION 
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FIGURE 4.16. NAVY INCREMENTAL CE SCATTER PLOT – ADENOVIRUS 
VACCINATION VERSUS NO VACCINATION 
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FIGURE 4.17. MARINE CORPS INCREMENTAL CE SCATTER PLOT – 
ADENOVIRUS VACCINATION VERSUS NO VACCINATION  
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FIGURE 4.18. AIR FORCE INCREMENTAL CE SCATTER PLOT – 
ADENOVIRUS VACCINATION VERSUS NO VACCINATION 
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FIGURE 4.19. COAST GUARD INCREMENTAL CE SCATTER PLOT – 




 QUADRANT I 
 97% 
 
 3% (C2) 











  CHAPTER 5: DISCUSSION AND CONCLUSIONS 
 
5.1. INTRODUCTION 
Chapter 5 includes a discussion of base – case results, results from sensitivity analyses, 
and an interpretation of the results from part I and part II of this study. In addition, a 
comparison of results to current literature, study limitations, and suggestions for future 
research are discussed.  
5.2. BASE – CASE AND SENSITIVITY ANALYSES RESULTS 
In part I of this study, adenovirus vaccination of basic trainees was cost – effective as 
measured by FRI hospitalization cases prevented in all US military service branches but 
the Coast Guard. The model showed that introducing the adenovirus vaccine to basic 
trainees saved the Army, 5.8 million, the Navy, $1 million, Marine Corps, $238,000, and 
the Air Force $5.2 million, annually. In addition, AdV vaccination prevented 1,221, 543, 
317, 677, and 13 cases of FRI hospitalization annually in the Army, Navy, Marine Corps, 
Air Force, and Coast Guard respectively. Cost – effectiveness ratios were negative in all 
branches but the Coast Guard. In general, the cost – effectiveness of AdV vaccination 
was robust in the Army, Navy, Marine Corps, and Air Force. One – way sensitivity 
analyses showed that the majority of results of the Part I model were insensitive to 
changes in all variables but the cost of the vaccine. The Army’s tornado diagram 
indicates that the probability of hospitalization due to FRI had a huge impact on the 
model. However, the one – way sensitivity analysis showed that changes in this 
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parameter would not change the ICER. The average threshold value for the cost of the 
adenovirus vaccine in the Army, Navy, and Marine Corps was approximately $164.   
In part II of this study, adenovirus vaccination of basic trainees was cost – effective as 
measured by training days lost (TDL) averted in all US military service branches but the 
Marine Corps and the Coast Guard. The ICER for the Marine Corps was $37.63, which is 
interpreted as a cost of $37.63 per TDL averted. The ICER for the Coast Guard indicated 
that it would cost the Coast Guard $563.78 per TDL averted. Probabilistic sensitivity 
analyses showed that the adenovirus vaccination strategy was cost – effective in 98%, 
90%, 75%, 98%, and 3% for the Army, Navy, Marine Corps, Air Force and Coast Guard 
respectively at the $200 WTP threshold.  
5.3. COMPARISON TO LITERATURE 
Before this study, only three published studies examined the cost – effectiveness of the 
adenovirus vaccine in US military basic trainees. 7, 9 – 10 Howell et al. looked at the use of 
the adenovirus vaccine in male Army basic trainees and found that a year – round vaccine 
program would prevent 7,800 hospitalized cases of FRI and save the Army $15.5 million 
over no vaccination. 9 The economic analysis for the first part of this dissertation used the 
same model Howell used with current data and found that the adenovirus vaccine would 
prevent 6,030 hospitalized cases of FRI and save the Army $5.8 million over no 
vaccination in US Army basic trainees. The difference between results is likely due to the 
high incidence used in the previous study. The incidence of FRI used in Howell et al.’s 
study was 4.06 cases per 100 trainee-weeks, which is four times the incidence used in this 
158 
 
current study. The Army uses a FRI threshold rate of 1.5 FRI admissions per 100 trainee 
– weeks to indicate an epidemic that needs to be investigated. 9 The incidence used by 
Howell et al. is almost three times the epidemic threshold and indicates that all Army 
basic training sites experience an epidemic for half of the year. Therefore, results from 
Howell et al.’s study may be overestimated due to the inflated incidence rate. However, 
both studies showed that an adenovirus vaccination program is cost – effective when 
compared to no vaccination in Army basic trainees in terms of hospital admissions for 
FRI prevented.  
In 2000, Hyer et al. did a cost – effectiveness study on the adenovirus vaccine in male 
and female Navy basic trainees. Hyer’s study showed that a year – round adenovirus 
vaccination program would prevent 4,555 hospital admissions for FRI and save the Navy 
$2.6 million. 10 The analysis done in this dissertation in Navy basic trainees found that 
use of the adenovirus vaccine prevented 3,591 hospital admissions for FRI and saved the 
Navy $1.1 million. Hyer et al. also used an incidence that was above the FRI epidemic 
threshold. Results from both of the studies on Navy basic trainees showed that an 
adenovirus vaccination is cost – effective when compared to no vaccination in terms of 
hospital admissions for FRI prevented.  
The study presented here is the first to determine the cost – effectiveness of the 
adenovirus vaccine in US service branches besides the Army and Navy. As shown in the 
presented study, results vary greatly between service branches in terms of cost - 
effectiveness because incidence and cost estimates differ between service branches.  
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5.4. STUDY LIMITATIONS 
Economic modelling and specifically this study have several limitations. One of the 
biggest limitations to this study is limited data on adenovirus transmission and the 
adenovirus vaccine for all service branches. The adenovirus vaccine is only used in US 
military basic trainees, so all research was performed by the US military in the late 1950s 
to early 1960s, before the original adenovirus vaccine was used. The majority of this 
early research focused on one service branch, the Army. No further research was 
performed on adenovirus in basic trainees until adenovirus vaccination ceased in the late 
1990s. Research in the late 1990s focused on the need for a new adenovirus vaccine 
manufacturer and the increase in adenovirus incidence.  Research focusing on the Air 
Force, Marine Corps, and Coast Guard is limited, so collecting data specific to their 
service branches for this analysis was difficult. Since the Coast Guard is not part of the 
Department of Defense, average values for the other service branches were used for 
several variables in the model.  In addition, the number of basic trainees in the US Coast 
Guard may not be large enough to adequately determine the cost – effectiveness in this 
service branch.  
The model did not include the cost of recycling a basic trainee due to missed training 
days. If a basic trainee misses too many training days, he/she has to restart basic training. 
Epidemiologic investigations at Army basic training sites during FRI epidemics showed 
that no basic trainees were recycled due to FRI. 49 Conversely, a study in Navy basic 
trainees estimated that up to 200 basic trainees with adenovirus had to be recycled after 
an outbreak in 2001. 61 Taking into consideration the results from these two studies, it is 
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difficult to determine the impact basic trainee recycling has on the cost – effectiveness of 
the adenovirus vaccine.  
Two limitations of the study have to do with the manufacturing and shipping of the 
adenovirus vaccine. The military has a contract with Teva to buy 250,000 doses (type 4 + 
7) of the adenovirus vaccine annually, whether it is used or not (Personal communication, 
Dr. Snyder). This model did not take into account those doses that were bought by the 
DoD and not distributed. Adenovirus vaccine type 4 and type 7 are each manufactured in 
bottles of 100 doses. Adenovirus vaccines must remain refrigerated and not exposed to 
any moisture during transport to the basic training facility. Loss or destruction of 
vaccines during transport were not considered. 
This analysis used average incidence rates for a five – year period when the adenovirus 
vaccine was not available to estimate incidence for the no vaccination arm of the 
analysis. One limitation of this measurement is that it assumes that the incidence rate 
remains constant throughout the year. However, research shows that adenovirus 
incidence depends on several factors like season, basic training population size, and 
serotype, and varies throughout the year. Incidence can either be over or underestimated 
but both models were robust when varying this parameter. 
Cost estimates used in this analysis are TRICARE reimbursement amounts for the FY 
2013. This analysis assumed that the reimbursement amount was the actual amount paid 
by the DoD, but rebates or other discounts may impact the final price the DoD pays. 
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Several assumptions were made about CPT codes and DRG groups that can lead to 
overestimation of costs.  
5.5. CONCLUSION AND DIRECTIONS FOR FUTURE RESEARCH 
As mentioned above, health economics research, specifically on the adenovirus vaccine, 
focusing on the separate military service branches is rarely found in the literature. Either 
the research is not being performed or the US military is not publishing their research. 
Future research should focus on service branch - specific health economics research, 
adenovirus serotype distribution and changes in distribution, and the impact of herd 
immunity due to adenovirus vaccination of basic trainees. Performing cost analyses on 
each service branch can highlight areas where costs are not used efficiently, which can 
eventually result in cost savings to the DoD. Too many differences exist between military 
service branches, especially in terms of serotype distribution and health care costs, to 
analyze the entire military as one combined population. As shown in this analysis, a 
vaccine may cost the same for all basic trainees but that does not mean it is cost – 
effective in all service branches. 
For years, military physicians considered risk of FRI in all service branches to be equal. 
With current information on serotype variation and antigenic drift, assuming that all 
service branches and basic training sites have the same risk of FRI is misleading. 
Adenovirus serotype and genome type distribution is another area where more research 
needs to be performed. An article published in 2006 showed that adenoviral co – 
infections (simultaneous infection by multiple pathogenic adenovirus species) emerged in 
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previously vaccinated military basic trainees. Many of the co – infections were species 
not generally associated with FRI in the military. In addition, co – infections can lead to 
recombination which plays a major role in creating new, more virulent strains of 
adenovirus. Since the adenovirus vaccine is specific to serotypes 4 and 7, changes in 
adenovirus serotypes can impact adenovirus vaccine cost – effectiveness. The Navy and 
Army currently perform adenovirus serotype surveillance, but this surveillance must 
continue and concentrate on changes in adenovirus serotypes since redeployment of the 
adenovirus vaccine because these changes can impact the cost – effectiveness of the 
adenovirus vaccine.  
Lastly, more research needs to focus on adenovirus transmission and herd immunity in 
US military basic trainees. Literature shows that adenovirus transmission includes person 
– to – person contact and environmental exposure, but which transmission route is most 
significant is unclear. Unsuspected environmental routes of transmission may contribute 
significantly to transmission, while suspected routes of person – to – person transmission 
may be non - significant. Transmission dynamics of adenovirus are very complex and 
serotypes differ in terms of infectiousness and survival of the pathogen, so transmission 
for all serotypes needs to be understood. Understanding adenovirus transmission 
dynamics allows for more complex economic models that include herd immunity to be 
built.  
This study provides evidence supporting the cost – effectiveness of using the adenovirus 
vaccine in US basic trainees in all service branches but the Coast Guard. Results from the 
part I and part II cost – effectiveness analyses show that an adenovirus vaccination 
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strategy is favorable when compared to no vaccination. The probabilistic sensitivity 
analysis provides additional evidence on the cost – effectiveness of the adenovirus 
vaccine in terms of training days lost averted as the results were insensitive to varying 
estimates. Results from these analyses are a compelling reason to continue adenovirus 




APPENDIX A. MODEL VARIABLE DESCRIPTIONS 
PART I MODELVARIABLE DESCRIPTIONS 
VARIABLE DESCRIPTION 
cVAX Cost of adenovirus vaccine per basic trainee 
cHOSP_FRI Cost of inpatient hospitalization due to FRI 
cOUTPT Cost of one outpatient visit, new patient 
cOUTPT_FLLWUP Cost of one outpatient visit, established patient 
cTRAIN Cost to train basic trainee per day 
effNOVAX 
Expected number of admissions to hospital due to FRI when vaccine not in 
use 
effVAX Expected number of admissions to hospital due to FRI when vaccine in use 
pFRI_NOVAX 
Probability of developing FRI during basic training when adenovirus 
vaccine not in use 
pFRIVAX 
Probability of developing FRI during basic training after receiving 
adenovirus vaccine 
pHOSP Probability of being admitted to the hospital for FRI 
















PART II MODEL VARIABLE DESCRIPTIONS 
VARIABLE DESCRIPTION 
cADV_VAX Cost of adenovirus vaccine per basic trainee 
cADVP Cost of hospitalization due to adenoviral pneumonia 
cFLLW_UP Cost out one outpatient visit, established patient 
cGBS Cost to treat Guillain - Barre Syndrome in basic trainees 
cHOSP Cost of hospitalization due to FRI 
cOUTPT Cost of one outpatient visit, new patient 
cTRAIN Cost to train basic trainee per day 
effAdV_HOSP 
Training days lost due to time spent in hospital because of adenoviral 
pneumonia 
effFRI_HOSP Training days lost due to time spent in hospital because of FRI 
effGBS Training days lost due to Guillain - Barre Syndrome 
effLP Training days lost due to lost productivity 
effMAE 
Training days lost as a result of minor systemic reactions to adenovirus 
vaccine 
effNOFRI Training days lost due to no FRI 
effOUTPT Training days lost due to time spent at outpatient visit 
effSIQ Training days lost due to time spent in sick quarters 
pADVP Probability of developing adenoviral pneumonia as complication of FRI 
pFRI_NOVAX Probability of developing FRI when adenovirus vaccine is not available 
pFRI_VAX Probability of developing FRI after receiving an adenovirus vaccine 
pGBS 
Probability of developing Guillain - Barre Syndrome after adenovirus 
vaccination 
pHOSP_VAX Probability of hospitalization as a result of FRI 
pMAE Probability of experiencing a minor systemic reaction to adenovirus vaccine 
pSIQ_ONLY 








APPENDIX B. ONE – WAY SENSITIVITY ANALYSES RESULTS 
VARIABLE: cADV_VAX – Cost of adenovirus vaccine 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
100.98 Adenovirus Vaccination 137.50 0.05 2564.78 0.00 0.00 0.00  
100.98 No Vaccination 221.29 0.35 635.96 83.79 -0.29 -284.66 (Dominated) 
138.235 Adenovirus Vaccination 174.75 0.05 3259.70 0.00 0.00 0.00  
138.235 No Vaccination 221.29 0.35 635.96 46.53 -0.29 -158.09 (Dominated) 
175.49 Adenovirus Vaccination 212.01 0.05 3954.62 0.00 0.00 0.00  
175.49 No Vaccination 221.29 0.35 635.96 9.28 -0.29 -31.52 (Dominated) 
212.745 No Vaccination 221.29 0.35 635.96 0.00 0.00 0.00  
212.745 Adenovirus Vaccination 249.26 0.05 4649.55 27.98 0.29 95.05 Not Dominated 
250 No Vaccination 221.29 0.35 635.96 0.00 0.00 0.00  
250 Adenovirus Vaccination 286.52 0.05 5344.47 65.23 0.29 221.61 Not Dominated 
 
VARIABLE: cADVP – Cost of adenoviral pneumonia hospitalization 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
5598.3 Adenovirus Vaccination 161.98 0.05 3021.40 0.00 0.00 0.00  
5598.3 No Vaccination 214.11 0.35 615.33 52.13 -0.29 -177.11 (Dominated) 
6298.09 Adenovirus Vaccination 162.09 0.05 3023.41 0.00 0.00 0.00  
6298.09 No Vaccination 215.12 0.35 618.25 53.04 -0.29 -180.19 (Dominated) 
6997.88 Adenovirus Vaccination 162.19 0.05 3025.41 0.00 0.00 0.00  
6997.88 No Vaccination 216.14 0.35 621.16 53.94 -0.29 -183.27 (Dominated) 
7697.67 Adenovirus Vaccination 162.30 0.05 3027.41 0.00 0.00 0.00  
7697.67 No Vaccination 217.15 0.35 624.07 54.85 -0.29 -186.34 (Dominated) 
8397.46 Adenovirus Vaccination 162.41 0.05 3029.41 0.00 0.00 0.00  




VARIABLE: cFLLW_UP – Cost of follow – up outpatient visits 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
43.92 Adenovirus Vaccination 162.71 0.05 3034.98 0.00 0.00 0.00  
43.92 No Vaccination 220.98 0.35 635.08 58.27 -0.29 -197.98 (Dominated) 
51.285 Adenovirus Vaccination 162.74 0.05 3035.55 0.00 0.00 0.00  
51.285 No Vaccination 221.27 0.35 635.92 58.54 -0.29 -198.87 (Dominated) 
58.65 Adenovirus Vaccination 162.77 0.05 3036.13 0.00 0.00 0.00  
58.65 No Vaccination 221.56 0.35 636.76 58.80 -0.29 -199.75 (Dominated) 
66.015 Adenovirus Vaccination 162.80 0.05 3036.70 0.00 0.00 0.00  
66.015 No Vaccination 221.85 0.35 637.59 59.06 -0.29 -200.64 (Dominated) 
73.38 Adenovirus Vaccination 162.83 0.05 3037.28 0.00 0.00 0.00  
73.38 No Vaccination 222.15 0.35 638.43 59.32 -0.29 -201.52 (Dominated) 
 
VARIABLE: cGBS – Cost of Guillain – Barre Syndrome 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
194674.13 Adenovirus Vaccination 160.30 0.05 2990.19 0.00 0.00 0.00  
194674.13 No Vaccination 221.29 0.35 635.96 60.98 -0.29 -207.18 (Dominated) 
219008.42 Adenovirus Vaccination 161.52 0.05 3012.89 0.00 0.00 0.00  
219008.42 No Vaccination 221.29 0.35 635.96 59.77 -0.29 -203.05 (Dominated) 
243342.71 Adenovirus Vaccination 162.74 0.05 3035.58 0.00 0.00 0.00  
243342.71 No Vaccination 221.29 0.35 635.96 58.55 -0.29 -198.91 (Dominated) 
267677 Adenovirus Vaccination 163.95 0.05 3058.28 0.00 0.00 0.00  
267677 No Vaccination 221.29 0.35 635.96 57.33 -0.29 -194.78 (Dominated) 
292011.29 Adenovirus Vaccination 165.17 0.05 3080.97 0.00 0.00 0.00  





VARIABLE: cHOSP – Cost of FRI hospitalization 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
5379.91 Adenovirus Vaccination 159.57 0.05 2976.53 0.00 0.00 0.00  
5379.91 No Vaccination 191.39 0.35 550.04 31.82 -0.29 -108.09 (Dominated) 
6187.4 Adenovirus Vaccination 161.00 0.05 3003.10 0.00 0.00 0.00  
6187.4 No Vaccination 204.84 0.35 588.69 43.84 -0.29 -148.95 (Dominated) 
6994.89 Adenovirus Vaccination 162.42 0.05 3029.66 0.00 0.00 0.00  
6994.89 No Vaccination 218.29 0.35 627.35 55.87 -0.29 -189.80 (Dominated) 
7802.38 Adenovirus Vaccination 163.84 0.05 3056.22 0.00 0.00 0.00  
7802.38 No Vaccination 231.74 0.35 666.00 67.89 -0.29 -230.66 (Dominated) 
8609.87 Adenovirus Vaccination 165.27 0.05 3082.79 0.00 0.00 0.00  
8609.87 No Vaccination 245.19 0.35 704.65 79.92 -0.29 -271.52 (Dominated) 
 
VARIABLE: cOUTPT – Cost of outpatient visits (New patient) 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
72.53 Adenovirus Vaccination 162.66 0.05 3034.16 0.00 0.00 0.00  
72.53 No Vaccination 220.57 0.35 633.89 57.90 -0.29 -196.72 (Dominated) 
82.6425 Adenovirus Vaccination 162.73 0.05 3035.49 0.00 0.00 0.00  
82.6425 No Vaccination 221.24 0.35 635.83 58.51 -0.29 -198.78 (Dominated) 
92.755 Adenovirus Vaccination 162.81 0.05 3036.83 0.00 0.00 0.00  
92.755 No Vaccination 221.92 0.35 637.78 59.11 -0.29 -200.83 (Dominated) 
102.8675 Adenovirus Vaccination 162.88 0.05 3038.16 0.00 0.00 0.00  
102.8675 No Vaccination 222.60 0.35 639.72 59.72 -0.29 -202.89 (Dominated) 
112.98 Adenovirus Vaccination 162.95 0.05 3039.50 0.00 0.00 0.00  





VARIABLE: cTRAIN – Cost to train basic trainee per day 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
241.52 Adenovirus Vaccination 159.42 0.05 2973.64 0.00 0.00 0.00  
241.52 No Vaccination 193.04 0.35 554.78 33.62 -0.29 -114.23 (Dominated) 
290.7425 Adenovirus Vaccination 160.63 0.05 2996.26 0.00 0.00 0.00  
290.7425 No Vaccination 203.36 0.35 584.44 42.73 -0.29 -145.16 (Dominated) 
339.965 Adenovirus Vaccination 161.84 0.05 3018.89 0.00 0.00 0.00  
339.965 No Vaccination 213.68 0.35 614.09 51.83 -0.29 -176.10 (Dominated) 
389.1875 Adenovirus Vaccination 163.06 0.05 3041.52 0.00 0.00 0.00  
389.1875 No Vaccination 223.99 0.35 643.74 60.94 -0.29 -207.03 (Dominated) 
438.41 Adenovirus Vaccination 164.27 0.05 3064.15 0.00 0.00 0.00  
438.41 No Vaccination 234.31 0.35 673.40 70.04 -0.29 -237.96 (Dominated) 
 
VARIABLE: effADVP_HOSP – Training days lost to adenoviral pneumonia hospitalization 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
3 Adenovirus Vaccination 162.68 0.05 3043.21 0.00 0.00 0.00  
3 No Vaccination 220.74 0.35 637.05 58.06 -0.29 -198.13 (Dominated) 
4 Adenovirus Vaccination 162.74 0.05 3035.58 0.00 0.00 0.00  
4 No Vaccination 221.29 0.35 635.96 58.55 -0.29 -198.91 (Dominated) 
5 Adenovirus Vaccination 162.80 0.05 3028.00 0.00 0.00 0.00  
5 No Vaccination 221.83 0.35 634.89 59.04 -0.30 -199.69 (Dominated) 
6 Adenovirus Vaccination 162.85 0.05 3020.45 0.00 0.00 0.00  
6 No Vaccination 222.38 0.35 633.82 59.52 -0.30 -200.46 (Dominated) 
7 Adenovirus Vaccination 162.91 0.05 3012.95 0.00 0.00 0.00  





VARIABLE: effFRI_HOSP – Training days lost due to FRI hospitalization 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
1 Adenovirus Vaccination 161.41 0.05 3030.77 0.00 0.00 0.00  
1 No Vaccination 208.75 0.31 663.46 47.34 -0.26 -181.12 (Dominated) 
3.75 Adenovirus Vaccination 163.24 0.05 3037.37 0.00 0.00 0.00  
3.75 No Vaccination 225.99 0.36 626.96 62.75 -0.31 -204.60 (Dominated) 
6.5 Adenovirus Vaccination 165.06 0.05 3043.86 0.00 0.00 0.00  
6.5 No Vaccination 243.22 0.41 598.70 78.16 -0.35 -222.03 (Dominated) 
9.25 Adenovirus Vaccination 166.89 0.05 3050.23 0.00 0.00 0.00  
9.25 No Vaccination 260.46 0.45 576.16 93.57 -0.40 -235.49 (Dominated) 
12 Adenovirus Vaccination 168.71 0.06 3056.48 0.00 0.00 0.00  
12 No Vaccination 277.69 0.50 557.77 108.98 -0.44 -246.20 (Dominated) 
 
VARIABLE: effGBS – Training days lost due to Guillain – Barre Syndrome 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
39 Adenovirus Vaccination 162.55 0.05 3060.62 0.00 0.00 0.00  
39 No Vaccination 221.29 0.35 635.96 58.74 -0.29 -199.21 (Dominated) 
44 Adenovirus Vaccination 162.64 0.05 3048.04 0.00 0.00 0.00  
44 No Vaccination 221.29 0.35 635.96 58.64 -0.29 -199.06 (Dominated) 
49 Adenovirus Vaccination 162.74 0.05 3035.58 0.00 0.00 0.00  
49 No Vaccination 221.29 0.35 635.96 58.55 -0.29 -198.91 (Dominated) 
54 Adenovirus Vaccination 162.83 0.05 3023.24 0.00 0.00 0.00  
54 No Vaccination 221.29 0.35 635.96 58.45 -0.29 -198.76 (Dominated) 
59 Adenovirus Vaccination 162.93 0.05 3011.01 0.00 0.00 0.00  





VARIABLE: effLOST_PRO – Training days lost due to lost productivity 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.93 Adenovirus Vaccination 162.74 0.05 3420.27 0.00 0.00 0.00  
0.93 No Vaccination 221.29 0.29 754.61 58.55 -0.25 -238.33 (Dominated) 
1.24 Adenovirus Vaccination 162.74 0.05 3230.83 0.00 0.00 0.00  
1.24 No Vaccination 221.29 0.32 694.65 58.55 -0.27 -218.31 (Dominated) 
1.55 Adenovirus Vaccination 162.74 0.05 3061.28 0.00 0.00 0.00  
1.55 No Vaccination 221.29 0.34 643.51 58.55 -0.29 -201.40 (Dominated) 
1.86 Adenovirus Vaccination 162.74 0.06 2908.63 0.00 0.00 0.00  
1.86 No Vaccination 221.29 0.37 599.39 58.55 -0.31 -186.92 (Dominated) 
2.17 Adenovirus Vaccination 162.74 0.06 2770.48 0.00 0.00 0.00  
2.17 No Vaccination 221.29 0.39 560.93 58.55 -0.34 -174.38 (Dominated) 
 
VARIABLE: effMAE – Training days lost due to minor systemic reactions 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.03 Adenovirus Vaccination 162.74 0.04 3911.01 0.00 0.00 0.00  
0.03 No Vaccination 221.29 0.35 635.96 58.55 -0.31 -191.12 (Dominated) 
0.0675 Adenovirus Vaccination 162.74 0.05 3587.68 0.00 0.00 0.00  
0.0675 No Vaccination 221.29 0.35 635.96 58.55 -0.30 -193.49 (Dominated) 
0.105 Adenovirus Vaccination 162.74 0.05 3313.73 0.00 0.00 0.00  
0.105 No Vaccination 221.29 0.35 635.96 58.55 -0.30 -195.92 (Dominated) 
0.1425 Adenovirus Vaccination 162.74 0.05 3078.65 0.00 0.00 0.00  
0.1425 No Vaccination 221.29 0.35 635.96 58.55 -0.30 -198.41 (Dominated) 
0.18 Adenovirus Vaccination 162.74 0.06 2874.71 0.00 0.00 0.00  





VARIABLE: effOUTPT – Training days lost due to outpatient visits 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.084 Adenovirus Vaccination 162.74 0.05 3027.92 0.00 0.00 0.00  
0.084 No Vaccination 221.29 0.35 633.17 58.55 -0.30 -197.97 (Dominated) 
0.203 Adenovirus Vaccination 162.74 0.05 2964.37 0.00 0.00 0.00  
0.203 No Vaccination 221.29 0.36 610.35 58.55 -0.31 -190.30 (Dominated) 
0.322 Adenovirus Vaccination 162.74 0.06 2903.42 0.00 0.00 0.00  
0.322 No Vaccination 221.29 0.38 589.12 58.55 -0.32 -183.21 (Dominated) 
0.441 Adenovirus Vaccination 162.74 0.06 2844.94 0.00 0.00 0.00  
0.441 No Vaccination 221.29 0.39 569.32 58.55 -0.33 -176.62 (Dominated) 
0.56 Adenovirus Vaccination 162.74 0.06 2788.76 0.00 0.00 0.00  
0.56 No Vaccination 221.29 0.40 550.80 58.55 -0.34 -170.50 (Dominated) 
 
VARIABLE: effSIQ – Training days lost due to time spent in sick quarters 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
1 Adenovirus Vaccination 159.27 0.04 3761.83 0.00 0.00 0.00  
1 No Vaccination 188.57 0.26 722.49 29.29 -0.22 -133.96 (Dominated) 
1.5 Adenovirus Vaccination 160.61 0.05 3440.99 0.00 0.00 0.00  
1.5 No Vaccination 201.15 0.29 683.16 40.54 -0.25 -163.64 (Dominated) 
2 Adenovirus Vaccination 161.94 0.05 3174.69 0.00 0.00 0.00  
2 No Vaccination 213.74 0.33 651.86 51.80 -0.28 -187.08 (Dominated) 
2.5 Adenovirus Vaccination 163.27 0.06 2950.10 0.00 0.00 0.00  
2.5 No Vaccination 226.32 0.36 626.35 63.05 -0.31 -206.05 (Dominated) 
3 Adenovirus Vaccination 164.60 0.06 2758.15 0.00 0.00 0.00  





VARIABLE: pFRI_NOVAX – Probability of FRI when vaccine not available 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.068 Adenovirus Vaccination 162.74 0.05 3035.58 0.00 0.00 0.00  
0.068 No Vaccination 177.03 0.28 635.96 14.29 -0.22 -63.59 (Dominated) 
0.0765 Adenovirus Vaccination 162.74 0.05 3035.58 0.00 0.00 0.00  
0.0765 No Vaccination 199.16 0.31 635.96 36.42 -0.26 -140.32 (Dominated) 
0.085 Adenovirus Vaccination 162.74 0.05 3035.58 0.00 0.00 0.00  
0.085 No Vaccination 221.29 0.35 635.96 58.55 -0.29 -198.91 (Dominated) 
0.0935 Adenovirus Vaccination 162.74 0.05 3035.58 0.00 0.00 0.00  
0.0935 No Vaccination 243.42 0.38 635.96 80.68 -0.33 -245.12 (Dominated) 
0.102 Adenovirus Vaccination 162.74 0.05 3035.58 0.00 0.00 0.00  
0.102 No Vaccination 265.54 0.42 635.96 102.81 -0.36 -282.48 (Dominated) 
 
VARIABLE: pFRIVAX – Probability of FRI after receiving adenovirus vaccine 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.0081 Adenovirus Vaccination 160.40 0.05 3208.28 0.00 0.00 0.00  
0.0081 No Vaccination 221.29 0.35 635.96 60.89 -0.30 -204.36 (Dominated) 
0.00855 Adenovirus Vaccination 161.57 0.05 3118.92 0.00 0.00 0.00  
0.00855 No Vaccination 221.29 0.35 635.96 59.72 -0.30 -201.65 (Dominated) 
0.009 Adenovirus Vaccination 162.74 0.05 3035.58 0.00 0.00 0.00  
0.009 No Vaccination 221.29 0.35 635.96 58.55 -0.29 -198.91 (Dominated) 
0.00945 Adenovirus Vaccination 163.91 0.06 2957.68 0.00 0.00 0.00  
0.00945 No Vaccination 221.29 0.35 635.96 57.38 -0.29 -196.14 (Dominated) 
0.0099 Adenovirus Vaccination 165.08 0.06 2884.71 0.00 0.00 0.00  





VARIABLE: pGBS – Probability of developing Guillain – Barre Syndrome after receiving adenovirus vaccine 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0 Adenovirus Vaccination 150.96 0.05 2936.56 0.00 0.00 0.00  
0 No Vaccination 221.29 0.35 635.96 70.33 -0.30 -237.15 (Dominated) 
1.30E-04 Adenovirus Vaccination 183.35 0.06 3190.60 0.00 0.00 0.00  
1.30E-04 No Vaccination 221.29 0.35 635.96 37.94 -0.29 -130.59 (Dominated) 
2.50E-04 Adenovirus Vaccination 215.74 0.06 3396.18 0.00 0.00 0.00  
2.50E-04 No Vaccination 221.29 0.35 635.96 5.54 -0.28 -19.49 (Dominated) 
3.80E-04 No Vaccination 221.29 0.35 635.96 0.00 0.00 0.00  
3.80E-04 Adenovirus Vaccination 248.14 0.07 3565.96 26.85 0.28 96.45 Not Dominated 
5.00E-04 No Vaccination 221.29 0.35 635.96 0.00 0.00 0.00  
5.00E-04 Adenovirus Vaccination 280.53 0.08 3708.54 59.24 0.27 217.55 Not Dominated 
 
VARIABLE: pHOSP_VAX – Probability of hospitalization with FRI 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.135 Adenovirus Vaccination 157.29 0.05 2942.07 0.00 0.00 0.00  
0.135 No Vaccination 169.86 0.34 496.92 12.57 -0.29 -43.59 (Dominated) 
0.21125 Adenovirus Vaccination 162.62 0.05 3033.49 0.00 0.00 0.00  
0.21125 No Vaccination 220.13 0.35 632.90 57.52 -0.29 -195.50 (Dominated) 
0.2875 Adenovirus Vaccination 167.94 0.05 3124.42 0.00 0.00 0.00  
0.2875 No Vaccination 270.40 0.35 764.28 102.46 -0.30 -341.49 (Dominated) 
0.36375 Adenovirus Vaccination 173.26 0.05 3214.86 0.00 0.00 0.00  
0.36375 No Vaccination 320.67 0.36 891.29 147.41 -0.31 -481.91 (Dominated) 
0.44 Adenovirus Vaccination 178.58 0.05 3304.83 0.00 0.00 0.00  





VARIABLE: pMAE – Probability of minor systemic adverse reactions 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.08 Adenovirus Vaccination 162.74 0.05 3217.25 0.00 0.00 0.00  
0.08 No Vaccination 221.29 0.35 635.96 58.55 -0.30 -196.89 (Dominated) 
0.09 Adenovirus Vaccination 162.74 0.05 3123.77 0.00 0.00 0.00  
0.09 No Vaccination 221.29 0.35 635.96 58.55 -0.30 -197.89 (Dominated) 
0.1 Adenovirus Vaccination 162.74 0.05 3035.58 0.00 0.00 0.00  
0.1 No Vaccination 221.29 0.35 635.96 58.55 -0.29 -198.91 (Dominated) 
0.11 Adenovirus Vaccination 162.74 0.06 2952.23 0.00 0.00 0.00  
0.11 No Vaccination 221.29 0.35 635.96 58.55 -0.29 -199.94 (Dominated) 
0.12 Adenovirus Vaccination 162.74 0.06 2873.33 0.00 0.00 0.00  
0.12 No Vaccination 221.29 0.35 635.96 58.55 -0.29 -200.98 (Dominated) 
 
VARIABLE: pSIQ_ONLY – Probability of outpatient visit resulting in sick quarters  
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.76 Adenovirus Vaccination 162.81 0.05 3031.55 0.00 0.00 0.00  
0.76 No Vaccination 221.94 0.33 673.78 59.14 -0.28 -214.50 (Dominated) 
0.8175 Adenovirus Vaccination 162.79 0.05 3032.77 0.00 0.00 0.00  
0.8175 No Vaccination 221.74 0.34 661.90 58.96 -0.28 -209.56 (Dominated) 
0.875 Adenovirus Vaccination 162.77 0.05 3033.99 0.00 0.00 0.00  
0.875 No Vaccination 221.55 0.34 650.40 58.78 -0.29 -204.82 (Dominated) 
0.9325 Adenovirus Vaccination 162.74 0.05 3035.21 0.00 0.00 0.00  
0.9325 No Vaccination 221.35 0.35 639.28 58.60 -0.29 -200.26 (Dominated) 
0.99 Adenovirus Vaccination 162.72 0.05 3036.43 0.00 0.00 0.00  





VARIABLE: pADVP – Probability of developing adenoviral pneumonia 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.072 Adenovirus Vaccination 162.68 0.05 3035.98 0.00 0.00 0.00  
0.072 No Vaccination 220.74 0.35 634.66 58.06 -0.29 -197.34 (Dominated) 
0.092 Adenovirus Vaccination 162.82 0.05 3034.99 0.00 0.00 0.00  
0.092 No Vaccination 222.10 0.35 637.91 59.28 -0.29 -201.27 (Dominated) 
0.112 Adenovirus Vaccination 162.97 0.05 3034.00 0.00 0.00 0.00  
0.112 No Vaccination 223.46 0.35 641.15 60.49 -0.29 -205.19 (Dominated) 
0.132 Adenovirus Vaccination 163.11 0.05 3033.02 0.00 0.00 0.00  
0.132 No Vaccination 224.82 0.35 644.38 61.71 -0.30 -209.10 (Dominated) 
0.152 Adenovirus Vaccination 163.26 0.05 3032.03 0.00 0.00 0.00  













NAVY ONE – WAY SENSITIVITY ANALYSES RESULTS 
VARIABLE: cADVP – Cost of adenoviral pneumonia hospitalization 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
3171.54 Adenovirus Vaccination 156.83 0.06 2693.94 0.00 0.00 0.00  
3171.54 No Vaccination 162.75 0.38 428.68 5.92 -0.32 -18.43 (Dominated) 
3567.9775 Adenovirus Vaccination 156.89 0.06 2694.92 0.00 0.00 0.00  
3567.9775 No Vaccination 163.28 0.38 430.07 6.40 -0.32 -19.90 (Dominated) 
3964.415 Adenovirus Vaccination 156.94 0.06 2695.91 0.00 0.00 0.00  
3964.415 No Vaccination 163.81 0.38 431.46 6.87 -0.32 -21.36 (Dominated) 
4360.8525 Adenovirus Vaccination 157.00 0.06 2696.90 0.00 0.00 0.00  
4360.8525 No Vaccination 164.34 0.38 432.85 7.34 -0.32 -22.82 (Dominated) 
4757.29 Adenovirus Vaccination 157.06 0.06 2697.88 0.00 0.00 0.00  
4757.29 No Vaccination 164.86 0.38 434.25 7.81 -0.32 -24.29 (Dominated) 
 
VARIABLE: cADV_VAX – Cost of adenovirus vaccine 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
100.98 Adenovirus Vaccination 132.03 0.06 2267.93 0.00 0.00 0.00  
100.98 No Vaccination 166.80 0.38 439.34 34.77 -0.32 -108.17 (Dominated) 
138.235 No Vaccination 166.80 0.38 439.34 0.00 0.00 0.00  
138.235 Adenovirus Vaccination 169.28 0.06 2907.88 2.48 0.32 7.73 Not Dominated 
175.49 No Vaccination 166.80 0.38 439.34 0.00 0.00 0.00  
175.49 Adenovirus Vaccination 206.54 0.06 3547.84 39.74 0.32 123.63 Not Dominated 
212.745 No Vaccination 166.80 0.38 439.34 0.00 0.00 0.00  
212.745 Adenovirus Vaccination 243.79 0.06 4187.79 76.99 0.32 239.53 Not Dominated 
250 No Vaccination 166.80 0.38 439.34 0.00 0.00 0.00  




VARIABLE: cFLLW_UP – Cost of outpatient visits for established patient 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
49.28 Adenovirus Vaccination 157.23 0.06 2700.90 0.00 0.00 0.00  
49.28 No Vaccination 166.48 0.38 438.49 9.24 -0.32 -28.76 (Dominated) 
57.73 Adenovirus Vaccination 157.27 0.06 2701.48 0.00 0.00 0.00  
57.73 No Vaccination 166.79 0.38 439.32 9.52 -0.32 -29.63 (Dominated) 
66.18 Adenovirus Vaccination 157.30 0.06 2702.06 0.00 0.00 0.00  
66.18 No Vaccination 167.10 0.38 440.14 9.80 -0.32 -30.50 (Dominated) 
74.63 Adenovirus Vaccination 157.33 0.06 2702.63 0.00 0.00 0.00  
74.63 No Vaccination 167.42 0.38 440.97 10.08 -0.32 -31.37 (Dominated) 
83.08 Adenovirus Vaccination 157.37 0.06 2703.21 0.00 0.00 0.00  
83.08 No Vaccination 167.73 0.38 441.79 10.36 -0.32 -32.23 (Dominated) 
 
VARIABLE: cGBS – Cost of Guillain – Barre Syndrome 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
194674.13 Adenovirus Vaccination 154.83 0.06 2659.69 0.00 0.00 0.00  
194674.13 No Vaccination 166.80 0.38 439.34 11.96 -0.32 -37.22 (Dominated) 
219008.395 Adenovirus Vaccination 156.05 0.06 2680.59 0.00 0.00 0.00  
219008.395 No Vaccination 166.80 0.38 439.34 10.75 -0.32 -33.44 (Dominated) 
243342.66 Adenovirus Vaccination 157.27 0.06 2701.49 0.00 0.00 0.00  
243342.66 No Vaccination 166.80 0.38 439.34 9.53 -0.32 -29.65 (Dominated) 
267676.925 Adenovirus Vaccination 158.48 0.06 2722.39 0.00 0.00 0.00  
267676.925 No Vaccination 166.80 0.38 439.34 8.31 -0.32 -25.87 (Dominated) 
292011.19 Adenovirus Vaccination 159.70 0.06 2743.29 0.00 0.00 0.00  





VARIABLE: cHOSP – Cost of FRI hospitalization 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
3257.76 No Vaccination 154.44 0.38 406.78 0.00 0.00 0.00  
3257.76 Adenovirus Vaccination 155.92 0.06 2678.41 1.49 0.32 4.63 Not Dominated 
3662.73 Adenovirus Vaccination 156.60 0.06 2690.00 0.00 0.00 0.00  
3662.73 No Vaccination 160.64 0.38 423.12 4.04 -0.32 -12.57 (Dominated) 
4067.7 Adenovirus Vaccination 157.27 0.06 2701.58 0.00 0.00 0.00  
4067.7 No Vaccination 166.84 0.38 439.46 9.57 -0.32 -29.78 (Dominated) 
4472.67 Adenovirus Vaccination 157.95 0.06 2713.16 0.00 0.00 0.00  
4472.67 No Vaccination 173.05 0.38 455.80 15.10 -0.32 -46.98 (Dominated) 
4877.64 Adenovirus Vaccination 158.62 0.06 2724.75 0.00 0.00 0.00  
4877.64 No Vaccination 179.25 0.38 472.14 20.63 -0.32 -64.18 (Dominated) 
 
VARIABLE: cOUTPT – Cost of outpatient visit for new patient 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
82.58 Adenovirus Vaccination 157.15 0.06 2699.44 0.00 0.00 0.00  
82.58 No Vaccination 165.70 0.38 436.45 8.55 -0.32 -26.61 (Dominated) 
94.2125 Adenovirus Vaccination 157.24 0.06 2701.08 0.00 0.00 0.00  
94.2125 No Vaccination 166.58 0.38 438.76 9.33 -0.32 -29.04 (Dominated) 
105.845 Adenovirus Vaccination 157.34 0.06 2702.72 0.00 0.00 0.00  
105.845 No Vaccination 167.45 0.38 441.06 10.11 -0.32 -31.47 (Dominated) 
117.4775 Adenovirus Vaccination 157.43 0.06 2704.35 0.00 0.00 0.00  
117.4775 No Vaccination 168.33 0.38 443.37 10.90 -0.32 -33.90 (Dominated) 
129.11 Adenovirus Vaccination 157.53 0.06 2705.99 0.00 0.00 0.00  





VARIABLE: cTRAIN – Cost of training basic trainee per day 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
262.15 No Vaccination 138.89 0.38 365.82 0.00 0.00 0.00  
262.15 Adenovirus Vaccination 153.99 0.06 2645.22 15.10 0.32 46.99 Not Dominated 
311.3875 No Vaccination 149.94 0.38 394.95 0.00 0.00 0.00  
311.3875 Adenovirus Vaccination 155.29 0.06 2667.51 5.34 0.32 16.63 Not Dominated 
360.625 Adenovirus Vaccination 156.59 0.06 2689.81 0.00 0.00 0.00  
360.625 No Vaccination 161.00 0.38 424.07 4.42 -0.32 -13.74 (Dominated) 
409.8625 Adenovirus Vaccination 157.89 0.06 2712.10 0.00 0.00 0.00  
409.8625 No Vaccination 172.06 0.38 453.20 14.18 -0.32 -44.10 (Dominated) 
459.1 Adenovirus Vaccination 159.18 0.06 2734.40 0.00 0.00 0.00  
459.1 No Vaccination 183.12 0.38 482.33 23.94 -0.32 -74.46 (Dominated) 
 
VARIABLE: effAdV_HOSP – Training days lost due to adenoviral pneumonia 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
3 Adenovirus Vaccination 157.21 0.06 2707.27 0.00 0.00 0.00  
3 No Vaccination 166.28 0.38 439.53 9.07 -0.32 -28.33 (Dominated) 
4 Adenovirus Vaccination 157.27 0.06 2701.49 0.00 0.00 0.00  
4 No Vaccination 166.80 0.38 439.34 9.53 -0.32 -29.65 (Dominated) 
5 Adenovirus Vaccination 157.32 0.06 2695.75 0.00 0.00 0.00  
5 No Vaccination 167.31 0.38 439.15 9.99 -0.32 -30.96 (Dominated) 
6 Adenovirus Vaccination 157.38 0.06 2690.03 0.00 0.00 0.00  
6 No Vaccination 167.83 0.38 438.97 10.45 -0.32 -32.27 (Dominated) 
7 Adenovirus Vaccination 157.44 0.06 2684.35 0.00 0.00 0.00  





VARIABLE: effFRI_HOSP – Training days lost due to FRI hospitalization 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
1 No Vaccination 154.96 0.35 443.98 0.00 0.00 0.00  
1 Adenovirus Vaccination 155.98 0.05 2841.96 1.02 0.29 3.48 Not Dominated 
3.75 Adenovirus Vaccination 157.75 0.06 2652.87 0.00 0.00 0.00  
3.75 No Vaccination 171.24 0.39 437.78 13.49 -0.33 -40.67 (Dominated) 
6.5 Adenovirus Vaccination 159.52 0.06 2490.82 0.00 0.00 0.00  
6.5 No Vaccination 187.52 0.43 432.79 28.00 -0.37 -75.83 (Dominated) 
9.25 Adenovirus Vaccination 161.29 0.07 2350.40 0.00 0.00 0.00  
9.25 No Vaccination 203.80 0.48 428.68 42.51 -0.41 -104.50 (Dominated) 
12 Adenovirus Vaccination 163.06 0.07 2227.54 0.00 0.00 0.00  
12 No Vaccination 220.08 0.52 425.24 57.02 -0.44 -128.33 (Dominated) 
 
VARIABLE: effGBS – Training days lost due to Guillain – Barre Syndrome 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
31 Adenovirus Vaccination 157.11 0.06 2717.51 0.00 0.00 0.00  
31 No Vaccination 166.80 0.38 439.34 9.69 -0.32 -30.09 (Dominated) 
35 Adenovirus Vaccination 157.19 0.06 2709.47 0.00 0.00 0.00  
35 No Vaccination 166.80 0.38 439.34 9.61 -0.32 -29.87 (Dominated) 
39 Adenovirus Vaccination 157.27 0.06 2701.49 0.00 0.00 0.00  
39 No Vaccination 166.80 0.38 439.34 9.53 -0.32 -29.65 (Dominated) 
43 Adenovirus Vaccination 157.34 0.06 2693.57 0.00 0.00 0.00  
43 No Vaccination 166.80 0.38 439.34 9.45 -0.32 -29.43 (Dominated) 
47 Adenovirus Vaccination 157.42 0.06 2685.69 0.00 0.00 0.00  





VARIABLE: effLP – Training days lost due to lost productivity 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.93 Adenovirus Vaccination 157.27 0.05 3052.83 0.00 0.00 0.00  
0.93 No Vaccination 166.80 0.32 524.49 9.53 -0.27 -35.76 (Dominated) 
1.24 Adenovirus Vaccination 157.27 0.05 2879.55 0.00 0.00 0.00  
1.24 No Vaccination 166.80 0.35 481.33 9.53 -0.29 -32.65 (Dominated) 
1.55 Adenovirus Vaccination 157.27 0.06 2724.90 0.00 0.00 0.00  
1.55 No Vaccination 166.80 0.38 444.73 9.53 -0.32 -30.03 (Dominated) 
1.86 Adenovirus Vaccination 157.27 0.06 2586.00 0.00 0.00 0.00  
1.86 No Vaccination 166.80 0.40 413.30 9.53 -0.34 -27.81 (Dominated) 
2.17 Adenovirus Vaccination 157.27 0.06 2460.58 0.00 0.00 0.00  
2.17 No Vaccination 166.80 0.43 386.02 9.53 -0.37 -25.89 (Dominated) 
 
VARIABLE: effMAE – Training days lost due to minor vaccine systemic reactions 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.03 Adenovirus Vaccination 157.27 0.05 3402.95 0.00 0.00 0.00  
0.03 No Vaccination 166.80 0.38 439.34 9.53 -0.33 -28.58 (Dominated) 
0.0675 Adenovirus Vaccination 157.27 0.05 3147.55 0.00 0.00 0.00  
0.0675 No Vaccination 166.80 0.38 439.34 9.53 -0.33 -28.91 (Dominated) 
0.105 Adenovirus Vaccination 157.27 0.05 2927.81 0.00 0.00 0.00  
0.105 No Vaccination 166.80 0.38 439.34 9.53 -0.33 -29.24 (Dominated) 
0.1425 Adenovirus Vaccination 157.27 0.06 2736.75 0.00 0.00 0.00  
0.1425 No Vaccination 166.80 0.38 439.34 9.53 -0.32 -29.58 (Dominated) 
0.18 Adenovirus Vaccination 157.27 0.06 2569.10 0.00 0.00 0.00  





VARIABLE: effOUTPT – Training days lost due to outpatient visits 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.056 Adenovirus Vaccination 157.27 0.06 2709.45 0.00 0.00 0.00  
0.056 No Vaccination 166.80 0.38 441.17 9.53 -0.32 -29.78 (Dominated) 
0.063 Adenovirus Vaccination 157.27 0.06 2705.47 0.00 0.00 0.00  
0.063 No Vaccination 166.80 0.38 440.25 9.53 -0.32 -29.72 (Dominated) 
0.07 Adenovirus Vaccination 157.27 0.06 2701.49 0.00 0.00 0.00  
0.07 No Vaccination 166.80 0.38 439.34 9.53 -0.32 -29.65 (Dominated) 
0.077 Adenovirus Vaccination 157.27 0.06 2697.53 0.00 0.00 0.00  
0.077 No Vaccination 166.80 0.38 438.43 9.53 -0.32 -29.59 (Dominated) 
0.084 Adenovirus Vaccination 157.27 0.06 2693.58 0.00 0.00 0.00  
0.084 No Vaccination 166.80 0.38 437.53 9.53 -0.32 -29.52 (Dominated) 
 
VARIABLE: effSIQ – Training days lost due to time in sick quarters 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
1 No Vaccination 128.95 0.28 457.74 0.00 0.00 0.00  
1 Adenovirus Vaccination 153.15 0.05 3219.63 24.21 0.23 103.39 Not Dominated 
1.5 No Vaccination 143.51 0.32 449.32 0.00 0.00 0.00  
1.5 Adenovirus Vaccination 154.74 0.05 2995.08 11.23 0.27 41.95 Not Dominated 
2 Adenovirus Vaccination 156.32 0.06 2803.50 0.00 0.00 0.00  
2 No Vaccination 158.06 0.36 442.69 1.75 -0.30 -5.79 (Dominated) 
2.5 Adenovirus Vaccination 157.90 0.06 2638.14 0.00 0.00 0.00  
2.5 No Vaccination 172.62 0.39 437.32 14.72 -0.33 -43.96 (Dominated) 
3 Adenovirus Vaccination 159.48 0.06 2493.95 0.00 0.00 0.00  





VARIABLE: pADVP – Probability of developing adenoviral pneumonia 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.064 Adenovirus Vaccination 157.19 0.06 2701.58 0.00 0.00 0.00  
0.064 No Vaccination 166.12 0.38 437.87 8.93 -0.32 -27.80 (Dominated) 
0.086 Adenovirus Vaccination 157.30 0.06 2701.46 0.00 0.00 0.00  
0.086 No Vaccination 167.05 0.38 439.89 9.76 -0.32 -30.34 (Dominated) 
0.108 Adenovirus Vaccination 157.40 0.06 2701.34 0.00 0.00 0.00  
0.108 No Vaccination 167.98 0.38 441.90 10.58 -0.32 -32.88 (Dominated) 
0.13 Adenovirus Vaccination 157.50 0.06 2701.23 0.00 0.00 0.00  
0.13 No Vaccination 168.91 0.38 443.92 11.41 -0.32 -35.41 (Dominated) 
0.152 Adenovirus Vaccination 157.60 0.06 2701.11 0.00 0.00 0.00  
0.152 No Vaccination 169.83 0.38 445.92 12.24 -0.32 -37.94 (Dominated) 
 
VARIABLE: pFRI_NOVAX – Probability of FRI when vaccine not available 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.0736 No Vaccination 133.44 0.30 439.34 0.00 0.00 0.00  
0.0736 Adenovirus Vaccination 157.27 0.06 2701.49 23.83 0.25 97.06 Not Dominated 
0.2217 Adenovirus Vaccination 157.27 0.06 2701.49 0.00 0.00 0.00  
0.2217 No Vaccination 401.95 0.91 439.34 244.68 -0.86 -285.62 (Dominated) 
0.3698 Adenovirus Vaccination 157.27 0.06 2701.49 0.00 0.00 0.00  
0.3698 No Vaccination 670.46 1.53 439.34 513.19 -1.47 -349.62 (Dominated) 
0.5179 Adenovirus Vaccination 157.27 0.06 2701.49 0.00 0.00 0.00  
0.5179 No Vaccination 938.97 2.14 439.34 781.70 -2.08 -376.00 (Dominated) 
0.666 Adenovirus Vaccination 157.27 0.06 2701.49 0.00 0.00 0.00  





VARIABLE: pFRI_VAX – Probability of FRI after vaccination  
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.008 Adenovirus Vaccination 153.64 0.05 3075.18 0.00 0.00 0.00  
0.008 No Vaccination 166.80 0.38 439.34 13.16 -0.33 -39.90 (Dominated) 
0.009 Adenovirus Vaccination 155.45 0.05 2874.08 0.00 0.00 0.00  
0.009 No Vaccination 166.80 0.38 439.34 11.34 -0.33 -34.84 (Dominated) 
0.01 Adenovirus Vaccination 157.27 0.06 2701.49 0.00 0.00 0.00  
0.01 No Vaccination 166.80 0.38 439.34 9.53 -0.32 -29.65 (Dominated) 
0.011 Adenovirus Vaccination 159.08 0.06 2551.75 0.00 0.00 0.00  
0.011 No Vaccination 166.80 0.38 439.34 7.72 -0.32 -24.32 (Dominated) 
0.012 Adenovirus Vaccination 160.89 0.07 2420.61 0.00 0.00 0.00  
0.012 No Vaccination 166.80 0.38 439.34 5.91 -0.31 -18.86 (Dominated) 
 
VARIABLE: pGBS – Probability of Guillain – Barre Syndrome after adenovirus vaccination 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
5.00E-05 Adenovirus Vaccination 157.27 0.06 2701.49 0.00 0.00 0.00  
5.00E-05 No Vaccination 166.80 0.38 439.34 9.53 -0.32 -29.65 (Dominated) 
1.60E-04 No Vaccination 166.80 0.38 439.34 0.00 0.00 0.00  
1.60E-04 Adenovirus Vaccination 186.34 0.06 2976.73 19.54 0.32 61.62 Not Dominated 
2.80E-04 No Vaccination 166.80 0.38 439.34 0.00 0.00 0.00  
2.80E-04 Adenovirus Vaccination 215.41 0.07 3215.94 48.61 0.31 155.46 Not Dominated 
3.90E-04 No Vaccination 166.80 0.38 439.34 0.00 0.00 0.00  
3.90E-04 Adenovirus Vaccination 244.48 0.07 3425.78 77.68 0.31 251.96 Not Dominated 
5.00E-04 No Vaccination 166.80 0.38 439.34 0.00 0.00 0.00  





VARIABLE: pHOSP_VAX – Probability of hospitalization due to FRI 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.145 No Vaccination 151.72 0.38 402.59 0.00 0.00 0.00  
0.145 Adenovirus Vaccination 155.63 0.06 2687.40 3.91 0.32 12.26 Not Dominated 
0.163 Adenovirus Vaccination 156.45 0.06 2694.47 0.00 0.00 0.00  
0.163 No Vaccination 159.26 0.38 421.03 2.81 -0.32 -8.78 (Dominated) 
0.181 Adenovirus Vaccination 157.27 0.06 2701.49 0.00 0.00 0.00  
0.181 No Vaccination 166.80 0.38 439.34 9.53 -0.32 -29.65 (Dominated) 
0.199 Adenovirus Vaccination 158.09 0.06 2708.48 0.00 0.00 0.00  
0.199 No Vaccination 174.34 0.38 457.51 16.25 -0.32 -50.36 (Dominated) 
0.217 Adenovirus Vaccination 158.91 0.06 2715.44 0.00 0.00 0.00  
0.217 No Vaccination 181.88 0.38 475.55 22.97 -0.32 -70.92 (Dominated) 
 
VARIABLE: pMAE – Probability of minor systemic reactions after adenovirus vaccination 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.08 Adenovirus Vaccination 157.27 0.06 2848.28 0.00 0.00 0.00  
0.08 No Vaccination 166.80 0.38 439.34 9.53 -0.32 -29.37 (Dominated) 
0.09 Adenovirus Vaccination 157.27 0.06 2772.95 0.00 0.00 0.00  
0.09 No Vaccination 166.80 0.38 439.34 9.53 -0.32 -29.51 (Dominated) 
0.1 Adenovirus Vaccination 157.27 0.06 2701.49 0.00 0.00 0.00  
0.1 No Vaccination 166.80 0.38 439.34 9.53 -0.32 -29.65 (Dominated) 
0.11 Adenovirus Vaccination 157.27 0.06 2633.63 0.00 0.00 0.00  
0.11 No Vaccination 166.80 0.38 439.34 9.53 -0.32 -29.79 (Dominated) 
0.12 Adenovirus Vaccination 157.27 0.06 2569.09 0.00 0.00 0.00  





VARIABLE: pSIQ_ONLY – Probability of outpatient visit resulting in sick quarters 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.76 Adenovirus Vaccination 157.35 0.06 2697.84 0.00 0.00 0.00  
0.76 No Vaccination 167.63 0.38 440.36 10.28 -0.32 -31.89 (Dominated) 
0.8175 Adenovirus Vaccination 157.32 0.06 2698.94 0.00 0.00 0.00  
0.8175 No Vaccination 167.38 0.38 440.05 10.05 -0.32 -31.21 (Dominated) 
0.875 Adenovirus Vaccination 157.30 0.06 2700.05 0.00 0.00 0.00  
0.875 No Vaccination 167.13 0.38 439.74 9.83 -0.32 -30.54 (Dominated) 
0.9325 Adenovirus Vaccination 157.28 0.06 2701.16 0.00 0.00 0.00  
0.9325 No Vaccination 166.88 0.38 439.43 9.60 -0.32 -29.86 (Dominated) 
0.99 Adenovirus Vaccination 157.25 0.06 2702.26 0.00 0.00 0.00  














MARINE CORPS ONE – WAY SENSITIVITY ANALYSIS RESULTS 
VARIABLE: cADVP – Cost of hospitalization due to adenoviral pneumonia 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
10557.89 No Adenovirus Vaccines 143.45 0.19 760.31 0.00 0.00 0.00  
10557.89 Adenovirus Vaccine 152.04 0.02 7620.95 8.58 0.17 50.88 Not Dominated 
11875.38 No Adenovirus Vaccines 144.68 0.19 766.82 0.00 0.00 0.00  
11875.38 Adenovirus Vaccine 152.14 0.02 7626.42 7.47 0.17 44.25 Not Dominated 
13192.86 No Adenovirus Vaccines 145.91 0.19 773.34 0.00 0.00 0.00  
13192.86 Adenovirus Vaccine 152.25 0.02 7631.90 6.35 0.17 37.61 Not Dominated 
14510.35 No Adenovirus Vaccines 147.14 0.19 779.85 0.00 0.00 0.00  
14510.35 Adenovirus Vaccine 152.36 0.02 7637.37 5.23 0.17 30.98 Not Dominated 
15827.83 No Adenovirus Vaccines 148.36 0.19 786.36 0.00 0.00 0.00  
15827.83 Adenovirus Vaccine 152.47 0.02 7642.84 4.11 0.17 24.35 Not Dominated 
 
VARIABLE: cADV_VAX – Cost of adenovirus vaccine 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
100.98 Adenovirus Vaccine 127.01 0.02 6366.70 0.00 0.00 0.00  
100.98 No Adenovirus Vaccines 145.90 0.19 773.32 18.89 -0.17 -111.97 (Dominated) 
138.24 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  
138.24 Adenovirus Vaccine 164.27 0.02 8234.15 18.36 0.17 108.84 Not Dominated 
175.49 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  
175.49 Adenovirus Vaccine 201.52 0.02 10101.60 55.62 0.17 329.64 Not Dominated 
212.75 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  
212.75 Adenovirus Vaccine 238.78 0.02 11969.04 92.87 0.17 550.45 Not Dominated 
250.00 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  





VARIABLE: cFLLW_UP – Cost of outpatient visit for established patient 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
41.95 No Adenovirus Vaccines 145.64 0.19 771.89 0.00 0.00 0.00  
41.95 Adenovirus Vaccine 152.23 0.02 7630.68 6.59 0.17 39.08 Not Dominated 
49.55 No Adenovirus Vaccines 145.83 0.19 772.90 0.00 0.00 0.00  
49.55 Adenovirus Vaccine 152.25 0.02 7631.53 6.42 0.17 38.06 Not Dominated 
57.14 No Adenovirus Vaccines 146.02 0.19 773.90 0.00 0.00 0.00  
57.14 Adenovirus Vaccine 152.26 0.02 7632.38 6.25 0.17 37.03 Not Dominated 
64.74 No Adenovirus Vaccines 146.20 0.19 774.91 0.00 0.00 0.00  
64.74 Adenovirus Vaccine 152.28 0.02 7633.22 6.08 0.17 36.01 Not Dominated 
72.33 No Adenovirus Vaccines 146.39 0.19 775.91 0.00 0.00 0.00  
72.33 Adenovirus Vaccine 152.30 0.02 7634.07 5.90 0.17 34.98 Not Dominated 
 
VARIABLE: cGBS – Cost of Guillain – Barre Syndrome 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
194674.13 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  
194674.13 Adenovirus Vaccine 149.82 0.02 7509.91 3.92 0.17 23.21 Not Dominated 
219008.40 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  
219008.40 Adenovirus Vaccine 151.04 0.02 7570.90 5.13 0.17 30.42 Not Dominated 
243342.66 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  
243342.66 Adenovirus Vaccine 152.25 0.02 7631.88 6.35 0.17 37.63 Not Dominated 
267676.93 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  
267676.93 Adenovirus Vaccine 153.47 0.02 7692.87 7.57 0.17 44.84 Not Dominated 
292011.19 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  





VARIABLE: cHOSP – Cost of hospitalization due to FRI 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
7259.88 No Adenovirus Vaccines 126.44 0.19 670.17 0.00 0.00 0.00  
7259.88 Adenovirus Vaccine 150.52 0.02 7545.18 24.08 0.17 142.72 Not Dominated 
8167.36 No Adenovirus Vaccines 136.17 0.19 721.75 0.00 0.00 0.00  
8167.36 Adenovirus Vaccine 151.39 0.02 7588.53 15.21 0.17 90.17 Not Dominated 
9074.84 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  
9074.84 Adenovirus Vaccine 152.25 0.02 7631.88 6.35 0.17 37.63 Not Dominated 
9982.32 Adenovirus Vaccine 153.12 0.02 7675.24 0.00 0.00 0.00  
9982.32 No Adenovirus Vaccines 155.64 0.19 824.89 2.52 -0.17 -14.92 (Dominated) 
10889.80 Adenovirus Vaccine 153.98 0.02 7718.59 0.00 0.00 0.00  
10889.80 No Adenovirus Vaccines 165.37 0.19 876.47 11.38 -0.17 -67.46 (Dominated) 
 
VARIABLE: cOUTPT – Cost of outpatient visit for new patient 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
73.80 No Adenovirus Vaccines 145.48 0.19 771.05 0.00 0.00 0.00  
73.80 Adenovirus Vaccine 152.22 0.02 7629.98 6.74 0.17 39.94 Not Dominated 
84.64 No Adenovirus Vaccines 145.84 0.19 772.97 0.00 0.00 0.00  
84.64 Adenovirus Vaccine 152.25 0.02 7631.59 6.41 0.17 37.99 Not Dominated 
95.48 No Adenovirus Vaccines 146.20 0.19 774.88 0.00 0.00 0.00  
95.48 Adenovirus Vaccine 152.28 0.02 7633.20 6.08 0.17 36.04 Not Dominated 
106.31 No Adenovirus Vaccines 146.56 0.19 776.80 0.00 0.00 0.00  
106.31 Adenovirus Vaccine 152.31 0.02 7634.81 5.75 0.17 34.08 Not Dominated 
117.15 No Adenovirus Vaccines 146.92 0.19 778.71 0.00 0.00 0.00  





VARIABLE: cTRAIN – Cost of training basic trainee per day 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
262.15 No Adenovirus Vaccines 143.33 0.19 759.65 0.00 0.00 0.00   
262.15 Adenovirus Vaccine 151.95 0.02 7616.77 8.63 0.17 51.13 Not Dominated 
311.39 No Adenovirus Vaccines 148.87 0.19 789.03 0.00 0.00 0.00  
311.39 Adenovirus Vaccine 152.60 0.02 7649.25 3.73 0.17 22.11 Not Dominated 
360.63 Adenovirus Vaccine 153.25 0.02 7681.72 0.00 0.00 0.00   
360.63 No Adenovirus Vaccines 154.41 0.19 818.41 1.16 -0.17 -6.90 (Dominated) 
409.86 Adenovirus Vaccine 153.90 0.02 7714.20 0.00 0.00 0.00  
409.86 No Adenovirus Vaccines 159.96 0.19 847.80 6.06 -0.17 -35.92 (Dominated) 
459.10 Adenovirus Vaccine 154.54 0.02 7746.67 0.00 0.00 0.00  
459.10 No Adenovirus Vaccines 165.50 0.19 877.18 10.96 -0.17 -64.94 (Dominated) 
 
VARIABLE: effADV_HOSP – Training days lost due to adenoviral pneumonia hospitalization 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
3 No Adenovirus Vaccines 145.64 0.19 775.75 0.00 0.00 0.00  
3 Adenovirus Vaccine 152.23 0.02 7662.53 6.59 0.17 39.26 Not Dominated 
4 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  
4 Adenovirus Vaccine 152.25 0.02 7631.88 6.35 0.17 37.63 Not Dominated 
5 No Adenovirus Vaccines 146.17 0.19 770.92 0.00 0.00 0.00  
5 Adenovirus Vaccine 152.28 0.02 7601.49 6.11 0.17 36.01 Not Dominated 
6 No Adenovirus Vaccines 146.44 0.19 768.54 0.00 0.00 0.00  
6 Adenovirus Vaccine 152.30 0.02 7571.35 5.86 0.17 34.41 Not Dominated 
7 No Adenovirus Vaccines 146.70 0.19 766.19 0.00 0.00 0.00  





VARIABLE: effFRI_HOSP – Training days lost due to FRI hospitalization 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
1.00 No Adenovirus Vaccines 139.79 0.17 835.93 0.00 0.00 0.00  
1.00 Adenovirus Vaccine 151.71 0.02 8408.01 11.92 0.15 79.89 Not Dominated 
3.75 No Adenovirus Vaccines 148.20 0.20 753.36 0.00 0.00 0.00  
3.75 Adenovirus Vaccine 152.46 0.02 7377.75 4.26 0.18 24.20 Not Dominated 
6.50 Adenovirus Vaccine 153.20 0.02 6579.42 0.00 0.00 0.00  
6.50 No Adenovirus Vaccines 156.60 0.23 692.31 3.40 -0.20 -16.75 (Dominated) 
9.25 Adenovirus Vaccine 153.95 0.03 5942.62 0.00 0.00 0.00  
9.25 No Adenovirus Vaccines 165.01 0.26 645.35 11.06 -0.23 -48.12 (Dominated) 
12.00 Adenovirus Vaccine 154.70 0.03 5422.83 0.00 0.00 0.00  
12.00 No Adenovirus Vaccines 173.41 0.29 608.09 18.72 -0.26 -72.92 (Dominated) 
 
VARIABLE: effGBS – Training days lost due to Guillain – Barre Syndrome 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
50.00 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  
50.00 Adenovirus Vaccine 152.07 0.02 7879.32 6.16 0.17 36.39 Not Dominated 
56.50 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  
56.50 Adenovirus Vaccine 152.16 0.02 7753.55 6.26 0.17 37.01 Not Dominated 
63.00 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  
63.00 Adenovirus Vaccine 152.25 0.02 7631.88 6.35 0.17 37.63 Not Dominated 
69.50 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  
69.50 Adenovirus Vaccine 152.35 0.02 7514.12 6.44 0.17 38.25 Not Dominated 
76.00 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  





VARIABLE: effLP – Training days lost due to lost productivity 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.93 No Adenovirus Vaccines 145.90 0.16 920.40 0.00 0.00 0.00  
0.93 Adenovirus Vaccine 152.25 0.02 8816.17 6.35 0.14 44.95 Not Dominated 
1.24 No Adenovirus Vaccines 145.90 0.17 845.96 0.00 0.00 0.00  
1.24 Adenovirus Vaccine 152.25 0.02 8225.59 6.35 0.15 41.24 Not Dominated 
1.55 No Adenovirus Vaccines 145.90 0.19 782.65 0.00 0.00 0.00  
1.55 Adenovirus Vaccine 152.25 0.02 7709.17 6.35 0.17 38.09 Not Dominated 
1.86 No Adenovirus Vaccines 145.90 0.20 728.17 0.00 0.00 0.00  
1.86 Adenovirus Vaccine 152.25 0.02 7253.76 6.35 0.18 35.39 Not Dominated 
2.17 No Adenovirus Vaccines 145.90 0.21 680.77 0.00 0.00 0.00  
2.17 Adenovirus Vaccine 152.25 0.02 6849.15 6.35 0.19 33.05 Not Dominated 
 
VARIABLE: effMAE – Training days lost due to minor systemic reactions to adenovirus vaccine 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.03 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  
0.03 Adenovirus Vaccine 152.25 0.02 7642.61 6.35 0.17 37.62 Not Dominated 
0.07 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  
0.07 Adenovirus Vaccine 152.25 0.02 7636.86 6.35 0.17 37.63 Not Dominated 
0.11 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  
0.11 Adenovirus Vaccine 152.25 0.02 7631.12 6.35 0.17 37.63 Not Dominated 
0.14 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  
0.14 Adenovirus Vaccine 152.25 0.02 7625.39 6.35 0.17 37.63 Not Dominated 
0.18 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  





VARIABLE: effOUPT – Training days lost due to outpatient office visits 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.056 No Adenovirus Vaccines 145.90 0.19 776.68 0.00 0.00 0.00  
0.056 Adenovirus Vaccine 152.25 0.02 7658.95 6.35 0.17 37.80 Not Dominated 
0.063 No Adenovirus Vaccines 145.90 0.19 775.00 0.00 0.00 0.00  
0.063 Adenovirus Vaccine 152.25 0.02 7645.39 6.35 0.17 37.71 Not Dominated 
0.07 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  
0.07 Adenovirus Vaccine 152.25 0.02 7631.88 6.35 0.17 37.63 Not Dominated 
0.077 No Adenovirus Vaccines 145.90 0.19 771.65 0.00 0.00 0.00  
0.077 Adenovirus Vaccine 152.25 0.02 7618.43 6.35 0.17 37.55 Not Dominated 
0.084 No Adenovirus Vaccines 145.90 0.19 769.99 0.00 0.00 0.00  
0.084 Adenovirus Vaccine 152.25 0.02 7605.01 6.35 0.17 37.46 Not Dominated 
 
VARIABLE: effSIQ – Training days lost due to time spend in sick quarters 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
1 No Adenovirus Vaccines 133.55 0.15 918.96 0.00 0.00 0.00  
1 Adenovirus Vaccine 151.16 0.02 9390.47 17.61 0.13 136.25 Not Dominated 
1.5 No Adenovirus Vaccines 138.30 0.16 853.72 0.00 0.00 0.00  
1.5 Adenovirus Vaccine 151.58 0.02 8622.86 13.28 0.14 91.93 Not Dominated 
2 No Adenovirus Vaccines 143.05 0.18 800.66 0.00 0.00 0.00  
2 Adenovirus Vaccine 152.00 0.02 7974.61 8.95 0.16 56.05 Not Dominated 
2.5 No Adenovirus Vaccines 147.81 0.20 756.65 0.00 0.00 0.00  
2.5 Adenovirus Vaccine 152.42 0.02 7419.89 4.62 0.17 26.41 Not Dominated 
3 No Adenovirus Vaccines 152.56 0.21 719.57 0.00 0.00 0.00  




VARIABLE: pADVP – Probability of developing adenoviral pneumonia 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.067 No Adenovirus Vaccines 145.24 0.19 770.41 0.00 0.00 0.00  
0.067 Adenovirus Vaccine 152.19 0.02 7633.42 6.96 0.17 41.26 Not Dominated 
0.08825 No Adenovirus Vaccines 146.33 0.19 775.17 0.00 0.00 0.00  
0.08825 Adenovirus Vaccine 152.29 0.02 7630.91 5.96 0.17 35.32 Not Dominated 
0.1095 No Adenovirus Vaccines 147.42 0.19 779.92 0.00 0.00 0.00  
0.1095 Adenovirus Vaccine 152.39 0.02 7628.41 4.97 0.17 29.40 Not Dominated 
0.13075 No Adenovirus Vaccines 148.51 0.19 784.65 0.00 0.00 0.00  
0.13075 Adenovirus Vaccine 152.49 0.02 7625.92 3.98 0.17 23.50 Not Dominated 
0.152 No Adenovirus Vaccines 149.60 0.19 789.38 0.00 0.00 0.00  
0.152 Adenovirus Vaccine 152.58 0.02 7623.42 2.98 0.17 17.61 Not Dominated 
 
VARIABLE: pFRI_NOVAX – Probability of FRI when adenovirus vaccine not available 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.07 Adenovirus Vaccine 152.25 0.02 7631.88 0.00 0.00 0.00  
0.07 No Adenovirus Vaccines 238.64 0.31 773.32 86.38 -0.29 -299.28 (Dominated) 
0.08 Adenovirus Vaccine 152.25 0.02 7631.88 0.00 0.00 0.00  
0.08 No Adenovirus Vaccines 268.47 0.35 773.32 116.21 -0.33 -355.16 (Dominated) 
0.09 Adenovirus Vaccine 152.25 0.02 7631.88 0.00 0.00 0.00  
0.09 No Adenovirus Vaccines 298.29 0.39 773.32 146.04 -0.37 -399.26 (Dominated) 
0.10 Adenovirus Vaccine 152.25 0.02 7631.88 0.00 0.00 0.00  
0.10 No Adenovirus Vaccines 328.12 0.42 773.32 175.87 -0.40 -434.94 (Dominated) 
0.11 Adenovirus Vaccine 152.25 0.02 7631.88 0.00 0.00 0.00  





VARIABLE: pFRI_VAX – Probability of FRI after receiving adenovirus vaccine 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.008 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  
0.008 Adenovirus Vaccine 165.22 0.04 4495.92 19.32 0.15 127.15 Not Dominated 
0.009 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  
0.009 Adenovirus Vaccine 168.46 0.04 4113.98 22.56 0.15 152.71 Not Dominated 
0.01 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  
0.01 Adenovirus Vaccine 171.71 0.05 3803.09 25.80 0.14 179.77 Not Dominated 
0.011 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  
0.011 Adenovirus Vaccine 174.95 0.05 3545.13 29.04 0.14 208.46 Not Dominated 
0.012 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  
0.012 Adenovirus Vaccine 178.19 0.05 3327.62 32.29 0.14 238.94 Not Dominated 
 
VARIABLE: pGBS – Probability of developing Guillain – Barre Syndrome after vaccination 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0 Adenovirus Vaccine 140.50 0.02 8208.71 0.00 0.00 0.00  
0 No Adenovirus Vaccines 145.90 0.19 773.32 5.41 -0.17 -31.53 (Dominated) 
0.00013 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  
0.00013 Adenovirus Vaccine 172.83 0.02 6938.29 26.93 0.16 164.41 Not Dominated 
0.00025 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  
0.00025 Adenovirus Vaccine 205.16 0.03 6273.42 59.26 0.16 379.94 Not Dominated 
0.00038 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  
0.00038 Adenovirus Vaccine 237.50 0.04 5864.47 91.59 0.15 618.15 Not Dominated 
0.0005 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  





VARIABLE: pHOSP_VAX – Probability of hospitalization due to FRI 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.145 No Adenovirus Vaccines 96.44 0.18 523.18 0.00 0.00 0.00  
0.145 Adenovirus Vaccine 147.86 0.02 7555.94 51.42 0.16 312.08 Not Dominated 
0.163 No Adenovirus Vaccines 104.25 0.19 563.46 0.00 0.00 0.00  
0.163 Adenovirus Vaccine 148.55 0.02 7568.13 44.30 0.17 267.87 Not Dominated 
0.181 No Adenovirus Vaccines 112.06 0.19 603.44 0.00 0.00 0.00  
0.181 Adenovirus Vaccine 149.25 0.02 7580.24 37.19 0.17 223.99 Not Dominated 
0.199 No Adenovirus Vaccines 119.87 0.19 643.12 0.00 0.00 0.00  
0.199 Adenovirus Vaccine 149.94 0.02 7592.28 30.07 0.17 180.45 Not Dominated 
0.217 No Adenovirus Vaccines 127.68 0.19 682.51 0.00 0.00 0.00  
0.217 Adenovirus Vaccine 150.63 0.02 7604.25 22.95 0.17 137.23 Not Dominated 
 
VARIABLE: pMAE – Probability of minor systemic reactions due to adenovirus vaccine 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.08 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  
0.08 Adenovirus Vaccine 152.25 0.02 7635.04 6.35 0.17 37.63 Not Dominated 
0.09 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  
0.09 Adenovirus Vaccine 152.25 0.02 7633.46 6.35 0.17 37.63 Not Dominated 
0.1 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  
0.1 Adenovirus Vaccine 152.25 0.02 7631.88 6.35 0.17 37.63 Not Dominated 
0.11 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  
0.11 Adenovirus Vaccine 152.25 0.02 7630.31 6.35 0.17 37.63 Not Dominated 
0.12 No Adenovirus Vaccines 145.90 0.19 773.32 0.00 0.00 0.00  





VARIABLE: pSIQ_ONLY – Probability of going to sick quarters after outpatient office visit 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.76 No Adenovirus Vaccines 146.24 0.19 773.27 0.00 0.00 0.00  
0.76 Adenovirus Vaccine 152.28 0.02 7618.32 6.04 0.17 35.74 Not Dominated 
0.8175 No Adenovirus Vaccines 146.14 0.19 773.29 0.00 0.00 0.00  
0.8175 Adenovirus Vaccine 152.27 0.02 7622.42 6.14 0.17 36.31 Not Dominated 
0.875 No Adenovirus Vaccines 146.04 0.19 773.30 0.00 0.00 0.00  
0.875 Adenovirus Vaccine 152.27 0.02 7626.52 6.23 0.17 36.88 Not Dominated 
0.9325 No Adenovirus Vaccines 145.94 0.19 773.32 0.00 0.00 0.00  
0.9325 Adenovirus Vaccine 152.26 0.02 7630.63 6.32 0.17 37.45 Not Dominated 
0.99 No Adenovirus Vaccines 145.83 0.19 773.33 0.00 0.00 0.00  














AIR FORCE ONE –WAY SENSITIVITY ANALYSES RESULTS 
VARIABLE: cADVP – Cost of hospitalization due to adenoviral pneumonia 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
8455.06 Adenovirus Vaccine 177.23 0.06 2952.17 0.00 0.00 0.00  
8455.06 No Adenovirus Vaccine 296.34 0.45 662.59 119.11 -0.39 -307.60 (Dominated) 
9511.94 Adenovirus Vaccine 177.47 0.06 2956.07 0.00 0.00 0.00  
9511.94 No Adenovirus Vaccine 298.15 0.45 666.64 120.68 -0.39 -311.67 (Dominated) 
10568.82 Adenovirus Vaccine 177.70 0.06 2959.98 0.00 0.00 0.00  
10568.82 No Adenovirus Vaccine 299.95 0.45 670.68 122.25 -0.39 -315.73 (Dominated) 
11625.7 Adenovirus Vaccine 177.94 0.06 2963.88 0.00 0.00 0.00  
11625.7 No Adenovirus Vaccine 301.76 0.45 674.72 123.83 -0.39 -319.80 (Dominated) 
12682.58 Adenovirus Vaccine 178.17 0.06 2967.79 0.00 0.00 0.00  
12682.58 No Adenovirus Vaccine 303.57 0.45 678.77 125.40 -0.39 -323.86 (Dominated) 
 
VARIABLE: cADV_VAX – Cost of adenovirus vaccine 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
100.98 Adenovirus Vaccine 153.65 0.06 2559.39 0.00 0.00 0.00  
100.98 No Adenovirus Vaccine 309.14 0.45 691.22 155.49 -0.39 -401.57 (Dominated) 
138.235 Adenovirus Vaccine 190.91 0.06 3179.95 0.00 0.00 0.00  
138.235 No Adenovirus Vaccine 309.14 0.45 691.22 118.24 -0.39 -305.36 (Dominated) 
175.49 Adenovirus Vaccine 228.16 0.06 3800.51 0.00 0.00 0.00  
175.49 No Adenovirus Vaccine 309.14 0.45 691.22 80.98 -0.39 -209.14 (Dominated) 
212.745 Adenovirus Vaccine 265.42 0.06 4421.07 0.00 0.00 0.00  
212.745 No Adenovirus Vaccine 309.14 0.45 691.22 43.73 -0.39 -112.93 (Dominated) 
250 Adenovirus Vaccine 302.67 0.06 5041.62 0.00 0.00 0.00  




VARIABLE: cFLLW_UP – Cost of outpatient office visit for established patient 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
43.91 Adenovirus Vaccine 178.84 0.06 2979.03 0.00 0.00 0.00  
43.91 No Adenovirus Vaccine 308.78 0.45 690.41 129.93 -0.39 -335.57 (Dominated) 
51.2925 Adenovirus Vaccine 178.89 0.06 2979.78 0.00 0.00 0.00  
51.2925 No Adenovirus Vaccine 309.13 0.45 691.18 130.24 -0.39 -336.35 (Dominated) 
58.675 Adenovirus Vaccine 178.94 0.06 2980.53 0.00 0.00 0.00  
58.675 No Adenovirus Vaccine 309.47 0.45 691.96 130.54 -0.39 -337.13 (Dominated) 
66.0575 Adenovirus Vaccine 178.98 0.06 2981.28 0.00 0.00 0.00  
66.0575 No Adenovirus Vaccine 309.82 0.45 692.74 130.84 -0.39 -337.91 (Dominated) 
73.44 Adenovirus Vaccine 179.03 0.06 2982.03 0.00 0.00 0.00  
73.44 No Adenovirus Vaccine 310.17 0.45 693.52 131.14 -0.39 -338.69 (Dominated) 
 
VARIABLE: cGBS – Cost of Guillain – Barre Syndrome 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
194674.13 Adenovirus Vaccine 176.46 0.06 2939.28 0.00 0.00 0.00  
194674.13 No Adenovirus Vaccine 309.14 0.45 691.22 132.68 -0.39 -342.67 (Dominated) 
219008.395 Adenovirus Vaccine 177.68 0.06 2959.55 0.00 0.00 0.00  
219008.395 No Adenovirus Vaccine 309.14 0.45 691.22 131.47 -0.39 -339.53 (Dominated) 
243342.66 Adenovirus Vaccine 178.89 0.06 2979.82 0.00 0.00 0.00  
243342.66 No Adenovirus Vaccine 309.14 0.45 691.22 130.25 -0.39 -336.39 (Dominated) 
267676.925 Adenovirus Vaccine 180.11 0.06 3000.08 0.00 0.00 0.00  
267676.925 No Adenovirus Vaccine 309.14 0.45 691.22 129.03 -0.39 -333.24 (Dominated) 
292011.19 Adenovirus Vaccine 181.33 0.06 3020.35 0.00 0.00 0.00  





VARIABLE: cHOSP – Cost of hospitalization for FRI 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
8668.91 Adenovirus Vaccine 173.37 0.06 2887.76 0.00 0.00 0.00  
8668.91 No Adenovirus Vaccine 266.51 0.45 595.89 93.14 -0.39 -240.55 (Dominated) 
9752.52 Adenovirus Vaccine 176.13 0.06 2933.79 0.00 0.00 0.00  
9752.52 No Adenovirus Vaccine 287.82 0.45 643.56 111.70 -0.39 -288.47 (Dominated) 
10836.13 Adenovirus Vaccine 178.89 0.06 2979.82 0.00 0.00 0.00  
10836.13 No Adenovirus Vaccine 309.14 0.45 691.22 130.25 -0.39 -336.39 (Dominated) 
11919.74 Adenovirus Vaccine 181.66 0.06 3025.84 0.00 0.00 0.00  
11919.74 No Adenovirus Vaccine 330.46 0.45 738.89 148.81 -0.39 -384.31 (Dominated) 
13003.35 Adenovirus Vaccine 184.42 0.06 3071.87 0.00 0.00 0.00  
13003.35 No Adenovirus Vaccine 351.78 0.45 786.56 167.36 -0.39 -432.23 (Dominated) 
 
VARIABLE: cOUTPT – Cost of outpatient visit for new patient 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
72.53 Adenovirus Vaccine 178.75 0.06 2977.42 0.00 0.00 0.00  
72.53 No Adenovirus Vaccine 308.03 0.45 688.75 129.29 -0.39 -333.90 (Dominated) 
82.6625 Adenovirus Vaccine 178.86 0.06 2979.32 0.00 0.00 0.00  
82.6625 No Adenovirus Vaccine 308.91 0.45 690.71 130.05 -0.39 -335.87 (Dominated) 
92.795 Adenovirus Vaccine 178.98 0.06 2981.21 0.00 0.00 0.00  
92.795 No Adenovirus Vaccine 309.79 0.45 692.67 130.81 -0.39 -337.84 (Dominated) 
102.9275 Adenovirus Vaccine 179.09 0.06 2983.11 0.00 0.00 0.00  
102.9275 No Adenovirus Vaccine 310.67 0.45 694.63 131.58 -0.39 -339.81 (Dominated) 
113.06 Adenovirus Vaccine 179.20 0.06 2985.00 0.00 0.00 0.00  





VARIABLE: cTRAIN – Cost to train basic trainee per day 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
262.15 Adenovirus Vaccine 180.35 0.06 3004.05 0.00 0.00 0.00  
262.15 No Adenovirus Vaccine 319.76 0.45 714.97 139.42 -0.39 -360.06 (Dominated) 
311.3875 Adenovirus Vaccine 182.14 0.06 3033.83 0.00 0.00 0.00  
311.3875 No Adenovirus Vaccine 332.82 0.45 744.16 150.68 -0.39 -389.15 (Dominated) 
360.625 Adenovirus Vaccine 183.92 0.06 3063.61 0.00 0.00 0.00  
360.625 No Adenovirus Vaccine 345.87 0.45 773.34 161.95 -0.39 -418.24 (Dominated) 
409.8625 Adenovirus Vaccine 185.71 0.06 3093.39 0.00 0.00 0.00  
409.8625 No Adenovirus Vaccine 358.92 0.45 802.52 173.21 -0.39 -447.33 (Dominated) 
459.1 Adenovirus Vaccine 187.50 0.06 3123.17 0.00 0.00 0.00  
459.1 No Adenovirus Vaccine 371.97 0.45 831.71 184.47 -0.39 -476.42 (Dominated) 
 
VARIABLE: effADV_HOSP – Training days lost due to adenoviral pneumonia hospitalization 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
3 Adenovirus Vaccine 178.84 0.06 2990.04 0.00 0.00 0.00  
3 No Adenovirus Vaccine 308.76 0.45 693.02 129.92 -0.39 -336.83 (Dominated) 
4 Adenovirus Vaccine 178.89 0.06 2979.82 0.00 0.00 0.00  
4 No Adenovirus Vaccine 309.14 0.45 691.22 130.25 -0.39 -336.39 (Dominated) 
5 Adenovirus Vaccine 178.94 0.06 2969.67 0.00 0.00 0.00  
5 No Adenovirus Vaccine 309.52 0.45 689.44 130.58 -0.39 -335.95 (Dominated) 
6 Adenovirus Vaccine 178.99 0.06 2959.59 0.00 0.00 0.00  
6 No Adenovirus Vaccine 309.90 0.45 687.66 130.91 -0.39 -335.51 (Dominated) 
7 Adenovirus Vaccine 179.04 0.06 2949.59 0.00 0.00 0.00  





VARIABLE: effFRI_HOSP – Training days lost due to FRI hospitalization 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
1 Adenovirus Vaccine 177.76 0.05 3235.85 0.00 0.00 0.00  
1 No Adenovirus Vaccine 300.40 0.41 736.48 122.64 -0.35 -347.48 (Dominated) 
3.75 Adenovirus Vaccine 179.32 0.06 2894.67 0.00 0.00 0.00  
3.75 No Adenovirus Vaccine 312.42 0.46 676.24 133.10 -0.40 -332.72 (Dominated) 
6.5 Adenovirus Vaccine 180.87 0.07 2622.89 0.00 0.00 0.00  
6.5 No Adenovirus Vaccine 324.43 0.52 628.63 143.56 -0.45 -321.07 (Dominated) 
9.25 Adenovirus Vaccine 182.43 0.08 2401.28 0.00 0.00 0.00  
9.25 No Adenovirus Vaccine 336.45 0.57 590.06 154.02 -0.49 -311.63 (Dominated) 
12 Adenovirus Vaccine 183.99 0.08 2217.12 0.00 0.00 0.00  
12 No Adenovirus Vaccine 348.46 0.62 558.17 164.47 -0.54 -303.84 (Dominated) 
 
VARIABLE: effGBS – Training days lost due to Guillain – Barre Syndrome 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
31 Adenovirus Vaccine 178.80 0.06 2998.31 0.00 0.00 0.00  
31 No Adenovirus Vaccine 309.14 0.45 691.22 130.34 -0.39 -336.27 (Dominated) 
35 Adenovirus Vaccine 178.85 0.06 2989.03 0.00 0.00 0.00  
35 No Adenovirus Vaccine 309.14 0.45 691.22 130.29 -0.39 -336.33 (Dominated) 
39 Adenovirus Vaccine 178.89 0.06 2979.82 0.00 0.00 0.00  
39 No Adenovirus Vaccine 309.14 0.45 691.22 130.25 -0.39 -336.39 (Dominated) 
43 Adenovirus Vaccine 178.94 0.06 2970.66 0.00 0.00 0.00  
43 No Adenovirus Vaccine 309.14 0.45 691.22 130.21 -0.39 -336.45 (Dominated) 
47 Adenovirus Vaccine 178.98 0.06 2961.56 0.00 0.00 0.00  





VARIABLE: effLP – Training days lost due to lost productivity 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.93 Adenovirus Vaccine 178.89 0.05 3531.57 0.00 0.00 0.00  
0.93 No Adenovirus Vaccine 309.14 0.37 824.64 130.25 -0.32 -401.73 (Dominated) 
1.24 Adenovirus Vaccine 178.89 0.05 3252.89 0.00 0.00 0.00  
1.24 No Adenovirus Vaccine 309.14 0.41 757.04 130.25 -0.35 -368.60 (Dominated) 
1.55 Adenovirus Vaccine 178.89 0.06 3014.97 0.00 0.00 0.00  
1.55 No Adenovirus Vaccine 309.14 0.44 699.67 130.25 -0.38 -340.52 (Dominated) 
1.86 Adenovirus Vaccine 178.89 0.06 2809.48 0.00 0.00 0.00  
1.86 No Adenovirus Vaccine 309.14 0.48 650.39 130.25 -0.41 -316.41 (Dominated) 
2.17 Adenovirus Vaccine 178.89 0.07 2630.22 0.00 0.00 0.00  
2.17 No Adenovirus Vaccine 309.14 0.51 607.59 130.25 -0.44 -295.50 (Dominated) 
 
VARIABLE: effMAE – Training days lost due to minor systemic reactions  
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.03 Adenovirus Vaccine 178.89 0.06 2984.69 0.00 0.00 0.00  
0.03 No Adenovirus Vaccine 309.14 0.45 691.22 130.25 -0.39 -336.30 (Dominated) 
0.0675 Adenovirus Vaccine 178.89 0.06 2982.08 0.00 0.00 0.00  
0.0675 No Adenovirus Vaccine 309.14 0.45 691.22 130.25 -0.39 -336.35 (Dominated) 
0.105 Adenovirus Vaccine 178.89 0.06 2979.47 0.00 0.00 0.00  
0.105 No Adenovirus Vaccine 309.14 0.45 691.22 130.25 -0.39 -336.39 (Dominated) 
0.1425 Adenovirus Vaccine 178.89 0.06 2976.87 0.00 0.00 0.00  
0.1425 No Adenovirus Vaccine 309.14 0.45 691.22 130.25 -0.39 -336.44 (Dominated) 
0.18 Adenovirus Vaccine 178.89 0.06 2974.27 0.00 0.00 0.00  





VARIABLE: effOUTPT – Training days lost due to outpatient visits 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.056 Adenovirus Vaccine 178.89 0.06 2991.63 0.00 0.00 0.00  
0.056 No Adenovirus Vaccine 309.14 0.45 694.13 130.25 -0.39 -337.81 (Dominated) 
0.063 Adenovirus Vaccine 178.89 0.06 2985.71 0.00 0.00 0.00  
0.063 No Adenovirus Vaccine 309.14 0.45 692.67 130.25 -0.39 -337.10 (Dominated) 
0.07 Adenovirus Vaccine 178.89 0.06 2979.82 0.00 0.00 0.00  
0.07 No Adenovirus Vaccine 309.14 0.45 691.22 130.25 -0.39 -336.39 (Dominated) 
0.077 Adenovirus Vaccine 178.89 0.06 2973.94 0.00 0.00 0.00  
0.077 No Adenovirus Vaccine 309.14 0.45 689.78 130.25 -0.39 -335.68 (Dominated) 
0.084 Adenovirus Vaccine 178.89 0.06 2968.10 0.00 0.00 0.00  
0.084 No Adenovirus Vaccine 309.14 0.45 688.34 130.25 -0.39 -334.97 (Dominated) 
 
VARIABLE: effSIQ – Training days lost due to time spent in sick quarters 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
1 Adenovirus Vaccine 175.65 0.05 3865.64 0.00 0.00 0.00  
1 No Adenovirus Vaccine 284.14 0.33 849.08 108.49 -0.29 -375.12 (Dominated) 
1.5 Adenovirus Vaccine 176.90 0.05 3465.00 0.00 0.00 0.00  
1.5 No Adenovirus Vaccine 293.75 0.38 777.24 116.86 -0.33 -357.47 (Dominated) 
2 Adenovirus Vaccine 178.14 0.06 3143.73 0.00 0.00 0.00  
2 No Adenovirus Vaccine 303.37 0.42 720.16 125.23 -0.36 -343.48 (Dominated) 
2.5 Adenovirus Vaccine 179.39 0.06 2880.39 0.00 0.00 0.00  
2.5 No Adenovirus Vaccine 312.99 0.46 673.73 133.60 -0.40 -332.10 (Dominated) 
3 Adenovirus Vaccine 180.64 0.07 2660.59 0.00 0.00 0.00  





VARIABLE: pFRI_NOVAX – Probability of FRI when vaccine not available 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.0864 Adenovirus Vaccine 178.89 0.06 2979.82 0.00 0.00 0.00  
0.0864 No Adenovirus Vaccine 247.31 0.36 691.22 68.42 -0.30 -229.79 (Dominated) 
0.0972 Adenovirus Vaccine 178.89 0.06 2979.82 0.00 0.00 0.00  
0.0972 No Adenovirus Vaccine 278.23 0.40 691.22 99.34 -0.34 -290.05 (Dominated) 
0.108 Adenovirus Vaccine 178.89 0.06 2979.82 0.00 0.00 0.00  
0.108 No Adenovirus Vaccine 309.14 0.45 691.22 130.25 -0.39 -336.39 (Dominated) 
0.1188 Adenovirus Vaccine 178.89 0.06 2979.82 0.00 0.00 0.00  
0.1188 No Adenovirus Vaccine 340.06 0.49 691.22 161.16 -0.43 -373.13 (Dominated) 
0.1296 Adenovirus Vaccine 178.89 0.06 2979.82 0.00 0.00 0.00  
0.1296 No Adenovirus Vaccine 370.97 0.54 691.22 192.08 -0.48 -402.97 (Dominated) 
 
VARIABLE: pADVP – Probability of adenoviral pneumonia hospitalization 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.072 Adenovirus Vaccine 178.77 0.06 2978.81 0.00 0.00 0.00  
0.072 No Adenovirus Vaccine 308.23 0.45 689.45 129.46 -0.39 -334.47 (Dominated) 
0.092 Adenovirus Vaccine 179.07 0.06 2981.32 0.00 0.00 0.00  
0.092 No Adenovirus Vaccine 310.51 0.45 693.88 131.44 -0.39 -339.26 (Dominated) 
0.112 Adenovirus Vaccine 179.36 0.06 2983.83 0.00 0.00 0.00  
0.112 No Adenovirus Vaccine 312.79 0.45 698.30 133.42 -0.39 -344.04 (Dominated) 
0.132 Adenovirus Vaccine 179.66 0.06 2986.34 0.00 0.00 0.00  
0.132 No Adenovirus Vaccine 315.06 0.45 702.72 135.40 -0.39 -348.81 (Dominated) 
0.152 Adenovirus Vaccine 179.96 0.06 2988.84 0.00 0.00 0.00  





VARIABLE: pFRI_VAX – Probability of FRI after vaccination 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.0112 Adenovirus Vaccine 170.88 0.05 3529.24 0.00 0.00 0.00  
0.0112 No Adenovirus Vaccine 309.14 0.45 691.22 138.26 -0.40 -346.68 (Dominated) 
0.0126 Adenovirus Vaccine 174.89 0.05 3225.10 0.00 0.00 0.00  
0.0126 No Adenovirus Vaccine 309.14 0.45 691.22 134.26 -0.39 -341.61 (Dominated) 
0.014 Adenovirus Vaccine 178.89 0.06 2979.82 0.00 0.00 0.00  
0.014 No Adenovirus Vaccine 309.14 0.45 691.22 130.25 -0.39 -336.39 (Dominated) 
0.0154 Adenovirus Vaccine 182.90 0.07 2777.81 0.00 0.00 0.00  
0.0154 No Adenovirus Vaccine 309.14 0.45 691.22 126.24 -0.38 -331.00 (Dominated) 
0.0168 Adenovirus Vaccine 186.91 0.07 2608.55 0.00 0.00 0.00  
0.0168 No Adenovirus Vaccine 309.14 0.45 691.22 122.24 -0.38 -325.45 (Dominated) 
 
VARIABLE: pGBS – Probability of Guillain – Barre Syndrome after adenovirus vaccination 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0 Adenovirus Vaccine 167.55 0.06 2874.87 0.00 0.00 0.00  
0 No Adenovirus Vaccine 309.14 0.45 691.22 141.59 -0.39 -364.02 (Dominated) 
1.30E-04 Adenovirus Vaccine 198.73 0.06 3149.45 0.00 0.00 0.00  
1.30E-04 No Adenovirus Vaccine 309.14 0.45 691.22 110.41 -0.38 -287.42 (Dominated) 
2.50E-04 Adenovirus Vaccine 229.91 0.07 3385.06 0.00 0.00 0.00  
2.50E-04 No Adenovirus Vaccine 309.14 0.45 691.22 79.23 -0.38 -208.87 (Dominated) 
3.80E-04 Adenovirus Vaccine 261.10 0.07 3589.46 0.00 0.00 0.00  
3.80E-04 No Adenovirus Vaccine 309.14 0.45 691.22 48.05 -0.37 -128.30 (Dominated) 
5.00E-04 Adenovirus Vaccine 292.28 0.08 3768.45 0.00 0.00 0.00  





VARIABLE: pHOSP_VAX – Probability of hospitalization due to FRI 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.1584 Adenovirus Vaccine 172.55 0.06 2896.61 0.00 0.00 0.00  
0.1584 No Adenovirus Vaccine 260.25 0.44 586.64 87.69 -0.38 -228.33 (Dominated) 
0.1782 Adenovirus Vaccine 175.72 0.06 2938.38 0.00 0.00 0.00  
0.1782 No Adenovirus Vaccine 284.69 0.45 639.15 108.97 -0.39 -282.58 (Dominated) 
0.198 Adenovirus Vaccine 178.89 0.06 2979.82 0.00 0.00 0.00  
0.198 No Adenovirus Vaccine 309.14 0.45 691.22 130.25 -0.39 -336.39 (Dominated) 
0.2178 Adenovirus Vaccine 182.06 0.06 3020.94 0.00 0.00 0.00  
0.2178 No Adenovirus Vaccine 333.59 0.45 742.88 151.53 -0.39 -389.75 (Dominated) 
0.2376 Adenovirus Vaccine 185.23 0.06 3061.74 0.00 0.00 0.00  
0.2376 No Adenovirus Vaccine 358.04 0.45 794.13 172.81 -0.39 -442.69 (Dominated) 
 
VARIABLE: pMAE – Probability of minor systemic reactions due to adenovirus vaccine 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.08 Adenovirus Vaccine 178.89 0.06 2981.24 0.00 0.00 0.00  
0.08 No Adenovirus Vaccine 309.14 0.45 691.22 130.25 -0.39 -336.36 (Dominated) 
0.09 Adenovirus Vaccine 178.89 0.06 2980.53 0.00 0.00 0.00  
0.09 No Adenovirus Vaccine 309.14 0.45 691.22 130.25 -0.39 -336.37 (Dominated) 
0.1 Adenovirus Vaccine 178.89 0.06 2979.82 0.00 0.00 0.00  
0.1 No Adenovirus Vaccine 309.14 0.45 691.22 130.25 -0.39 -336.39 (Dominated) 
0.11 Adenovirus Vaccine 178.89 0.06 2979.11 0.00 0.00 0.00  
0.11 No Adenovirus Vaccine 309.14 0.45 691.22 130.25 -0.39 -336.40 (Dominated) 
0.12 Adenovirus Vaccine 178.89 0.06 2978.40 0.00 0.00 0.00  





VARIABLE: pSIQ_ONLY – Probability of being in sick quarters 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.76 Adenovirus Vaccine 179.00 0.06 2974.25 0.00 0.00 0.00  
0.76 No Adenovirus Vaccine 309.99 0.45 691.34 130.99 -0.39 -337.42 (Dominated) 
0.8175 Adenovirus Vaccine 178.97 0.06 2975.93 0.00 0.00 0.00  
0.8175 No Adenovirus Vaccine 309.74 0.45 691.31 130.77 -0.39 -337.11 (Dominated) 
0.875 Adenovirus Vaccine 178.94 0.06 2977.62 0.00 0.00 0.00  
0.875 No Adenovirus Vaccine 309.48 0.45 691.27 130.54 -0.39 -336.80 (Dominated) 
0.9325 Adenovirus Vaccine 178.90 0.06 2979.30 0.00 0.00 0.00  
0.9325 No Adenovirus Vaccine 309.22 0.45 691.23 130.32 -0.39 -336.48 (Dominated) 
0.99 Adenovirus Vaccine 178.87 0.06 2980.99 0.00 0.00 0.00  














COAST GUARD ONE – WAY SENSITIVITY ANALYSES RESULTS 
VARIABLE: cADVP – Cost of adenoviral pneumonia hospitalization 
 
VARIABLE: cADV_VAX – Cost of adenovirus vaccine 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
100.98 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
100.98 Adenovirus Vaccine 122.87 0.02 5430.96 52.74 0.14 381.30 Not Dominated 
113.60 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
113.60 Adenovirus Vaccine 135.49 0.02 5988.79 65.36 0.14 472.54 Not Dominated 
126.22 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
126.22 Adenovirus Vaccine 148.11 0.02 6546.62 77.98 0.14 563.78 Not Dominated 
138.84 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
138.84 Adenovirus Vaccine 160.73 0.02 7104.45 90.60 0.14 655.02 Not Dominated 
151.46 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
151.46 Adenovirus Vaccine 173.35 0.02 7662.28 103.22 0.14 746.26 Not Dominated 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
3292.17 No Adenovirus Vaccine 68.80 0.16 427.47 0.00 0.00 0.00  
3292.17 Adenovirus Vaccine 147.94 0.02 6539.10 79.14 0.14 572.15 Not Dominated 
3703.69 No Adenovirus Vaccine 69.03 0.16 428.92 0.00 0.00 0.00  
3703.69 Adenovirus Vaccine 147.97 0.02 6540.42 78.94 0.14 570.68 Not Dominated 
4115.21 No Adenovirus Vaccine 69.26 0.16 430.36 0.00 0.00 0.00  
4115.21 Adenovirus Vaccine 148.00 0.02 6541.74 78.73 0.14 569.22 Not Dominated 
4526.73 No Adenovirus Vaccine 69.50 0.16 431.81 0.00 0.00 0.00  
4526.73 Adenovirus Vaccine 148.03 0.02 6543.05 78.53 0.14 567.75 Not Dominated 
4938.25 No Adenovirus Vaccine 69.73 0.16 433.25 0.00 0.00 0.00  




VARIABLE: cFLLW_UP – Cost of outpatient visit for established patient 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
47.84 No Adenovirus Vaccine 69.99 0.16 434.90 0.00 0.00 0.00  
47.84 Adenovirus Vaccine 148.09 0.02 6545.87 78.10 0.14 564.62 Not Dominated 
56.68 No Adenovirus Vaccine 70.13 0.16 435.76 0.00 0.00 0.00  
56.68 Adenovirus Vaccine 148.11 0.02 6546.66 77.98 0.14 563.74 Not Dominated 
65.51 No Adenovirus Vaccine 70.27 0.16 436.62 0.00 0.00 0.00  
65.51 Adenovirus Vaccine 148.13 0.02 6547.44 77.85 0.14 562.87 Not Dominated 
74.35 No Adenovirus Vaccine 70.41 0.16 437.48 0.00 0.00 0.00  
74.35 Adenovirus Vaccine 148.14 0.02 6548.23 77.73 0.14 561.99 Not Dominated 
83.18 No Adenovirus Vaccine 70.55 0.16 438.35 0.00 0.00 0.00  
83.18 Adenovirus Vaccine 148.16 0.02 6549.02 77.61 0.14 561.12 Not Dominated 
 
VARIABLE: cGBS – Cost of Guillain – Barre Syndrome 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
194674.13 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
194674.13 Adenovirus Vaccine 145.67 0.02 6439.06 75.55 0.14 546.19 Not Dominated 
219008.40 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
219008.40 Adenovirus Vaccine 146.89 0.02 6492.84 76.76 0.14 554.98 Not Dominated 
243342.66 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
243342.66 Adenovirus Vaccine 148.11 0.02 6546.62 77.98 0.14 563.78 Not Dominated 
267676.93 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
267676.93 Adenovirus Vaccine 149.32 0.02 6600.40 79.20 0.14 572.58 Not Dominated 
292011.19 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  





VARIABLE: cHOSP – Cost of hospitalization due to FRI 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
3375.44 No Adenovirus Vaccine 64.65 0.16 401.67 0.00 0.00 0.00  
3375.44 Adenovirus Vaccine 147.40 0.02 6515.57 82.76 0.14 598.32 Not Dominated 
3797.37 No Adenovirus Vaccine 67.39 0.16 418.70 0.00 0.00 0.00  
3797.37 Adenovirus Vaccine 147.76 0.02 6531.09 80.37 0.14 581.05 Not Dominated 
4219.30 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
4219.30 Adenovirus Vaccine 148.11 0.02 6546.62 77.98 0.14 563.78 Not Dominated 
4641.23 No Adenovirus Vaccine 72.87 0.16 452.75 0.00 0.00 0.00  
4641.23 Adenovirus Vaccine 148.46 0.02 6562.15 75.59 0.14 546.51 Not Dominated 
5063.16 No Adenovirus Vaccine 75.61 0.16 469.77 0.00 0.00 0.00  
5063.16 Adenovirus Vaccine 148.81 0.02 6577.68 73.20 0.14 529.24 Not Dominated 
 
 
VARIABLE: cOUTPT – Cost of outpatient visit for new patient 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
79.33 No Adenovirus Vaccine 69.64 0.16 432.71 0.00 0.00 0.00  
79.33 Adenovirus Vaccine 148.04 0.02 6543.87 78.40 0.14 566.84 Not Dominated 
91.38 No Adenovirus Vaccine 70.03 0.16 435.10 0.00 0.00 0.00  
91.38 Adenovirus Vaccine 148.09 0.02 6546.05 78.07 0.14 564.41 Not Dominated 
103.43 No Adenovirus Vaccine 70.41 0.16 437.49 0.00 0.00 0.00  
103.43 Adenovirus Vaccine 148.14 0.02 6548.23 77.73 0.14 561.99 Not Dominated 
115.47 No Adenovirus Vaccine 70.80 0.16 439.88 0.00 0.00 0.00  
115.47 Adenovirus Vaccine 148.19 0.02 6550.41 77.40 0.14 559.56 Not Dominated 
127.52 No Adenovirus Vaccine 71.18 0.16 442.27 0.00 0.00 0.00  




VARIABLE: cTRAIN – Cost to train basic trainee per day 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
299.43 No Adenovirus Vaccine 63.00 0.16 391.44 0.00 0.00 0.00  
299.43 Adenovirus Vaccine 147.05 0.02 6499.78 84.05 0.14 607.65 Not Dominated 
336.86 No Adenovirus Vaccine 66.56 0.16 413.58 0.00 0.00 0.00  
336.86 Adenovirus Vaccine 147.58 0.02 6523.20 81.02 0.14 585.71 Not Dominated 
374.29 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
374.29 Adenovirus Vaccine 148.11 0.02 6546.62 77.98 0.14 563.78 Not Dominated 
411.72 No Adenovirus Vaccine 73.69 0.16 457.86 0.00 0.00 0.00  
411.72 Adenovirus Vaccine 148.64 0.02 6570.04 74.95 0.14 541.85 Not Dominated 
449.15 No Adenovirus Vaccine 77.25 0.16 480.00 0.00 0.00 0.00  
449.15 Adenovirus Vaccine 149.17 0.02 6593.46 71.91 0.14 519.91 Not Dominated 
 
VARIABLE: effADV_HOSP – Training days lost due to hospitalization for adenoviral pneumonia 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
3.00 No Adenovirus Vaccine 69.91 0.16 435.94 0.00 0.00 0.00  
3.00 Adenovirus Vaccine 148.08 0.02 6566.44 78.17 0.14 567.13 Not Dominated 
4.00 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
4.00 Adenovirus Vaccine 148.11 0.02 6546.62 77.98 0.14 563.78 Not Dominated 
5.00 No Adenovirus Vaccine 70.34 0.16 435.51 0.00 0.00 0.00  
5.00 Adenovirus Vaccine 148.13 0.02 6526.93 77.80 0.14 560.45 Not Dominated 
6.00 No Adenovirus Vaccine 70.55 0.16 435.29 0.00 0.00 0.00  
6.00 Adenovirus Vaccine 148.16 0.02 6507.37 77.61 0.14 557.15 Not Dominated 
7.00 No Adenovirus Vaccine 70.76 0.16 435.08 0.00 0.00 0.00  





VARIABLE: effFRI_HOSP – Training days lost due to FRI hospitalization 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
1.00 No Adenovirus Vaccine 65.26 0.15 441.11 0.00 0.00 0.00  
1.00 Adenovirus Vaccine 147.48 0.02 7037.01 82.22 0.13 647.42 Not Dominated 
3.75 No Adenovirus Vaccine 71.95 0.17 433.92 0.00 0.00 0.00  
3.75 Adenovirus Vaccine 148.34 0.02 6380.84 76.39 0.14 535.84 Not Dominated 
6.50 No Adenovirus Vaccine 78.63 0.18 428.12 0.00 0.00 0.00  
6.50 Adenovirus Vaccine 149.20 0.03 5842.33 70.56 0.16 446.23 Not Dominated 
9.25 No Adenovirus Vaccine 85.32 0.20 423.35 0.00 0.00 0.00  
9.25 Adenovirus Vaccine 150.05 0.03 5392.43 64.74 0.17 372.68 Not Dominated 
12.00 No Adenovirus Vaccine 92.00 0.22 419.35 0.00 0.00 0.00  
12.00 Adenovirus Vaccine 150.91 0.03 5010.94 58.91 0.19 311.24 Not Dominated 
 
 
VARIABLE: effGBS – Training days lost due to Guillain – Barre Syndrome 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
31.00 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
31.00 Adenovirus Vaccine 147.96 0.02 6657.72 77.83 0.14 561.08 Not Dominated 
35.00 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
35.00 Adenovirus Vaccine 148.03 0.02 6601.67 77.91 0.14 562.43 Not Dominated 
39.00 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
39.00 Adenovirus Vaccine 148.11 0.02 6546.62 77.98 0.14 563.78 Not Dominated 
43.00 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
43.00 Adenovirus Vaccine 148.18 0.02 6492.53 78.06 0.14 565.14 Not Dominated 
47.00 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  





VARIABLE: effLP – Training days lost due to lost productivity 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.93 No Adenovirus Vaccine 70.13 0.13 520.17 0.00 0.00 0.00  
0.93 Adenovirus Vaccine 148.11 0.02 7684.45 77.98 0.12 674.94 Not Dominated 
1.24 No Adenovirus Vaccine 70.13 0.15 477.36 0.00 0.00 0.00  
1.24 Adenovirus Vaccine 148.11 0.02 7112.49 77.98 0.13 618.51 Not Dominated  
1.55 No Adenovirus Vaccine 70.13 0.16 441.06 0.00 0.00 0.00  
1.55 Adenovirus Vaccine 148.11 0.02 6619.77 77.98 0.14 570.80 Not Dominated 
1.86 No Adenovirus Vaccine 70.13 0.17 409.90 0.00 0.00 0.00  
1.86 Adenovirus Vaccine 148.11 0.02 6190.89 77.98 0.15 529.91 Not Dominated 
2.17 No Adenovirus Vaccine 70.13 0.18 382.84 0.00 0.00 0.00  
2.17 Adenovirus Vaccine 148.11 0.03 5814.21 77.98 0.16 494.50 Not Dominated 
 
VARIABLE: effMAE – Training days lost due to minor systemic reactions 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.03 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
0.03 Adenovirus Vaccine 148.11 0.02 6556.77 77.98 0.14 563.64 Not Dominated 
0.07 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
0.07 Adenovirus Vaccine 148.11 0.02 6551.33 77.98 0.14 563.71 Not Dominated 
0.11 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
0.11 Adenovirus Vaccine 148.11 0.02 6545.90 77.98 0.14 563.79 Not Dominated 
0.14 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
0.14 Adenovirus Vaccine 148.11 0.02 6540.48 77.98 0.14 563.87 Not Dominated 
0.18 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  





VARIABLE: effOUTPT – Training days lost due to outpatient visits 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.06 No Adenovirus Vaccine 70.13 0.16 437.53 0.00 0.00 0.00  
0.06 Adenovirus Vaccine 148.11 0.02 6570.93 77.98 0.14 566.17 Not Dominated 
0.06 No Adenovirus Vaccine 70.13 0.16 436.63 0.00 0.00 0.00  
0.06 Adenovirus Vaccine 148.11 0.02 6558.76 77.98 0.14 564.97 Not Dominated 
0.07 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
0.07 Adenovirus Vaccine 148.11 0.02 6546.62 77.98 0.14 563.78 Not Dominated 
0.08 No Adenovirus Vaccine 70.13 0.16 434.82 0.00 0.00 0.00  
0.08 Adenovirus Vaccine 148.11 0.02 6534.53 77.98 0.14 562.59 Not Dominated 
0.08 No Adenovirus Vaccine 70.13 0.16 433.92 0.00 0.00 0.00  
0.08 Adenovirus Vaccine 148.11 0.02 6522.49 77.98 0.14 561.41 Not Dominated 
 
VARIABLE: effSIQ – Training days lost due to time spent in sick quarters 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
1.00 No Adenovirus Vaccine 54.58 0.12 457.08 0.00 0.00 0.00  
1.00 Adenovirus Vaccine 146.11 0.02 8445.84 91.53 0.10 896.32 Not Dominated 
1.50 No Adenovirus Vaccine 60.56 0.14 447.32 0.00 0.00 0.00  
1.50 Adenovirus Vaccine 146.88 0.02 7591.69 86.32 0.12 743.87 Not Dominated 
2.00 No Adenovirus Vaccine 66.54 0.15 439.61 0.00 0.00 0.00  
2.00 Adenovirus Vaccine 147.65 0.02 6901.02 81.11 0.13 624.08 Not Dominated 
2.50 No Adenovirus Vaccine 72.52 0.17 433.38 0.00 0.00 0.00  
2.50 Adenovirus Vaccine 148.41 0.02 6330.99 75.90 0.14 527.47 Not Dominated 
3.00 No Adenovirus Vaccine 78.49 0.18 428.23 0.00 0.00 0.00  





VARIABLE: pADVP – Probability of developing adenoviral pneumonia 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.07 No Adenovirus Vaccine 70.02 0.16 435.24 0.00 0.00 0.00  
0.07 Adenovirus Vaccine 148.09 0.02 6547.88 78.07 0.14 564.62 Not Dominated 
0.09 No Adenovirus Vaccine 70.28 0.16 436.44 0.00 0.00 0.00  
0.09 Adenovirus Vaccine 148.13 0.02 6544.74 77.85 0.14 562.51 Not Dominated 
0.11 No Adenovirus Vaccine 70.53 0.16 437.63 0.00 0.00 0.00  
0.11 Adenovirus Vaccine 148.16 0.02 6541.60 77.63 0.14 560.41 Not Dominated 
0.13 No Adenovirus Vaccine 70.79 0.16 438.82 0.00 0.00 0.00  
0.13 Adenovirus Vaccine 148.19 0.02 6538.47 77.41 0.14 558.31 Not Dominated 
0.15 No Adenovirus Vaccine 71.04 0.16 440.01 0.00 0.00 0.00  
0.15 Adenovirus Vaccine 148.22 0.02 6535.35 77.18 0.14 556.21 Not Dominated 
 
VARIABLE: pFRI_NOVAX – Probability of developing FRI when adenovirus vaccine is not available 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.03 No Adenovirus Vaccine 56.10 0.13 435.72 0.00 0.00 0.00  
0.03 Adenovirus Vaccine 148.11 0.02 6546.62 92.01 0.11 866.92 Not Dominated 
0.04 No Adenovirus Vaccine 63.11 0.14 435.72 0.00 0.00 0.00  
0.04 Adenovirus Vaccine 148.11 0.02 6546.62 84.99 0.12 695.39 Not Dominated 
0.04 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
0.04 Adenovirus Vaccine 148.11 0.02 6546.62 77.98 0.14 563.78 Not Dominated 
0.04 No Adenovirus Vaccine 77.14 0.18 435.72 0.00 0.00 0.00  
0.04 Adenovirus Vaccine 148.11 0.02 6546.62 70.97 0.15 459.60 Not Dominated 
0.05 No Adenovirus Vaccine 84.15 0.19 435.72 0.00 0.00 0.00  





VARIABLE: pFRI_VAX – Probability of developing FRI after adenovirus vaccination 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.00 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
0.00 Adenovirus Vaccine 146.31 0.02 7913.41 76.18 0.14 534.80 Not Dominated 
0.00 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
0.00 Adenovirus Vaccine 147.21 0.02 7161.29 77.08 0.14 549.07 Not Dominated 
0.01 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
0.01 Adenovirus Vaccine 148.11 0.02 6546.62 77.98 0.14 563.78 Not Dominated 
0.01 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
0.01 Adenovirus Vaccine 149.01 0.02 6034.89 78.88 0.14 578.93 Not Dominated 
0.01 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
0.01 Adenovirus Vaccine 149.91 0.03 5602.23 79.78 0.13 594.55 Not Dominated 
 
VARIABLE: pGBS – Probability of developing Guillain – Barre Syndrome after adenovirus vaccine 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.00 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
0.00 Adenovirus Vaccine 136.50 0.02 6540.70 66.37 0.14 473.86 Not Dominated 
0.00 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
0.00 Adenovirus Vaccine 168.42 0.03 6555.04 98.29 0.14 726.76 Not Dominated 
0.00 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
0.00 Adenovirus Vaccine 200.34 0.03 6564.85 130.21 0.13 998.37 Not Dominated 
0.00 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
0.00 Adenovirus Vaccine 232.26 0.04 6571.99 162.13 0.13 1290.84 Not Dominated 
0.00 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  





VARIABLE: pHOSP_VAX – Probability of being hospitalized due to FRI 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.14 No Adenovirus Vaccine 63.57 0.16 397.97 0.00 0.00 0.00  
0.14 Adenovirus Vaccine 147.27 0.02 6553.35 83.69 0.14 609.67 Not Dominated 
0.16 No Adenovirus Vaccine 66.85 0.16 416.92 0.00 0.00 0.00  
0.16 Adenovirus Vaccine 147.69 0.02 6549.97 80.84 0.14 586.64 Not Dominated 
0.18 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
0.18 Adenovirus Vaccine 148.11 0.02 6546.62 77.98 0.14 563.78 Not Dominated 
0.20 No Adenovirus Vaccine 73.40 0.16 454.39 0.00 0.00 0.00  
0.20 Adenovirus Vaccine 148.53 0.02 6543.29 75.13 0.14 541.09 Not Dominated 
0.22 No Adenovirus Vaccine 76.68 0.16 472.91 0.00 0.00 0.00  
0.22 Adenovirus Vaccine 148.95 0.02 6539.98 72.27 0.14 518.58 Not Dominated 
 
VARIABLE: pMAE – Probability of minor systemic reactions after adenovirus vaccination 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.08 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
0.08 Adenovirus Vaccine 148.11 0.02 6549.58 77.98 0.14 563.74 Not Dominated 
0.09 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
0.09 Adenovirus Vaccine 148.11 0.02 6548.10 77.98 0.14 563.76 Not Dominated 
0.10 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
0.10 Adenovirus Vaccine 148.11 0.02 6546.62 77.98 0.14 563.78 Not Dominated 
0.11 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  
0.11 Adenovirus Vaccine 148.11 0.02 6545.15 77.98 0.14 563.80 Not Dominated 
0.12 No Adenovirus Vaccine 70.13 0.16 435.72 0.00 0.00 0.00  





VARIABLE: pSIQ_ONLY – Probability of spending time in sick quarters 
VARIABLE STRATEGY COST EFF CE INCRCOST INCREFF INCRCE DOMINATED 
0.76 No Adenovirus Vaccine 70.47 0.16 436.69 0.00 0.00 0.00  
0.76 Adenovirus Vaccine 148.15 0.02 6532.83 77.68 0.14 560.13 Not Dominated 
0.82 No Adenovirus Vaccine 70.36 0.16 436.40 0.00 0.00 0.00  
0.82 Adenovirus Vaccine 148.14 0.02 6537.00 77.77 0.14 561.23 Not Dominated 
0.88 No Adenovirus Vaccine 70.26 0.16 436.10 0.00 0.00 0.00  
0.88 Adenovirus Vaccine 148.12 0.02 6541.17 77.86 0.14 562.34 Not Dominated 
0.93 No Adenovirus Vaccine 70.16 0.16 435.81 0.00 0.00 0.00  
0.93 Adenovirus Vaccine 148.11 0.02 6545.35 77.95 0.14 563.44 Not Dominated 
0.99 No Adenovirus Vaccine 70.05 0.16 435.52 0.00 0.00 0.00  





APPENDIX C.  
 
                         
                             QUADRANT II  QUADRANT I 
 
  
                      C - 4 
                                   C – 6        C - 2  
                     
                              C - 5        C - 1 
        C - 3 
                           QUADRANT III                   QUADRANT IV 
                                             INCREMENTAL EFFECTIVENESS 
 
 C – 1 – Comparator is less costly and more effective. Comparator is recommended 
because it absolutely dominates baseline 
 
 C – 2 – Comparator is more costly and more effective. Comparator is recommended 
because the ICER does not exceed the WTP  
 
 C – 3 – Comparator is less costly and less effective. Comparator is recommended 
because the ICER does not exceed the WTP 
 
 C – 4 – Comparator is more costly and more effective. Comparator is not recommended 
because the ICER exceeds the WTP 
 
 C – 5 – Comparator is less costly and less effective. Comparator is not recommended 
because the ICER exceeds the WTP  
 
 C – 6 – Comparator is more costly and less effective. Comparator is not recommended 
because it is absolutely dominated by the baseline.  
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